{"protocolSection":{"identificationModule":{"nctId":"NCT04955626","orgStudyIdInfo":{"id":"C4591031"},"secondaryIdInfos":[{"id":"2021-005197-25","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"BioNTech SE","class":"INDUSTRY"},"briefTitle":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","officialTitle":"A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-07-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-05-25","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-25","type":"ACTUAL"},"studyFirstSubmitDate":"2021-06-09","studyFirstSubmitQcDate":"2021-06-29","studyFirstPostDateStruct":{"date":"2021-07-09","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-05-15","resultsFirstSubmitQcDate":"2025-10-24","resultsFirstPostDateStruct":{"date":"2025-11-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-24","lastUpdatePostDateStruct":{"date":"2025-11-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BioNTech SE","class":"INDUSTRY"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.\n\nThe study is designed to describe vaccine efficacy of a booster dose of BNT162b2 over time against COVID-19\n\n* At a dose of 30µg (as studied in the Phase 2/3 study C4591001)\n* In healthy adults 16 years of age and older\n* The duration of the study for each participant will be up to approximately 12 months.\n* The study will be conducted in the United States, Brazil and South Africa\n\nSubstudy B: The study will assess the safety and tolerability of a single dose of BNT162b2 as compared to placebo control, through the potential analysis of serum troponin levels, in participants ≥12 and ≤30 years of age who have received 2 or 3 prior doses of BNT162b2 (30-µg doses) with their last dose at least 4 months (120 days) prior to randomization.\n\n* Blood samples will be collected for troponin testing\n* The duration of the study for each participant will be up to approximately 2 months.\n* The study will be conducted in the United States, Germany, Poland and South Africa\n\nSubstudy C: The study will assess the safety, tolerability, and immunogenicity of a booster (third) dose of BNT162b2 at doses of 10 µg or 30 µg in participants who have completed a 2-dose primary series of BNT162b2 (30 µg doses) at least 5 months (150 days) prior to randomization.\n\n* In healthy adults 12 years of age and older\n* The duration of the study for each participant will be up to approximately 12 months.\n* The study will be conducted in the United States, Germany and South Africa\n\nSubstudy D: The study will assess the safety, tolerability, and immunogenicity of a 2-dose primary series of BNT162b2 OMI, and as a booster (third, fourth or fifth) dose\n\n* Participants in Cohort 1 will have completed a 2-dose primary series of BNT162b2 (30-µg doses), with their last dose 90 to 240 days prior to enrolment\n* Participants in Cohort 2 will be enrolled from Study C4591001 and C4591031 Substudy A and will have completed a 2-dose primary series and received a single booster (third) dose of BNT162b2, with their last dose 90 to 180 days prior to randomization\n* Participants in Cohort 3 who are COVID-19 vaccine-naïve and have not experienced COVID-19 will be enrolled to receive 2 doses (primary series) of BNT162b2 OMI, 3 weeks apart, with a dose of BNT162b2 approximately 5 months (150 days) later. If participants do not consent to receive BNT162b2 as a third dose, they will not receive a third dose. No participants should receive BNT162b2 OMI as a third dose.\n\n  * In healthy adults 18 to 55 years of age\n  * The duration of the study for each participant will be up to approximately 12 months.\n  * The study will be conducted in the United States and South Africa\n\nSubstudy E: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose\n\n* In healthy adults 18 years of age and older who have received 3 prior doses of BNT162b2 (30 µg) with the most recent dose being 5 to 12 months (150 to 360 days) prior to randomization\n* The duration of the study for each participant will be approximately 6 months.\n* The study will be conducted in the United States\n\nSubstudy F: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose.\n\n* In healthy adults 60 years of age and older who have received 3 prior doses of BNT162b2 (30 µg) with the most recent dose being ≥4 months prior to randomization\n* The duration of the study for each participant will be approximately 6 months.\n* The study will be conducted in Israel"},"conditionsModule":{"conditions":["SARS-CoV-2 Infection","COVID-19"],"keywords":["COVID-19","Coronavirus","Vaccine","SARS-CoV-2","RNA Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":16372,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"10 µg dose","type":"EXPERIMENTAL","description":"1 dose","interventionNames":["Biological: BNT162b2"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"1 dose","interventionNames":["Other: Placebo"]},{"label":"30 µg dose","type":"EXPERIMENTAL","description":"1 dose","interventionNames":["Biological: BNT162b2","Biological: BNT162b2 OMI","Biological: Combination BNT162b2 and BNT162b2 OMI","Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI"]},{"label":"60 µg dose","type":"EXPERIMENTAL","description":"1 dose","interventionNames":["Biological: BNT162b2","Biological: BNT162b2 OMI","Biological: Combination BNT162b2 and BNT162b2 OMI","Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI"]}],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b2","description":"Intramuscular Injection","armGroupLabels":["10 µg dose","30 µg dose","60 µg dose"]},{"type":"OTHER","name":"Placebo","description":"Intramuscular Injection","armGroupLabels":["Placebo"]},{"type":"BIOLOGICAL","name":"BNT162b2 OMI","description":"Intramuscular Injection","armGroupLabels":["30 µg dose","60 µg dose"]},{"type":"BIOLOGICAL","name":"Combination BNT162b2 and BNT162b2 OMI","description":"30-µg (15-µg each) or 60-µg (30-µg each)\n\nSite prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI\n\nIntramuscular Injection","armGroupLabels":["30 µg dose","60 µg dose"]},{"type":"BIOLOGICAL","name":"Combination (Bivalent) BNT162b2 and BNT162b2 OMI","description":"30-µg (15-µg each) or 60-µg (30-µg each)\n\nPreformulated bivalent mixture (no dilution required) presented in a single vial\n\nIntramuscular Injection","armGroupLabels":["30 µg dose","60 µg dose"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year [PY]) for BNT162b2 was 0.823 and for Placebo was 0.792"},{"measure":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 0.871 and for Placebo was 0.835"},{"measure":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.098 and for Placebo was 0.932"},{"measure":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.173 and for Placebo was 0.989"},{"measure":"SSA: Percentage of Participants Reporting Adverse Events","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.","timeFrame":"From booster dose (Day 1) to 1 month after booster dose"},{"measure":"SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)","description":"An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.","timeFrame":"BNT162b2 30 mcg, Placebo then BNT162b2 30 mcg: From BNT162b2 dose to 6 months after BNT162b2 dose; Placebo: From placebo dose to unblinding for original placebo participants. Median blinded follow-up period for Placebo group=2.8 months"},{"measure":"SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1","description":"Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.","timeFrame":"Pre-dose on Day 1 (Vaccination 1)"},{"measure":"SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1","description":"Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.","timeFrame":"Within 5 days after Vaccination 1"},{"measure":"SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)","description":"Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.","timeFrame":"Pre-Vaccination 2 (1 month after Vaccination 1)"},{"measure":"SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2","description":"Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.","timeFrame":"Within 5 days after vaccination 2"},{"measure":"SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2","description":"Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.","timeFrame":"1 month after Vaccination 2"},{"measure":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after Vaccination 1"},{"measure":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after Vaccination 2"},{"measure":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after Vaccination 1"},{"measure":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after Vaccination 2"},{"measure":"SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Vaccination 1 up to 1 Month After Vaccination 1"},{"measure":"SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Vaccination 2 up to 1 month after Vaccination 2"},{"measure":"SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Vaccination 1 up to 1 month after Vaccination 1"},{"measure":"SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Vaccination 2 up to 1 month after Vaccination 2"},{"measure":"SSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after the booster dose"},{"measure":"SSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after the booster dose"},{"measure":"SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From booster dose (Day 1) up to 1 month after booster dose"},{"measure":"SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From booster dose (Day 1) up to 6 months after booster dose"},{"measure":"SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"At baseline (pre-dose)"},{"measure":"SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"1 month after the booster dose"},{"measure":"SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From baseline to 1 month after the booster dose"},{"measure":"SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.","timeFrame":"1 month after the booster dose"},{"measure":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after Vaccination 1"},{"measure":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after Vaccination 2"},{"measure":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after Vaccination 3"},{"measure":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C, categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after Vaccination 1"},{"measure":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C, categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after Vaccination 2"},{"measure":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after Vaccination 3"},{"measure":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From Day 1 up to 1 month after last study vaccination"},{"measure":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From first study vaccination (Day 1) up to 1 month after Vaccination 1"},{"measure":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From Vaccination 2 up to 1 month after Vaccination 2"},{"measure":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From first study vaccination (Day 1) up to 1 month after Vaccination 2"},{"measure":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From Vaccination 3 up to 1 month after Vaccination 3"},{"measure":"SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From first study vaccination (Day 1) up to 6 months after last study vaccination"},{"measure":"SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From vaccination 1 (Day 1) up to 6 months after vaccination 1 (participants received 1 dose only); From vaccination 1 up to before vaccination 2 (participants received 2 doses)"},{"measure":"SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From first study vaccination (Day 1) up to 6 months after vaccination 2"},{"measure":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4","description":"GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"1 month after Vaccination 1"},{"measure":"SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.","timeFrame":"1 month after Vaccination 1"},{"measure":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"1 month after Vaccination 1"},{"measure":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b","description":"GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).","timeFrame":"For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2"},{"measure":"Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.","timeFrame":"1 month after Vaccination 1"},{"measure":"SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \\>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.","timeFrame":"For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2"},{"measure":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3","description":"GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).","timeFrame":"1 month after Vaccination 2"},{"measure":"SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3","description":"EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.","timeFrame":"1 month after Vaccination 2"},{"measure":"SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm),severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis/exfoliative dermatitis \\[redness\\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after study vaccination"},{"measure":"SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C \\& \\>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after study vaccination"},{"measure":"SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From study vaccination up to 1 Month after study vaccination"},{"measure":"SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From study vaccination up to 6 Months after study vaccination"},{"measure":"SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age","description":"Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.","timeFrame":"Before study vaccination (pre-dose)"},{"measure":"SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age","description":"Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.","timeFrame":"3 days after study vaccination"},{"measure":"SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination","description":"GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"1 month after study vaccination"},{"measure":"SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \\>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","timeFrame":"1 month after study vaccination"},{"measure":"SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"Before vaccination (pre-dose)"},{"measure":"SSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \\[swelling\\] or necrosis/exfoliative dermatitis \\[redness\\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","timeFrame":"Day 1 up to Day 7 after the study vaccination"},{"measure":"SSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C \\& \\>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","timeFrame":"Day 1 up to Day 7 after the study vaccination"},{"measure":"SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From study vaccination up to 1 Month after study vaccination"},{"measure":"SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From study vaccination up to 6 Months after study vaccination"},{"measure":"SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"Before vaccination (pre-dose)"},{"measure":"SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"Before vaccination (pre-dose)"},{"measure":"SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 3 (3 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 3 (3 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 3 (3 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 6 (6 month after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 6 (6 months after vaccination)"},{"measure":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","timeFrame":"Month 6 (6 months after vaccination)"},{"measure":"SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)"},{"measure":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 1 month after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 1 month after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 1 month after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 3 months after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 3 months after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 3 months after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 6 months after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 6 months after vaccination"},{"measure":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From before the study vaccination to 6 months after vaccination"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","timeFrame":"Day 7 (7 days after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","timeFrame":"Month 1 (1 month after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","timeFrame":"Month 3 (3 months after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","timeFrame":"Month 3 (3 months after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","timeFrame":"Month 3 (3 months after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","timeFrame":"Month 6 (6 months after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","timeFrame":"Month 6 (6 months after vaccination)"},{"measure":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","timeFrame":"Month 6 (6 months after vaccination)"}],"secondaryOutcomes":[{"measure":"SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population","description":"Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \\[\\>=\\]30 breaths per minute, heart rate \\>= 125 beats per minute, oxygen saturation less than or equal to \\[\\<=\\]93% on room air at sea level, or Horovitz quotient \\<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \\[BP\\] \\<90 mmHg, diastolic BP \\<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.105 and for Placebo was 0.951"},{"measure":"SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population","description":"Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \\>= 30 breaths per minute, heart rate \\>= 125 beats per minute, oxygen saturation \\<= 93% on room air at sea level, or Horovitz quotient \\<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \\<90 mm Hg, diastolic BP \\<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.182 and for Placebo was 1.011"},{"measure":"SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection","description":"Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.","timeFrame":"From 7 Days after booster vaccination"},{"measure":"SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection","description":"Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.","timeFrame":"From 7 Days after booster vaccination"},{"measure":"SSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose","description":"GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"At baseline and 7 days after the booster dose"},{"measure":"SSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose","description":"GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"At baseline and 7 days after booster dose"},{"measure":"SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From baseline (before booster dose) to 7 days after the booster dose"},{"measure":"SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose","description":"GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","timeFrame":"From baseline (before booster dose) to 7 days after the booster dose"},{"measure":"SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.","timeFrame":"7 days after the booster dose"},{"measure":"SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.","timeFrame":"7 days after the booster dose"},{"measure":"SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age","description":"GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","timeFrame":"1 month after study vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Substudy A\n\nInclusion Criteria:\n\n* Male or female participants ≥16 years of age at Visit 1 (Day 1) who participated in C4591001.\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving signed informed consent.\n* Participants who have received 2 prior doses of 30 µg BNT162b2 19-42 days apart, with the second dose being at least 175 days before Visit 1 (Day 1).\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID-19.\n* Prior receipt of more than 2 doses of BNT162b2 30 µg.\n* Participation in other studies involving study intervention within 28 days prior to study entry, other than C4591001, and/or within 28 days of confirmed receipt of BNT162b2 within the study.\n\nSubstudy B\n\nInclusion Criteria:\n\n* Male or female participants 12 to 30 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least at least 4 months (120 days) before Visit 1 (Day 1)\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID-19.\n* Prior receipt of more than 3 doses of BNT162b2 30 µg.\n* Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.\n\nSubstudy C\n\nInclusion Criteria:\n\n* Male or female participants ≥12 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least 150 days before Visit 301 (Day 1)\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID-19.\n* Prior receipt of more than 2 doses of BNT162b2 30 µg.\n* Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.\n\nSubstudy D\n\nInclusion Criteria:\n\n* Male or female participants 18 to 55 years of age inclusive\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Cohort 2: Participants who provided a serum sample at Visit 3 in Study C4591001, with Visit 3 occurring within the protocol-specified window.\n* Capable of giving signed informed consent\n* Cohort 1: Participants who have received 2 prior doses of 30 µg BNT162b2, with the second dose being 90 to 240 days before Visit 401 (Day 1) or Cohort 2: Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 90 to 180 days before Visit 401 (Day 1).\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Cohorts 1 and 2: prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Cohort 3 only: prior receipt of any COVID-19 vaccine.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID 19.\n* Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.\n\nSubstudy E\n\nInclusion Criteria:\n\n* Groups 1-6: Male or female participants \\>55 years of age\n* Groups 7-9: Male or female participants 18 to 55 years of age\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving signed informed consent.\n* Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 5 to 12 months (150 to 360 days) before Visit 601 (Day 1).\n* Groups 7 to 9 (sentinel participants): Screening troponin levels must be within normal range prior to randomization.\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID-19.\n* Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.\n\nSubstudy F\n\nInclusion Criteria:\n\n* Male or female participants ≥60 years of age\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving signed informed consent.\n* Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being ≥4 months before Visit 701 (Day 1).\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.\n* Prior receipt of any COVID-19 vaccine other than BNT162b2.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n* Receipt of medications intended to prevent COVID-19.\n* Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"North Alabama Research Center","city":"Athens","state":"Alabama","zip":"35611","country":"United States","geoPoint":{"lat":34.80243,"lon":-86.97219}},{"facility":"Accel Research Sites - Birmingham Clinical Research Unit","city":"Birmingham","state":"Alabama","zip":"35216","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Medical Affiliated Research Center","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"AMR Clinical","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Johns Hopkins Center for American Indian Health","city":"Chinle","state":"Arizona","zip":"86503","country":"United States","geoPoint":{"lat":36.15445,"lon":-109.55261}},{"facility":"Hope Research Institute","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"The Pain Center of Arizona","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"HOPE Research Institute","city":"Phoenix","state":"Arizona","zip":"85023","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Tempe","state":"Arizona","zip":"85281","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Johns Hopkins Center for American Indian Health","city":"Whiteriver","state":"Arizona","zip":"85941","country":"United States","geoPoint":{"lat":33.83699,"lon":-109.96427}},{"facility":"Whiteriver Indian Hospital- Garrett Building","city":"Whiteriver","state":"Arizona","zip":"85941","country":"United States","geoPoint":{"lat":33.83699,"lon":-109.96427}},{"facility":"Whiteriver Indian Hospital","city":"Whiteriver","state":"Arizona","zip":"85941","country":"United States","geoPoint":{"lat":33.83699,"lon":-109.96427}},{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Collaborative Neuroscience Research, LLC","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Collaborative Neuroscience Research, LLC","city":"Los Alamitos","state":"California","zip":"90720","country":"United States","geoPoint":{"lat":33.80307,"lon":-118.07256}},{"facility":"Kaiser Permanente Los Angeles Medical Center","city":"Los Angeles","state":"California","zip":"90027","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Kaiser Permenente Medical Center Infectious Disease","city":"Los Angeles","state":"California","zip":"90027","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Velocity Clinical Research, Los Angeles","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Velocity Clinical Research, North Hollywood","city":"North Hollywood","state":"California","zip":"91606","country":"United States","geoPoint":{"lat":34.17223,"lon":-118.37897}},{"facility":"Kaiser Permanente Oakland","city":"Oakland","state":"California","zip":"94611","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"Paradigm Clinical Research Centers, Inc","city":"Redding","state":"California","zip":"96001","country":"United States","geoPoint":{"lat":40.58654,"lon":-122.39168}},{"facility":"UC Davis Medical Center","city":"Sacramento","state":"California","zip":"95817","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"California Research Foundation","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Kaiser Permanente Santa Clara","city":"Santa Clara","state":"California","zip":"95051","country":"United States","geoPoint":{"lat":37.35411,"lon":-121.95524}},{"facility":"Bayview Research Group, LLC","city":"Valley Village","state":"California","zip":"91607","country":"United States","geoPoint":{"lat":34.16488,"lon":-118.3965}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Lynn Institute of Denver","city":"Aurora","state":"Colorado","zip":"80012","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Clinical Research Consulting","city":"Milford","state":"Connecticut","zip":"06460","country":"United States","geoPoint":{"lat":41.22232,"lon":-73.0565}},{"facility":"Yale University School of Medicine","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Yale-New Haven Hospital","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Yale Center for Clinical Investigation","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Indago Research & Health Center, Inc","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Research Centers of America ( Hollywood )","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Clinical Neuroscience Solutions, Inc. dba CNS Healthcare","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Acevedo Clinical Research Associates","city":"Miami","state":"Florida","zip":"33142","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"IACT Health","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Meridian Clinical Research","city":"Savannah","state":"Georgia","zip":"31406","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Clinical Research Atlanta","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"East-West Medical Research Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Solaris Clinical Research","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"University of Iowa","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Velocity Clinical Research, Sioux City","city":"Sioux City","state":"Iowa","zip":"51106","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"AMR Clinical","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"AMR Clinical","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Kentucky Pediatric/ Adult Research","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"Ochsner Clinic Foundation","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Louisiana State University Health Sciences Shreveport","city":"Shreveport","state":"Louisiana","zip":"71101","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Johns Hopkins Bayview Medical Center","city":"Baltimore","state":"Maryland","zip":"21224","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Boston Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"University of Massachusetts Chan Medical School","city":"Worcester","state":"Massachusetts","zip":"01655","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Michigan Center of Medical Research (MICHMER)","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Velocity Clinical Research, Covington","city":"Gulfport","state":"Mississippi","zip":"39503","country":"United States","geoPoint":{"lat":30.36742,"lon":-89.09282}},{"facility":"Clinical Research Professionals","city":"Chesterfield","state":"Missouri","zip":"63005","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"Sundance Clinical Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research","city":"Bozeman","state":"Montana","zip":"59715","country":"United States","geoPoint":{"lat":45.67965,"lon":-111.03856}},{"facility":"Bozeman Health Deaconess Hospital","city":"Bozeman","state":"Montana","zip":"59715","country":"United States","geoPoint":{"lat":45.67965,"lon":-111.03856}},{"facility":"Methodist Physicians Clinic/CCT Research","city":"Fremont","state":"Nebraska","zip":"68025","country":"United States","geoPoint":{"lat":41.43333,"lon":-96.49808}},{"facility":"Velocity Clinical Research, Norfolk","city":"Norfolk","state":"Nebraska","zip":"68701","country":"United States","geoPoint":{"lat":42.02834,"lon":-97.417}},{"facility":"Quality Clinical Research","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Velocity Clinical Research, Omaha","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Wake Research - Clinical Research Center of Nevada, LLC","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"South Jersey Infectious Disease","city":"Somers Point","state":"New Jersey","zip":"08244","country":"United States","geoPoint":{"lat":39.31762,"lon":-74.5946}},{"facility":"IMA Clinical Research Warren","city":"Warren Township","state":"New Jersey","zip":"07059","country":"United States","geoPoint":{"lat":40.60822,"lon":-74.51803}},{"facility":"Gallup Indian Medical Center","city":"Gallup","state":"New Mexico","zip":"87301","country":"United States","geoPoint":{"lat":35.52808,"lon":-108.74258}},{"facility":"Johns Hopkins Center for American Indian Health","city":"Gallup","state":"New Mexico","zip":"87301","country":"United States","geoPoint":{"lat":35.52808,"lon":-108.74258}},{"facility":"Johns Hopkins Center for American Indian Health","city":"Shiprock","state":"New Mexico","zip":"87420","country":"United States","geoPoint":{"lat":36.78555,"lon":-108.68703}},{"facility":"Northern Navajo Medical Center","city":"Shiprock","state":"New Mexico","zip":"87420","country":"United States","geoPoint":{"lat":36.78555,"lon":-108.68703}},{"facility":"Meridian Clinical Research LLC","city":"Binghamton","state":"New York","zip":"13901","country":"United States","geoPoint":{"lat":42.09869,"lon":-75.91797}},{"facility":"NYU Langone Health","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Icahn School of Medicine at Mount Sinai","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Rochester Clinical Research, Inc.","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"University of Rochester Medical Center- Kari Steinmetz","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"University of Rochester Medical Center","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"SUNY Upstate Medical University","city":"Syracuse","state":"New York","zip":"13215","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"Velocity Clinical Research, Vestal","city":"Vestal","state":"New York","zip":"13850","country":"United States","geoPoint":{"lat":42.08507,"lon":-76.05381}},{"facility":"Accellacare","city":"Cary","state":"North Carolina","zip":"27518","country":"United States","geoPoint":{"lat":35.79154,"lon":-78.78112}},{"facility":"Accellacare","city":"Charlotte","state":"North Carolina","zip":"28211","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Duke University - Main Hospital and Clinics","city":"Durham","state":"North Carolina","zip":"27703","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"PharmQuest Life Sciences, LLC","city":"Greensboro","state":"North Carolina","zip":"27408","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Accellacare","city":"Hickory","state":"North Carolina","zip":"28601","country":"United States","geoPoint":{"lat":35.73319,"lon":-81.3412}},{"facility":"Accellacare","city":"Raleigh","state":"North Carolina","zip":"27609","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"M3 Wake Research, Inc.","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Accellacare - Salisbury","city":"Salisbury","state":"North Carolina","zip":"28144","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"Accellacare (formerly PMG Research of Wilmington, LLC)","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Accellacare","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Accellacare","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Lillestol Research","city":"Fargo","state":"North Dakota","zip":"58104","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Meridian Clinical Research, LLC","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Cincinnati Children's Hospital Medical Center","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Cincinnati Children's Hospital","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Meridian Clinical Research","city":"Cincinnati","state":"Ohio","zip":"45246","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"University Hospitals Cleveland Medical Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"VA Northeast Ohio Healthcare System","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Velocity Clinical Research, Cleveland","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Centricity Research Columbus Ohio Multispecialty","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Dayton Clinical Research","city":"Dayton","state":"Ohio","zip":"45406","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Dayton Clinical Research","city":"Dayton","state":"Ohio","zip":"45409","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"PriMED Clinical Research","city":"Dayton","state":"Ohio","zip":"45419","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Senders Pediatrics","city":"South Euclid","state":"Ohio","zip":"44121","country":"United States","geoPoint":{"lat":41.52311,"lon":-81.51846}},{"facility":"Lynn Institute of Norman","city":"Norman","state":"Oklahoma","zip":"73072","country":"United States","geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"Kaiser Permanente Center for Health Research","city":"Portland","state":"Oregon","zip":"97227","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Lehigh Valley Health Network/Network Office of Research and Innovation","city":"Allentown","state":"Pennsylvania","zip":"18102","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"Velocity Clinical Research, Providence","city":"East Greenwich","state":"Rhode Island","zip":"02818","country":"United States","geoPoint":{"lat":41.66038,"lon":-71.45589}},{"facility":"Main Street Physician's Care","city":"Little River","state":"South Carolina","zip":"29566","country":"United States","geoPoint":{"lat":33.87323,"lon":-78.61418}},{"facility":"Holston Medical Group","city":"Bristol","state":"Tennessee","zip":"37620","country":"United States","geoPoint":{"lat":36.59511,"lon":-82.18874}},{"facility":"Holston Medical Group","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"Alliance for Multispecialty Research - Weisgarber Medical Park","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Clinical Neuroscience Solutions Inc.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Clinical Research Associates Inc","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Trinity Clinical Research","city":"Tullahoma","state":"Tennessee","zip":"37388","country":"United States","geoPoint":{"lat":35.36202,"lon":-86.20943}},{"facility":"Benchmark Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Innovo Research - Austin Regional Clinic","city":"Austin","state":"Texas","zip":"78726","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Tekton Research, Inc","city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"North Texas Infectious Diseases Consultants, P.A","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Ventavia Research Group","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Benchmark Research","city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"HG Pediatrics","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Renu Garg, MD Pediatrics","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Van Tran Family Practice","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Ventavia Research Group, LLC","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"DM Clinical Research - Bellaire","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"SCR of Texas, LLC","city":"Keller","state":"Texas","zip":"76248","country":"United States","geoPoint":{"lat":32.93457,"lon":-97.25168}},{"facility":"SMS Clinical Research","city":"Mesquite","state":"Texas","zip":"75149","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"LinQ Research, LLC","city":"Pearland","state":"Texas","zip":"77584","country":"United States","geoPoint":{"lat":29.56357,"lon":-95.28605}},{"facility":"Clinical Trials of Texas, Inc.","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Clinical Trials of Texas, LLC","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"IMA Clinical Research San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"DM Clinical Research - Kool Kids Pediatrics","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"DM Clinical Research","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic South","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Clinical Alliance for Research & Education - Infectious Diseases (CARE-ID)","city":"Annandale","state":"Virginia","zip":"22003","country":"United States","geoPoint":{"lat":38.83039,"lon":-77.19637}},{"facility":"Virginia Research Center","city":"Midlothian","state":"Virginia","zip":"23114","country":"United States","geoPoint":{"lat":37.50598,"lon":-77.64916}},{"facility":"Benaroya Research Institute at Virginia Mason","city":"Seattle","state":"Washington","zip":"98101","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Research Building","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"Wenatchee Valley Hospital","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"Obras Sociais Irma Dulce","city":"Salvador","state":"Estado de Bahia","zip":"40.415-006","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"CEPIC - Centro Paulista de Investigação Clínica","city":"São Paulo","zip":"04266-010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Studienzentrum Dr. Keller","city":"Frankfurt","zip":"60389","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"IKF Pneumologie GmbH & Co. KG","city":"Frankfurt","zip":"60596","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"Sheba Medical Center","city":"Ramat Gan","state":"Central District","zip":"5262100","country":"Israel"},{"facility":"Synergy Biomed Research Institute","city":"East London","state":"Eastern Cape","zip":"5201","country":"South Africa","geoPoint":{"lat":-33.01529,"lon":27.91162}},{"facility":"Worthwhile Clinical Trials","city":"Benoni","state":"Gauteng","zip":"1501","country":"South Africa","geoPoint":{"lat":-26.18848,"lon":28.32078}},{"facility":"Newtown Clinical Research","city":"Johannesburg","state":"Gauteng","zip":"2113","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Clinresco Centres","city":"Kempton Park","state":"Gauteng","zip":"1619","country":"South Africa","geoPoint":{"lat":-26.10859,"lon":28.2377}},{"facility":"Dr A Jacovides & Partners Inc.","city":"Midrand","state":"Gauteng","zip":"1685","country":"South Africa","geoPoint":{"lat":-25.976,"lon":28.118}},{"facility":"Botho Ke Bontle Health Services PTY LTD","city":"Pretoria","state":"Gauteng","zip":"0184","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Limpopo Clinical Research Initiative","city":"Thabazimbi","state":"Limpopo","zip":"0380","country":"South Africa","geoPoint":{"lat":-24.59165,"lon":27.41155}},{"facility":"TREAD Research","city":"Cape Town","state":"Parow","zip":"7500","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Tiervlei Trial Centre","city":"Cape Town","state":"Western Cape","zip":"7530","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Jongaie Research","city":"Pretoria","zip":"0183","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}}]},"referencesModule":{"references":[{"pmid":"42501282","type":"DERIVED","citation":"Fitz-Patrick D, Sahgal O, Fouche LF, Mitha E, Malahleha M, Gayed J, Keep G, Zhang Y, Modjarrad K, Belanger T, Xu X, Cooper D, Mensa FJ, Sahin U, Tureci Ӧ, Swanson KA, Anderson AS, Gurtman A, Kitchin N. Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive. Infect Dis Ther. 2026 Jul 25. doi: 10.1007/s40121-026-01409-1. Online ahead of print."},{"pmid":"41560517","type":"DERIVED","citation":"Winokur P, Diya O, Fitz-Patrick D, Dever M, Gayed J, Lockhart S, Xu X, Zhang Y, Bangad V, Wadsworth LT, Cannon K, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Tureci O, Sahin U, Swanson KA, Gruber WC, Kitchin N. Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old. Clin Infect Dis. 2026 May 20;82(5):e1083-e1092. doi: 10.1093/cid/ciag026."},{"pmid":"37527039","type":"DERIVED","citation":"Muik A, Lui BG, Quandt J, Diao H, Fu Y, Bacher M, Gordon J, Toker A, Grosser J, Ozhelvaci O, Grikscheit K, Hoehl S, Kohmer N, Lustig Y, Regev-Yochay G, Ciesek S, Beguir K, Poran A, Vogler I, Tureci O, Sahin U. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity. Cell Rep. 2023 Aug 29;42(8):112888. doi: 10.1016/j.celrep.2023.112888. Epub 2023 Jul 31."},{"pmid":"36652353","type":"DERIVED","citation":"Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Tureci O, Sahin U, Swanson KA, Gruber WC, Kitchin N; C4591031 Clinical Trial Group. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years. N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082."},{"pmid":"35320659","type":"DERIVED","citation":"Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings TW, Brandon DM, Cannon KD, Koren MJ, Denham DS, Berhe M, Fitz-Patrick D, Hammitt LL, Klein NP, Nell H, Keep G, Wang X, Koury K, Swanson KA, Cooper D, Lu C, Tureci O, Lagkadinou E, Tresnan DB, Dormitzer PR, Sahin U, Gruber WC, Jansen KU; C4591031 Clinical Trial Group. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022 May 19;386(20):1910-1921. doi: 10.1056/NEJMoa2200674. Epub 2022 Mar 23."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C4591031"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"SSA: 10133 participants randomized, 10121 vaccinated and evaluated. SSB: 1487 participants randomized,1485 vaccinated and evaluated. SSC: 140 participants randomized, vaccinated, evaluated. SSD: 1469 participants randomized 1467 vaccinated, 1465vaccinated with 30 mcg BNT162b2 and BNT162b2 OMI and evaluated. SSE: 3020 participants randomized, 3014 vaccinated, 3010 vaccinated with 30 and 60 mcg BNT162b2 and BNT162b2 OMI and evaluated. SSF: 123 participants randomized,122 vaccinated and evaluated.","recruitmentDetails":"This study was conducted in 6 parts: sub-study A (SSA), sub-study B (SSB), sub-study C (SSC), sub-study D (SSD), sub-study E (SSE) and sub-study F (SSF).","groups":[{"id":"FG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG001","title":"SSA: Placebo: Blinded Period, Then BNT162b2 30 mcg Open-Label Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly during the Double-Blinded period. Then, they could have received BNT162b2 30 mcg in the Open-Label Period."},{"id":"FG002","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"FG003","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."},{"id":"FG004","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG005","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG006","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG007","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"FG008","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG009","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"FG010","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"FG011","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."},{"id":"FG012","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG013","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG014","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG015","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG016","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG017","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG018","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG019","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG020","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG021","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG022","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG023","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG024","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG025","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG026","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG027","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG028","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG029","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG030","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG031","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG032","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG033","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG034","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"FG035","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"periods":[{"title":"Blinded Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Vaccinated with booster dose","numSubjects":"5080"},{"groupId":"FG001","comment":"Vaccinated with booster dose","numSubjects":"5041"},{"groupId":"FG002","comment":"Vaccinated with booster dose","numSubjects":"753"},{"groupId":"FG003","comment":"Vaccinated with booster dose","numSubjects":"732"},{"groupId":"FG004","comment":"Vaccinated with booster dose","numSubjects":"75"},{"groupId":"FG005","comment":"Vaccinated with booster dose","numSubjects":"65"},{"groupId":"FG006","comment":"Vaccinated with booster dose","numSubjects":"216"},{"groupId":"FG007","comment":"Vaccinated with booster dose","numSubjects":"197"},{"groupId":"FG008","comment":"Vaccinated with booster dose","numSubjects":"204"},{"groupId":"FG009","comment":"Vaccinated with booster dose","numSubjects":"315"},{"groupId":"FG010","comment":"Vaccinated with booster dose","numSubjects":"325"},{"groupId":"FG011","comment":"Vaccinated with booster dose","numSubjects":"210"},{"groupId":"FG012","comment":"Vaccinated with booster dose","numSubjects":"30"},{"groupId":"FG013","comment":"Vaccinated with booster dose","numSubjects":"30"},{"groupId":"FG014","comment":"Vaccinated with booster dose","numSubjects":"30"},{"groupId":"FG015","comment":"Vaccinated with booster dose","numSubjects":"482"},{"groupId":"FG016","comment":"Vaccinated with booster dose","numSubjects":"159"},{"groupId":"FG017","comment":"Vaccinated with booster dose","numSubjects":"321"},{"groupId":"FG018","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG019","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG020","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG021","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG022","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG023","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG024","comment":"Vaccinated with booster dose","numSubjects":"305"},{"groupId":"FG025","comment":"Vaccinated with booster dose","numSubjects":"302"},{"groupId":"FG026","comment":"Vaccinated with booster dose","numSubjects":"307"},{"groupId":"FG027","comment":"Vaccinated with booster dose","numSubjects":"307"},{"groupId":"FG028","comment":"Vaccinated with booster dose","numSubjects":"308"},{"groupId":"FG029","comment":"Vaccinated with booster dose","numSubjects":"313"},{"groupId":"FG030","comment":"Vaccinated with booster dose","numSubjects":"21"},{"groupId":"FG031","comment":"Vaccinated with booster dose","numSubjects":"19"},{"groupId":"FG032","comment":"Vaccinated with booster dose","numSubjects":"21"},{"groupId":"FG033","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG034","comment":"Vaccinated with booster dose","numSubjects":"20"},{"groupId":"FG035","comment":"Vaccinated with booster dose","numSubjects":"21"}]},{"type":"Safety Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"5080"},{"groupId":"FG001","numSubjects":"5041"},{"groupId":"FG002","numSubjects":"753"},{"groupId":"FG003","numSubjects":"732"},{"groupId":"FG004","numSubjects":"75"},{"groupId":"FG005","numSubjects":"65"},{"groupId":"FG006","numSubjects":"216"},{"groupId":"FG007","numSubjects":"197"},{"groupId":"FG008","numSubjects":"204"},{"groupId":"FG009","numSubjects":"315"},{"groupId":"FG010","numSubjects":"323"},{"groupId":"FG011","numSubjects":"210"},{"groupId":"FG012","numSubjects":"30"},{"groupId":"FG013","numSubjects":"30"},{"groupId":"FG014","numSubjects":"30"},{"groupId":"FG015","numSubjects":"482"},{"groupId":"FG016","numSubjects":"159"},{"groupId":"FG017","numSubjects":"321"},{"groupId":"FG018","numSubjects":"20"},{"groupId":"FG019","numSubjects":"20"},{"groupId":"FG020","numSubjects":"20"},{"groupId":"FG021","numSubjects":"20"},{"groupId":"FG022","numSubjects":"20"},{"groupId":"FG023","numSubjects":"20"},{"groupId":"FG024","numSubjects":"305"},{"groupId":"FG025","numSubjects":"302"},{"groupId":"FG026","numSubjects":"307"},{"groupId":"FG027","numSubjects":"307"},{"groupId":"FG028","numSubjects":"308"},{"groupId":"FG029","numSubjects":"313"},{"groupId":"FG030","numSubjects":"21"},{"groupId":"FG031","numSubjects":"19"},{"groupId":"FG032","numSubjects":"21"},{"groupId":"FG033","numSubjects":"20"},{"groupId":"FG034","numSubjects":"20"},{"groupId":"FG035","numSubjects":"21"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"421"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"726"},{"groupId":"FG003","numSubjects":"693"},{"groupId":"FG004","numSubjects":"69"},{"groupId":"FG005","numSubjects":"58"},{"groupId":"FG006","numSubjects":"197"},{"groupId":"FG007","numSubjects":"183"},{"groupId":"FG008","numSubjects":"193"},{"groupId":"FG009","numSubjects":"286"},{"groupId":"FG010","numSubjects":"293"},{"groupId":"FG011","numSubjects":"159"},{"groupId":"FG012","numSubjects":"28"},{"groupId":"FG013","numSubjects":"30"},{"groupId":"FG014","numSubjects":"27"},{"groupId":"FG015","numSubjects":"450"},{"groupId":"FG016","numSubjects":"151"},{"groupId":"FG017","numSubjects":"302"},{"groupId":"FG018","numSubjects":"19"},{"groupId":"FG019","numSubjects":"19"},{"groupId":"FG020","numSubjects":"19"},{"groupId":"FG021","numSubjects":"19"},{"groupId":"FG022","numSubjects":"20"},{"groupId":"FG023","numSubjects":"19"},{"groupId":"FG024","numSubjects":"292"},{"groupId":"FG025","numSubjects":"294"},{"groupId":"FG026","numSubjects":"291"},{"groupId":"FG027","numSubjects":"299"},{"groupId":"FG028","numSubjects":"294"},{"groupId":"FG029","numSubjects":"307"},{"groupId":"FG030","numSubjects":"21"},{"groupId":"FG031","numSubjects":"19"},{"groupId":"FG032","numSubjects":"21"},{"groupId":"FG033","numSubjects":"20"},{"groupId":"FG034","numSubjects":"20"},{"groupId":"FG035","numSubjects":"21"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4659"},{"groupId":"FG001","numSubjects":"5019"},{"groupId":"FG002","numSubjects":"27"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"7"},{"groupId":"FG006","numSubjects":"19"},{"groupId":"FG007","numSubjects":"14"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"29"},{"groupId":"FG010","numSubjects":"32"},{"groupId":"FG011","numSubjects":"51"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"3"},{"groupId":"FG015","numSubjects":"32"},{"groupId":"FG016","numSubjects":"8"},{"groupId":"FG017","numSubjects":"19"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"1"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"1"},{"groupId":"FG024","numSubjects":"13"},{"groupId":"FG025","numSubjects":"8"},{"groupId":"FG026","numSubjects":"16"},{"groupId":"FG027","numSubjects":"8"},{"groupId":"FG028","numSubjects":"14"},{"groupId":"FG029","numSubjects":"6"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"14"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"8"},{"groupId":"FG010","numSubjects":"10"},{"groupId":"FG011","numSubjects":"32"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"12"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"5"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"3"},{"groupId":"FG025","numSubjects":"1"},{"groupId":"FG026","numSubjects":"2"},{"groupId":"FG027","numSubjects":"2"},{"groupId":"FG028","numSubjects":"2"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"6"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"4"},{"groupId":"FG017","numSubjects":"6"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"1"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"4"},{"groupId":"FG025","numSubjects":"6"},{"groupId":"FG026","numSubjects":"5"},{"groupId":"FG027","numSubjects":"3"},{"groupId":"FG028","numSubjects":"4"},{"groupId":"FG029","numSubjects":"3"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"1"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"1"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"1"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"No longer meets eligibility criteria","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"3"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"1"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"1"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"2"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"5"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"62"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"15"},{"groupId":"FG010","numSubjects":"11"},{"groupId":"FG011","numSubjects":"7"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"11"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"5"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"5"},{"groupId":"FG025","numSubjects":"1"},{"groupId":"FG026","numSubjects":"5"},{"groupId":"FG027","numSubjects":"1"},{"groupId":"FG028","numSubjects":"4"},{"groupId":"FG029","numSubjects":"2"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Refused further study procedures","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Participants entered open label period","reasons":[{"groupId":"FG000","numSubjects":"4544"},{"groupId":"FG001","numSubjects":"4906"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Withdrawal by parent/guardian","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Medication error","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"4"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]}]},{"title":"Open-Label Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Participants received BNT162b2 30 mcg in blinded period then entered open label period.","numSubjects":"4544"},{"groupId":"FG001","comment":"Participants who received placebo in blinded period then either received BNT162b2 30 mcg in open label period or discontinued or completed the study without BNT162b2 administration.","numSubjects":"4906"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Received Open-label BNT162b2 30 mcg","achievements":[{"groupId":"FG000","numSubjects":"4544"},{"groupId":"FG001","numSubjects":"4430"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3272"},{"groupId":"FG001","numSubjects":"3878"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1272"},{"groupId":"FG001","numSubjects":"1028"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"377"},{"groupId":"FG001","numSubjects":"48"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"No longer meets eligibility criteria","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"621"},{"groupId":"FG001","numSubjects":"429"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"135"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Refused further study procedures","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Withdrawal by parent/guardian","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]},{"type":"Did not receive Open-label BNT162b2 30 mcg","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"476"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"},{"groupId":"FG029","numSubjects":"0"},{"groupId":"FG030","numSubjects":"0"},{"groupId":"FG031","numSubjects":"0"},{"groupId":"FG032","numSubjects":"0"},{"groupId":"FG033","numSubjects":"0"},{"groupId":"FG034","numSubjects":"0"},{"groupId":"FG035","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","groups":[{"id":"BG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."},{"id":"BG002","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"BG003","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."},{"id":"BG004","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG005","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG006","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG007","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"BG008","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG009","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"BG010","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"BG011","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."},{"id":"BG012","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG013","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG014","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG015","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG016","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG017","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG018","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG019","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG020","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG021","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG022","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG023","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG024","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG025","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG026","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG027","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG028","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG029","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG030","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG031","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG032","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG033","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG034","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG035","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"BG036","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"5080"},{"groupId":"BG001","value":"5041"},{"groupId":"BG002","value":"753"},{"groupId":"BG003","value":"732"},{"groupId":"BG004","value":"75"},{"groupId":"BG005","value":"65"},{"groupId":"BG006","value":"216"},{"groupId":"BG007","value":"197"},{"groupId":"BG008","value":"204"},{"groupId":"BG009","value":"315"},{"groupId":"BG010","value":"323"},{"groupId":"BG011","value":"210"},{"groupId":"BG012","value":"30"},{"groupId":"BG013","value":"30"},{"groupId":"BG014","value":"30"},{"groupId":"BG015","value":"482"},{"groupId":"BG016","value":"159"},{"groupId":"BG017","value":"321"},{"groupId":"BG018","value":"20"},{"groupId":"BG019","value":"20"},{"groupId":"BG020","value":"20"},{"groupId":"BG021","value":"20"},{"groupId":"BG022","value":"20"},{"groupId":"BG023","value":"20"},{"groupId":"BG024","value":"305"},{"groupId":"BG025","value":"302"},{"groupId":"BG026","value":"307"},{"groupId":"BG027","value":"307"},{"groupId":"BG028","value":"308"},{"groupId":"BG029","value":"313"},{"groupId":"BG030","value":"21"},{"groupId":"BG031","value":"19"},{"groupId":"BG032","value":"21"},{"groupId":"BG033","value":"20"},{"groupId":"BG034","value":"20"},{"groupId":"BG035","value":"21"},{"groupId":"BG036","value":"16347"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Adolescents (12-17 years)","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"233"},{"groupId":"BG003","value":"228"},{"groupId":"BG004","value":"75"},{"groupId":"BG005","value":"65"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"0"},{"groupId":"BG028","value":"0"},{"groupId":"BG029","value":"0"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"691"}]},{"title":"Adults (18-64 years)","measurements":[{"groupId":"BG000","value":"3859"},{"groupId":"BG001","value":"3811"},{"groupId":"BG002","value":"520"},{"groupId":"BG003","value":"504"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"216"},{"groupId":"BG007","value":"197"},{"groupId":"BG008","value":"204"},{"groupId":"BG009","value":"315"},{"groupId":"BG010","value":"323"},{"groupId":"BG011","value":"210"},{"groupId":"BG012","value":"30"},{"groupId":"BG013","value":"30"},{"groupId":"BG014","value":"30"},{"groupId":"BG015","value":"482"},{"groupId":"BG016","value":"159"},{"groupId":"BG017","value":"321"},{"groupId":"BG018","value":"6"},{"groupId":"BG019","value":"5"},{"groupId":"BG020","value":"5"},{"groupId":"BG021","value":"7"},{"groupId":"BG022","value":"5"},{"groupId":"BG023","value":"9"},{"groupId":"BG024","value":"126"},{"groupId":"BG025","value":"105"},{"groupId":"BG026","value":"121"},{"groupId":"BG027","value":"123"},{"groupId":"BG028","value":"112"},{"groupId":"BG029","value":"109"},{"groupId":"BG030","value":"6"},{"groupId":"BG031","value":"7"},{"groupId":"BG032","value":"6"},{"groupId":"BG033","value":"8"},{"groupId":"BG034","value":"9"},{"groupId":"BG035","value":"9"},{"groupId":"BG036","value":"11989"}]},{"title":"From 65-84 years","measurements":[{"groupId":"BG000","value":"1166"},{"groupId":"BG001","value":"1174"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"14"},{"groupId":"BG019","value":"15"},{"groupId":"BG020","value":"15"},{"groupId":"BG021","value":"13"},{"groupId":"BG022","value":"15"},{"groupId":"BG023","value":"10"},{"groupId":"BG024","value":"176"},{"groupId":"BG025","value":"196"},{"groupId":"BG026","value":"186"},{"groupId":"BG027","value":"183"},{"groupId":"BG028","value":"194"},{"groupId":"BG029","value":"199"},{"groupId":"BG030","value":"15"},{"groupId":"BG031","value":"12"},{"groupId":"BG032","value":"15"},{"groupId":"BG033","value":"12"},{"groupId":"BG034","value":"11"},{"groupId":"BG035","value":"12"},{"groupId":"BG036","value":"3633"}]},{"title":"85 years and over","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"1"},{"groupId":"BG024","value":"3"},{"groupId":"BG025","value":"1"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"1"},{"groupId":"BG028","value":"2"},{"groupId":"BG029","value":"5"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"34"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2624"},{"groupId":"BG001","value":"2526"},{"groupId":"BG002","value":"434"},{"groupId":"BG003","value":"447"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"33"},{"groupId":"BG006","value":"137"},{"groupId":"BG007","value":"119"},{"groupId":"BG008","value":"121"},{"groupId":"BG009","value":"152"},{"groupId":"BG010","value":"156"},{"groupId":"BG011","value":"106"},{"groupId":"BG012","value":"14"},{"groupId":"BG013","value":"17"},{"groupId":"BG014","value":"15"},{"groupId":"BG015","value":"269"},{"groupId":"BG016","value":"89"},{"groupId":"BG017","value":"180"},{"groupId":"BG018","value":"8"},{"groupId":"BG019","value":"9"},{"groupId":"BG020","value":"14"},{"groupId":"BG021","value":"12"},{"groupId":"BG022","value":"7"},{"groupId":"BG023","value":"11"},{"groupId":"BG024","value":"160"},{"groupId":"BG025","value":"157"},{"groupId":"BG026","value":"153"},{"groupId":"BG027","value":"154"},{"groupId":"BG028","value":"144"},{"groupId":"BG029","value":"162"},{"groupId":"BG030","value":"9"},{"groupId":"BG031","value":"9"},{"groupId":"BG032","value":"13"},{"groupId":"BG033","value":"10"},{"groupId":"BG034","value":"8"},{"groupId":"BG035","value":"12"},{"groupId":"BG036","value":"8528"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2456"},{"groupId":"BG001","value":"2515"},{"groupId":"BG002","value":"319"},{"groupId":"BG003","value":"285"},{"groupId":"BG004","value":"38"},{"groupId":"BG005","value":"32"},{"groupId":"BG006","value":"79"},{"groupId":"BG007","value":"78"},{"groupId":"BG008","value":"83"},{"groupId":"BG009","value":"163"},{"groupId":"BG010","value":"167"},{"groupId":"BG011","value":"104"},{"groupId":"BG012","value":"16"},{"groupId":"BG013","value":"13"},{"groupId":"BG014","value":"15"},{"groupId":"BG015","value":"213"},{"groupId":"BG016","value":"70"},{"groupId":"BG017","value":"141"},{"groupId":"BG018","value":"12"},{"groupId":"BG019","value":"11"},{"groupId":"BG020","value":"6"},{"groupId":"BG021","value":"8"},{"groupId":"BG022","value":"13"},{"groupId":"BG023","value":"9"},{"groupId":"BG024","value":"145"},{"groupId":"BG025","value":"145"},{"groupId":"BG026","value":"154"},{"groupId":"BG027","value":"153"},{"groupId":"BG028","value":"164"},{"groupId":"BG029","value":"151"},{"groupId":"BG030","value":"12"},{"groupId":"BG031","value":"10"},{"groupId":"BG032","value":"8"},{"groupId":"BG033","value":"10"},{"groupId":"BG034","value":"12"},{"groupId":"BG035","value":"9"},{"groupId":"BG036","value":"7819"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"3998"},{"groupId":"BG001","value":"4002"},{"groupId":"BG002","value":"491"},{"groupId":"BG003","value":"493"},{"groupId":"BG004","value":"55"},{"groupId":"BG005","value":"50"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"237"},{"groupId":"BG010","value":"224"},{"groupId":"BG011","value":"31"},{"groupId":"BG012","value":"25"},{"groupId":"BG013","value":"24"},{"groupId":"BG014","value":"26"},{"groupId":"BG015","value":"389"},{"groupId":"BG016","value":"124"},{"groupId":"BG017","value":"250"},{"groupId":"BG018","value":"16"},{"groupId":"BG019","value":"19"},{"groupId":"BG020","value":"15"},{"groupId":"BG021","value":"17"},{"groupId":"BG022","value":"14"},{"groupId":"BG023","value":"16"},{"groupId":"BG024","value":"268"},{"groupId":"BG025","value":"254"},{"groupId":"BG026","value":"261"},{"groupId":"BG027","value":"262"},{"groupId":"BG028","value":"277"},{"groupId":"BG029","value":"272"},{"groupId":"BG030","value":"21"},{"groupId":"BG031","value":"19"},{"groupId":"BG032","value":"21"},{"groupId":"BG033","value":"20"},{"groupId":"BG034","value":"20"},{"groupId":"BG035","value":"21"},{"groupId":"BG036","value":"12265"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"470"},{"groupId":"BG001","value":"457"},{"groupId":"BG002","value":"159"},{"groupId":"BG003","value":"155"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"176"},{"groupId":"BG007","value":"172"},{"groupId":"BG008","value":"178"},{"groupId":"BG009","value":"21"},{"groupId":"BG010","value":"34"},{"groupId":"BG011","value":"155"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"34"},{"groupId":"BG016","value":"10"},{"groupId":"BG017","value":"32"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"2"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"2"},{"groupId":"BG023","value":"1"},{"groupId":"BG024","value":"19"},{"groupId":"BG025","value":"22"},{"groupId":"BG026","value":"23"},{"groupId":"BG027","value":"20"},{"groupId":"BG028","value":"13"},{"groupId":"BG029","value":"19"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"2203"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"3"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"2"},{"groupId":"BG028","value":"0"},{"groupId":"BG029","value":"1"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"206"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"288"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"42"},{"groupId":"BG010","value":"45"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"42"},{"groupId":"BG016","value":"20"},{"groupId":"BG017","value":"25"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"2"},{"groupId":"BG021","value":"1"},{"groupId":"BG022","value":"4"},{"groupId":"BG023","value":"3"},{"groupId":"BG024","value":"13"},{"groupId":"BG025","value":"20"},{"groupId":"BG026","value":"16"},{"groupId":"BG027","value":"20"},{"groupId":"BG028","value":"16"},{"groupId":"BG029","value":"17"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"994"}]}]},{"title":"Native Hawaiian or other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"2"},{"groupId":"BG025","value":"1"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"0"},{"groupId":"BG028","value":"0"},{"groupId":"BG029","value":"0"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"34"}]}]},{"title":"Multiracial","categories":[{"measurements":[{"groupId":"BG000","value":"209"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"22"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"8"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"3"},{"groupId":"BG025","value":"5"},{"groupId":"BG026","value":"6"},{"groupId":"BG027","value":"3"},{"groupId":"BG028","value":"1"},{"groupId":"BG029","value":"3"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"559"}]}]},{"title":"Not reported","categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"2"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"1"},{"groupId":"BG027","value":"0"},{"groupId":"BG028","value":"1"},{"groupId":"BG029","value":"1"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"86"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Hispanic/Latino","categories":[{"measurements":[{"groupId":"BG000","value":"759"},{"groupId":"BG001","value":"750"},{"groupId":"BG002","value":"152"},{"groupId":"BG003","value":"150"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"48"},{"groupId":"BG010","value":"46"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"66"},{"groupId":"BG016","value":"17"},{"groupId":"BG017","value":"39"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"4"},{"groupId":"BG021","value":"3"},{"groupId":"BG022","value":"2"},{"groupId":"BG023","value":"4"},{"groupId":"BG024","value":"57"},{"groupId":"BG025","value":"38"},{"groupId":"BG026","value":"44"},{"groupId":"BG027","value":"46"},{"groupId":"BG028","value":"45"},{"groupId":"BG029","value":"44"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"0"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"2369"}]}]},{"title":"Non-Hispanic/non-Latino","categories":[{"measurements":[{"groupId":"BG000","value":"4309"},{"groupId":"BG001","value":"4283"},{"groupId":"BG002","value":"595"},{"groupId":"BG003","value":"577"},{"groupId":"BG004","value":"59"},{"groupId":"BG005","value":"53"},{"groupId":"BG006","value":"209"},{"groupId":"BG007","value":"196"},{"groupId":"BG008","value":"200"},{"groupId":"BG009","value":"266"},{"groupId":"BG010","value":"277"},{"groupId":"BG011","value":"202"},{"groupId":"BG012","value":"27"},{"groupId":"BG013","value":"26"},{"groupId":"BG014","value":"27"},{"groupId":"BG015","value":"413"},{"groupId":"BG016","value":"142"},{"groupId":"BG017","value":"282"},{"groupId":"BG018","value":"19"},{"groupId":"BG019","value":"19"},{"groupId":"BG020","value":"16"},{"groupId":"BG021","value":"17"},{"groupId":"BG022","value":"18"},{"groupId":"BG023","value":"16"},{"groupId":"BG024","value":"248"},{"groupId":"BG025","value":"264"},{"groupId":"BG026","value":"263"},{"groupId":"BG027","value":"261"},{"groupId":"BG028","value":"263"},{"groupId":"BG029","value":"269"},{"groupId":"BG030","value":"21"},{"groupId":"BG031","value":"19"},{"groupId":"BG032","value":"21"},{"groupId":"BG033","value":"20"},{"groupId":"BG034","value":"19"},{"groupId":"BG035","value":"21"},{"groupId":"BG036","value":"13937"}]}]},{"title":"Not reported","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"},{"groupId":"BG024","value":"0"},{"groupId":"BG025","value":"0"},{"groupId":"BG026","value":"0"},{"groupId":"BG027","value":"0"},{"groupId":"BG028","value":"0"},{"groupId":"BG029","value":"0"},{"groupId":"BG030","value":"0"},{"groupId":"BG031","value":"0"},{"groupId":"BG032","value":"0"},{"groupId":"BG033","value":"0"},{"groupId":"BG034","value":"1"},{"groupId":"BG035","value":"0"},{"groupId":"BG036","value":"41"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.","populationDescription":"SSA evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. Human Immunodeficiency Virus (HIV) positive participants were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of first Covid-19 cases/1000 PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year [PY]) for BNT162b2 was 0.823 and for Placebo was 0.792","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4659"},{"groupId":"OG001","value":"4614"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.290"},{"groupId":"OG001","value":"155.303"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Sided CI for Relative vaccine efficacy (RVE) is derived based on the Clopper and Pearson method adjusted for surveillance time.","nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"95.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"89.5","ciUpperLimit":"98.3"}]},{"type":"PRIMARY","title":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.","populationDescription":"SSA evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'Number of Subjects Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of first Covid-19 cases/1000 PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 0.871 and for Placebo was 0.835","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4934"},{"groupId":"OG001","value":"4863"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.037"},{"groupId":"OG001","value":"148.503"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Sided CI for RVE is derived based on the Clopper and Pearson method adjusted for surveillance time.","nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"94.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"88.5","ciUpperLimit":"97.9"}]},{"type":"PRIMARY","title":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.","populationDescription":"SSA evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'Number of participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of first Covid-19 cases/1000 PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.098 and for Placebo was 0.932","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4639"},{"groupId":"OG001","value":"4601"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.377"},{"groupId":"OG001","value":"158.798"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Sided CI for Relative Vaccine Efficacy (RVE) is derived based on the Clopper and Pearson method adjusted for surveillance time.","nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"63.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"51.1","ciUpperLimit":"73.5"}]},{"type":"PRIMARY","title":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population","description":"Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.","populationDescription":"SSA evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'Number of participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of first Covid-19 cases/1000 PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.173 and for Placebo was 0.989","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4903"},{"groupId":"OG001","value":"4846"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.118"},{"groupId":"OG001","value":"151.668"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Sided CI for RVE is derived based on the Clopper and Pearson method adjusted for surveillance time.","nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"62.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49.5","ciUpperLimit":"72.2"}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants Reporting Adverse Events","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. HIV positive participants were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From booster dose (Day 1) to 1 month after booster dose","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5054"},{"groupId":"OG001","value":"5016"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","lowerLimit":"25.0","upperLimit":"27.5"},{"groupId":"OG001","value":"7.1","lowerLimit":"6.4","upperLimit":"7.8"}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)","description":"An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. HIV positive participants were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"BNT162b2 30 mcg, Placebo then BNT162b2 30 mcg: From BNT162b2 dose to 6 months after BNT162b2 dose; Placebo: From placebo dose to unblinding for original placebo participants. Median blinded follow-up period for Placebo group=2.8 months","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."},{"id":"OG002","title":"SSA: Original Placebo/BNT162b2 30 mcg: Open Label Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly and then one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5054"},{"groupId":"OG001","value":"5016"},{"groupId":"OG002","value":"4405"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.1","upperLimit":"1.8"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.6","upperLimit":"1.1"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.7","upperLimit":"1.3"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1","description":"Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-dose on Day 1 (Vaccination 1)","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"751"},{"groupId":"OG001","value":"730"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.2","upperLimit":"1.5"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.4"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1","description":"Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 5 days after Vaccination 1","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"719"},{"groupId":"OG001","value":"693"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.4","upperLimit":"2.0"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)","description":"Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-Vaccination 2 (1 month after Vaccination 1)","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"628"},{"groupId":"OG001","value":"600"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.4","upperLimit":"2.3"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2","description":"Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 5 days after vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"667"},{"groupId":"OG001","value":"634"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.7","upperLimit":"2.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.1"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2","description":"Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"645"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.2","upperLimit":"1.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.1"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 1","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"728"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"4.2","upperLimit":"7.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.4"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"3.1","upperLimit":"6.1"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.1"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"4.9","upperLimit":"8.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.4"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.5","upperLimit":"6.8"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.7","upperLimit":"2.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"74.4","lowerLimit":"71.1","upperLimit":"77.5"},{"groupId":"OG001","value":"13.9","lowerLimit":"11.4","upperLimit":"16.6"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"48.7","lowerLimit":"45.1","upperLimit":"52.4"},{"groupId":"OG001","value":"12.2","lowerLimit":"9.9","upperLimit":"14.8"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.4","lowerLimit":"22.3","upperLimit":"28.7"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.9","upperLimit":"2.9"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Pain at injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"706"},{"groupId":"OG001","value":"672"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.2","upperLimit":"1.6"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.2","upperLimit":"6.5"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"2.8","lowerLimit":"1.7","upperLimit":"4.4"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"2.7"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.1"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"5.5","lowerLimit":"3.9","upperLimit":"7.5"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.2","upperLimit":"5.1"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.0","upperLimit":"3.3"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"6.8","upperLimit":"11.1"},{"groupId":"OG001","value":"71.7","lowerLimit":"68.2","upperLimit":"75.1"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"4.9","upperLimit":"8.8"},{"groupId":"OG001","value":"40.3","lowerLimit":"36.6","upperLimit":"44.1"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.2","upperLimit":"3.5"},{"groupId":"OG001","value":"30.5","lowerLimit":"27.0","upperLimit":"34.1"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.3","upperLimit":"1.9"}]}]},{"title":"Pain at injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 1","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"728"}]}],"classes":[{"title":"Fever: >=38 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"4.4","upperLimit":"8.0"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.1","upperLimit":"3.2"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"2.8","upperLimit":"5.8"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.7","upperLimit":"2.5"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.9","upperLimit":"3.0"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"54.2","lowerLimit":"50.6","upperLimit":"57.8"},{"groupId":"OG001","value":"31.9","lowerLimit":"28.5","upperLimit":"35.4"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"27.4","lowerLimit":"24.3","upperLimit":"30.8"},{"groupId":"OG001","value":"19.5","lowerLimit":"16.7","upperLimit":"22.6"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.3","lowerLimit":"22.2","upperLimit":"28.6"},{"groupId":"OG001","value":"12.2","lowerLimit":"9.9","upperLimit":"14.8"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.7","upperLimit":"2.6"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"39.0","upperLimit":"46.2"},{"groupId":"OG001","value":"28.3","lowerLimit":"25.0","upperLimit":"31.7"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"24.2","lowerLimit":"21.2","upperLimit":"27.5"},{"groupId":"OG001","value":"18.0","lowerLimit":"15.3","upperLimit":"21.0"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"14.6","upperLimit":"20.2"},{"groupId":"OG001","value":"10.0","lowerLimit":"7.9","upperLimit":"12.4"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.1"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"14.5","upperLimit":"20.0"},{"groupId":"OG001","value":"5.9","lowerLimit":"4.3","upperLimit":"7.9"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"8.5","upperLimit":"13.0"},{"groupId":"OG001","value":"4.4","lowerLimit":"3.0","upperLimit":"6.1"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"4.7","upperLimit":"8.3"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.8","upperLimit":"2.7"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.1","upperLimit":"4.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"1.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.7","upperLimit":"4.3"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.2","upperLimit":"1.6"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.6","upperLimit":"9.5"},{"groupId":"OG001","value":"7.4","lowerLimit":"5.6","upperLimit":"9.6"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"4.8","upperLimit":"8.4"},{"groupId":"OG001","value":"6.0","lowerLimit":"4.4","upperLimit":"8.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.4","upperLimit":"1.9"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.7","upperLimit":"2.5"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"27.6","lowerLimit":"24.4","upperLimit":"30.9"},{"groupId":"OG001","value":"7.7","lowerLimit":"5.9","upperLimit":"9.9"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"14.1","lowerLimit":"11.6","upperLimit":"16.8"},{"groupId":"OG001","value":"5.1","lowerLimit":"3.6","upperLimit":"6.9"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"10.9","upperLimit":"15.9"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"3.9"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.9","lowerLimit":"10.5","upperLimit":"15.5"},{"groupId":"OG001","value":"4.5","lowerLimit":"3.1","upperLimit":"6.3"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"6.4","upperLimit":"10.5"},{"groupId":"OG001","value":"3.0","lowerLimit":"1.9","upperLimit":"4.5"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"2.9","upperLimit":"6.0"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.8","upperLimit":"2.7"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"706"},{"groupId":"OG001","value":"672"}]}],"classes":[{"title":"Fever: >=38 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"4.3","lowerLimit":"2.9","upperLimit":"6.1"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"4.0"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.6","upperLimit":"2.5"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.3"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.6","lowerLimit":"14.8","upperLimit":"20.6"},{"groupId":"OG001","value":"47.3","lowerLimit":"43.5","upperLimit":"51.2"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"6.7","upperLimit":"11.0"},{"groupId":"OG001","value":"18.8","lowerLimit":"15.9","upperLimit":"21.9"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"6.5","upperLimit":"10.8"},{"groupId":"OG001","value":"27.1","lowerLimit":"23.8","upperLimit":"30.6"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"2.7"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"15.1","upperLimit":"20.9"},{"groupId":"OG001","value":"39.7","lowerLimit":"36.0","upperLimit":"43.5"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"8.2","upperLimit":"12.8"},{"groupId":"OG001","value":"19.8","lowerLimit":"16.8","upperLimit":"23.0"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"5.4","upperLimit":"9.4"},{"groupId":"OG001","value":"19.0","lowerLimit":"16.1","upperLimit":"22.2"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.3","upperLimit":"1.9"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"2.4","upperLimit":"5.3"},{"groupId":"OG001","value":"22.3","lowerLimit":"19.2","upperLimit":"25.7"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.3","upperLimit":"3.7"},{"groupId":"OG001","value":"13.2","lowerLimit":"10.8","upperLimit":"16.0"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.2"},{"groupId":"OG001","value":"8.8","lowerLimit":"6.8","upperLimit":"11.2"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.1"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.4","upperLimit":"2.0"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.0","upperLimit":"3.3"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.2","upperLimit":"1.6"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.9","upperLimit":"3.1"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"2.1","upperLimit":"4.8"},{"groupId":"OG001","value":"8.0","lowerLimit":"6.1","upperLimit":"10.4"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.2","upperLimit":"3.5"},{"groupId":"OG001","value":"6.5","lowerLimit":"4.8","upperLimit":"8.7"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.2"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"2.7"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"3.1","upperLimit":"6.3"},{"groupId":"OG001","value":"29.2","lowerLimit":"25.8","upperLimit":"32.8"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.3","upperLimit":"3.7"},{"groupId":"OG001","value":"15.9","lowerLimit":"13.2","upperLimit":"18.9"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.2","upperLimit":"3.5"},{"groupId":"OG001","value":"12.9","lowerLimit":"10.5","upperLimit":"15.7"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.1"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"2.0","upperLimit":"4.7"},{"groupId":"OG001","value":"12.2","lowerLimit":"9.8","upperLimit":"14.9"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.8","upperLimit":"2.8"},{"groupId":"OG001","value":"7.4","lowerLimit":"5.6","upperLimit":"9.7"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.8","upperLimit":"2.8"},{"groupId":"OG001","value":"4.8","lowerLimit":"3.3","upperLimit":"6.7"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participant who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Vaccination 1 up to 1 Month After Vaccination 1","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"753"},{"groupId":"OG001","value":"732"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"7.4","upperLimit":"11.7"},{"groupId":"OG001","value":"10.4","lowerLimit":"8.3","upperLimit":"12.8"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants who did not receive Vaccination 2 or who received an incorrect vaccine at Vaccination 2 were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Vaccination 2 up to 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"731"},{"groupId":"OG001","value":"700"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.1","upperLimit":"7.5"},{"groupId":"OG001","value":"7.4","lowerLimit":"5.6","upperLimit":"9.6"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Vaccination 1 up to 1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"753"},{"groupId":"OG001","value":"732"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for the specified outcome measure and received two doses of study vaccination for SSB.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Vaccination 2 up to 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSB: BNT162b2 30 mcg Then Placebo","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 1 and received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 28."},{"id":"OG001","title":"SSB: Placebo Then BNT162b2 30 mcg","description":"Participants received placebo (normal saline solution of 0.9 % sodium chloride) intramuscularly on Day 1 and one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm on Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"731"},{"groupId":"OG001","value":"700"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"SSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"1.7","upperLimit":"15.2"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"4.7","lowerLimit":"1.0","upperLimit":"13.1"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.3","upperLimit":"9.3"},{"groupId":"OG001","value":"9.4","lowerLimit":"3.5","upperLimit":"19.3"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.3","upperLimit":"9.3"},{"groupId":"OG001","value":"6.3","lowerLimit":"1.7","upperLimit":"15.2"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.4","upperLimit":"10.8"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"56.0","lowerLimit":"44.1","upperLimit":"67.5"},{"groupId":"OG001","value":"78.1","lowerLimit":"66.0","upperLimit":"87.5"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"28.9","upperLimit":"52.0"},{"groupId":"OG001","value":"46.9","lowerLimit":"34.3","upperLimit":"59.8"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"8.6","upperLimit":"26.3"},{"groupId":"OG001","value":"31.3","lowerLimit":"20.2","upperLimit":"44.1"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]}]},{"type":"PRIMARY","title":"SSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (deg C) and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' (N) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.8","upperLimit":"11.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"1.7","upperLimit":"15.2"}]}]},{"title":"Fever: >=38.0°C to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.3","upperLimit":"9.3"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.4","upperLimit":"10.8"}]}]},{"title":"Fever: >38.4°C to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Fever: >38.9°C to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"49.3","lowerLimit":"37.6","upperLimit":"61.1"},{"groupId":"OG001","value":"54.7","lowerLimit":"41.7","upperLimit":"67.2"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"13.8","upperLimit":"33.8"},{"groupId":"OG001","value":"25.0","lowerLimit":"15.0","upperLimit":"37.4"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.3","lowerLimit":"16.0","upperLimit":"36.7"},{"groupId":"OG001","value":"26.6","lowerLimit":"16.3","upperLimit":"39.1"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.4","upperLimit":"10.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"41.3","lowerLimit":"30.1","upperLimit":"53.3"},{"groupId":"OG001","value":"53.1","lowerLimit":"40.2","upperLimit":"65.7"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.3","lowerLimit":"12.7","upperLimit":"32.3"},{"groupId":"OG001","value":"31.3","lowerLimit":"20.2","upperLimit":"44.1"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"11.6","upperLimit":"30.8"},{"groupId":"OG001","value":"20.3","lowerLimit":"11.3","upperLimit":"32.2"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"6.6","upperLimit":"23.2"},{"groupId":"OG001","value":"23.4","lowerLimit":"13.8","upperLimit":"35.7"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"1.5","upperLimit":"13.1"},{"groupId":"OG001","value":"12.5","lowerLimit":"5.6","upperLimit":"23.2"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"3.0","upperLimit":"16.6"},{"groupId":"OG001","value":"10.9","lowerLimit":"4.5","upperLimit":"21.2"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.4","upperLimit":"10.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.0","upperLimit":"8.4"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.8","upperLimit":"11.2"},{"groupId":"OG001","value":"9.4","lowerLimit":"3.5","upperLimit":"19.3"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.3","upperLimit":"9.3"},{"groupId":"OG001","value":"9.4","lowerLimit":"3.5","upperLimit":"19.3"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.0","upperLimit":"7.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"14.9","upperLimit":"35.3"},{"groupId":"OG001","value":"37.5","lowerLimit":"25.7","upperLimit":"50.5"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.8","upperLimit":"11.2"},{"groupId":"OG001","value":"20.3","lowerLimit":"11.3","upperLimit":"32.2"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"11.6","upperLimit":"30.8"},{"groupId":"OG001","value":"17.2","lowerLimit":"8.9","upperLimit":"28.7"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"7.6","upperLimit":"24.7"},{"groupId":"OG001","value":"15.6","lowerLimit":"7.8","upperLimit":"26.9"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"1.5","upperLimit":"13.1"},{"groupId":"OG001","value":"10.9","lowerLimit":"4.5","upperLimit":"21.2"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"3.8","upperLimit":"18.3"},{"groupId":"OG001","value":"4.7","lowerLimit":"1.0","upperLimit":"13.1"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"5.6"}]}]}]},{"type":"PRIMARY","title":"SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From booster dose (Day 1) up to 1 month after booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.8","upperLimit":"11.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"2.5","upperLimit":"17.0"}]}]}]},{"type":"PRIMARY","title":"SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From booster dose (Day 1) up to 6 months after booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.0","upperLimit":"8.3"}]}]}]},{"type":"PRIMARY","title":"SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they are randomized, have valid and determinate immunogenicity result for Visit 303 (1 month after booster dose), have blood sample collected within an appropriate window (within 28-42 days after booster dose), and have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At baseline (pre-dose)","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1337.2","lowerLimit":"941.5","upperLimit":"1899.2"},{"groupId":"OG001","value":"1648.4","lowerLimit":"1087.5","upperLimit":"2498.6"}]}]}]},{"type":"PRIMARY","title":"SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they are randomized, have valid and determinate immunogenicity result for Visit 303 (1 month after booster dose), have blood sample collected within an appropriate window (within 28-42 days after booster dose), and have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11672.4","lowerLimit":"9754.8","upperLimit":"13967.0"},{"groupId":"OG001","value":"15680.7","lowerLimit":"13308.9","upperLimit":"18475.2"}]}]}]},{"type":"PRIMARY","title":"SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they are randomized, have valid and determinate immunogenicity result for Visit 303 (1 month after booster dose), have blood sample collected within an appropriate window (within 28-42 days after booster dose), and have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From baseline to 1 month after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"6.4","upperLimit":"11.6"},{"groupId":"OG001","value":"9.5","lowerLimit":"6.5","upperLimit":"13.9"}]}]}]},{"type":"PRIMARY","title":"SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they are randomized, have valid and determinate immunogenicity result for Visit 303 (1 month after booster dose), have blood sample collected within an appropriate window (within 28-42 days after booster dose), and have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","lowerLimit":"54.9","upperLimit":"78.8"},{"groupId":"OG001","value":"66.7","lowerLimit":"52.5","upperLimit":"78.9"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants who received Vaccination 1 and 'Number Analyzed (n)' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG004","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG005","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"1.4","upperLimit":"6.8"},{"groupId":"OG001","value":"5.7","lowerLimit":"2.9","upperLimit":"10.0"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.8","upperLimit":"5.7"},{"groupId":"OG003","value":"7.1","lowerLimit":"4.5","upperLimit":"10.7"},{"groupId":"OG004","value":"4.3","lowerLimit":"2.3","upperLimit":"7.2"},{"groupId":"OG005","value":"5.4","lowerLimit":"2.6","upperLimit":"9.7"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"4.2","lowerLimit":"1.8","upperLimit":"8.0"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"4.4","lowerLimit":"2.4","upperLimit":"7.4"},{"groupId":"OG004","value":"3.9","lowerLimit":"2.1","upperLimit":"6.8"},{"groupId":"OG005","value":"3.2","lowerLimit":"1.2","upperLimit":"6.9"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.3","upperLimit":"4.2"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.3","upperLimit":"4.5"},{"groupId":"OG002","value":"1.5","lowerLimit":"0.3","upperLimit":"4.3"},{"groupId":"OG003","value":"2.7","lowerLimit":"1.2","upperLimit":"5.3"},{"groupId":"OG004","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG005","value":"2.2","lowerLimit":"0.6","upperLimit":"5.4"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"4.9","upperLimit":"12.8"},{"groupId":"OG001","value":"7.3","lowerLimit":"4.0","upperLimit":"11.9"},{"groupId":"OG002","value":"5.5","lowerLimit":"2.8","upperLimit":"9.6"},{"groupId":"OG003","value":"8.5","lowerLimit":"5.6","upperLimit":"12.3"},{"groupId":"OG004","value":"8.9","lowerLimit":"5.9","upperLimit":"12.7"},{"groupId":"OG005","value":"11.3","lowerLimit":"7.1","upperLimit":"16.7"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"2.0","upperLimit":"8.1"},{"groupId":"OG001","value":"4.2","lowerLimit":"1.8","upperLimit":"8.0"},{"groupId":"OG002","value":"4.5","lowerLimit":"2.1","upperLimit":"8.3"},{"groupId":"OG003","value":"5.4","lowerLimit":"3.1","upperLimit":"8.7"},{"groupId":"OG004","value":"6.9","lowerLimit":"4.3","upperLimit":"10.4"},{"groupId":"OG005","value":"6.5","lowerLimit":"3.4","upperLimit":"11.0"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"1.7","upperLimit":"7.5"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.9","upperLimit":"6.0"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"3.1","lowerLimit":"1.4","upperLimit":"5.7"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.7","upperLimit":"4.2"},{"groupId":"OG005","value":"4.8","lowerLimit":"2.2","upperLimit":"9.0"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Injection site pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","lowerLimit":"39.4","upperLimit":"53.4"},{"groupId":"OG001","value":"42.7","lowerLimit":"35.6","upperLimit":"50.0"},{"groupId":"OG002","value":"42.3","lowerLimit":"35.4","upperLimit":"49.4"},{"groupId":"OG003","value":"78.2","lowerLimit":"73.1","upperLimit":"82.8"},{"groupId":"OG004","value":"78.9","lowerLimit":"73.9","upperLimit":"83.4"},{"groupId":"OG005","value":"54.3","lowerLimit":"46.8","upperLimit":"61.5"}]}]},{"title":"Injection site pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","lowerLimit":"24.7","upperLimit":"37.7"},{"groupId":"OG001","value":"27.1","lowerLimit":"20.9","upperLimit":"34.0"},{"groupId":"OG002","value":"32.3","lowerLimit":"25.9","upperLimit":"39.3"},{"groupId":"OG003","value":"59.2","lowerLimit":"53.3","upperLimit":"64.9"},{"groupId":"OG004","value":"61.5","lowerLimit":"55.8","upperLimit":"67.0"},{"groupId":"OG005","value":"27.7","lowerLimit":"21.4","upperLimit":"34.6"}]}]},{"title":"Injection site pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"10.4","upperLimit":"20.6"},{"groupId":"OG001","value":"14.1","lowerLimit":"9.5","upperLimit":"19.8"},{"groupId":"OG002","value":"9.5","lowerLimit":"5.8","upperLimit":"14.4"},{"groupId":"OG003","value":"18.4","lowerLimit":"14.1","upperLimit":"23.3"},{"groupId":"OG004","value":"16.4","lowerLimit":"12.5","upperLimit":"21.1"},{"groupId":"OG005","value":"26.1","lowerLimit":"19.9","upperLimit":"33.0"}]}]},{"title":"Injection site pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.3","upperLimit":"4.5"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG003","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Injection site pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.9"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants who received Vaccination 2 and 'Number Analyzed (n)' signifies participants evaluable for specified rows and received two doses of study vaccination for SSD. Participants of SSD: Cohort 1: Group 1 did not receive Vaccination 2 and therefore were not analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG002","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG003","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"2.7","upperLimit":"10.6"},{"groupId":"OG001","value":"5.1","lowerLimit":"2.5","upperLimit":"9.2"},{"groupId":"OG002","value":"4.1","lowerLimit":"1.9","upperLimit":"7.7"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.6","upperLimit":"9.1"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.0"},{"groupId":"OG001","value":"3.6","lowerLimit":"1.4","upperLimit":"7.2"},{"groupId":"OG002","value":"4.1","lowerLimit":"1.9","upperLimit":"7.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.3","upperLimit":"4.4"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","lowerLimit":"5.0","upperLimit":"14.5"},{"groupId":"OG001","value":"4.1","lowerLimit":"1.8","upperLimit":"7.9"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.6","upperLimit":"10.6"},{"groupId":"OG003","value":"9.2","lowerLimit":"5.0","upperLimit":"15.3"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"3.5","upperLimit":"12.2"},{"groupId":"OG001","value":"2.0","lowerLimit":"0.6","upperLimit":"5.1"},{"groupId":"OG002","value":"5.5","lowerLimit":"2.9","upperLimit":"9.5"},{"groupId":"OG003","value":"5.7","lowerLimit":"2.5","upperLimit":"10.9"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG001","value":"2.0","lowerLimit":"0.6","upperLimit":"5.1"},{"groupId":"OG002","value":"0.9","lowerLimit":"0.1","upperLimit":"3.3"},{"groupId":"OG003","value":"3.5","lowerLimit":"1.2","upperLimit":"8.1"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Injection site pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","lowerLimit":"32.4","upperLimit":"48.2"},{"groupId":"OG001","value":"74.5","lowerLimit":"67.8","upperLimit":"80.4"},{"groupId":"OG002","value":"70.6","lowerLimit":"64.1","upperLimit":"76.6"},{"groupId":"OG003","value":"34.5","lowerLimit":"26.7","upperLimit":"42.9"}]}]},{"title":"Injection site pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","lowerLimit":"22.9","upperLimit":"37.8"},{"groupId":"OG001","value":"55.6","lowerLimit":"48.4","upperLimit":"62.7"},{"groupId":"OG002","value":"57.8","lowerLimit":"50.9","upperLimit":"64.4"},{"groupId":"OG003","value":"21.1","lowerLimit":"14.7","upperLimit":"28.8"}]}]},{"title":"Injection site pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"5.9","upperLimit":"16.0"},{"groupId":"OG001","value":"18.9","lowerLimit":"13.7","upperLimit":"25.1"},{"groupId":"OG002","value":"12.4","lowerLimit":"8.3","upperLimit":"17.5"},{"groupId":"OG003","value":"13.4","lowerLimit":"8.3","upperLimit":"20.1"}]}]},{"title":"Injection site pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Injection site pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"218"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\\> 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants who received Vaccination 3. Participants of SSD: Cohort 1: Group 1, Group 2 and SSD Cohort 2: Group 3, Group 4 did not receive Vaccination 3 and therefore were not analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 3","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.1"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.1","upperLimit":"7.4"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"6.1","upperLimit":"16.3"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.1","upperLimit":"7.4"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"3.6","upperLimit":"12.4"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"39.0","lowerLimit":"31.2","upperLimit":"47.1"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"13.5","upperLimit":"26.6"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"13.0","upperLimit":"25.9"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C, categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants who received Vaccination 1.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG004","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG005","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"304"},{"groupId":"OG005","value":"186"}]}],"classes":[{"title":"Fever: Any","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.0","upperLimit":"9.9"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.9","upperLimit":"6.0"},{"groupId":"OG002","value":"5.0","lowerLimit":"2.4","upperLimit":"9.0"},{"groupId":"OG003","value":"8.8","lowerLimit":"5.9","upperLimit":"12.7"},{"groupId":"OG004","value":"7.2","lowerLimit":"4.6","upperLimit":"10.8"},{"groupId":"OG005","value":"4.8","lowerLimit":"2.2","upperLimit":"9.0"}]}]},{"title":"Fever: >=38.0 deg C to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"2.0","upperLimit":"8.1"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.3","upperLimit":"4.5"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.8","upperLimit":"5.7"},{"groupId":"OG003","value":"4.8","lowerLimit":"2.6","upperLimit":"7.9"},{"groupId":"OG004","value":"3.9","lowerLimit":"2.1","upperLimit":"6.8"},{"groupId":"OG005","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"}]}]},{"title":"Fever: >38.4 deg C to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"1.5","lowerLimit":"0.3","upperLimit":"4.3"},{"groupId":"OG003","value":"3.4","lowerLimit":"1.6","upperLimit":"6.2"},{"groupId":"OG004","value":"3.0","lowerLimit":"1.4","upperLimit":"5.5"},{"groupId":"OG005","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"}]}]},{"title":"Fever: >38.9 deg C to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG004","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG005","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Fever: Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"32.4","lowerLimit":"26.0","upperLimit":"39.2"},{"groupId":"OG001","value":"26.6","lowerLimit":"20.5","upperLimit":"33.4"},{"groupId":"OG002","value":"28.4","lowerLimit":"22.2","upperLimit":"35.1"},{"groupId":"OG003","value":"64.6","lowerLimit":"58.9","upperLimit":"70.1"},{"groupId":"OG004","value":"60.5","lowerLimit":"54.8","upperLimit":"66.1"},{"groupId":"OG005","value":"39.2","lowerLimit":"32.2","upperLimit":"46.7"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"13.8","upperLimit":"24.8"},{"groupId":"OG001","value":"14.6","lowerLimit":"9.9","upperLimit":"20.4"},{"groupId":"OG002","value":"16.4","lowerLimit":"11.6","upperLimit":"22.3"},{"groupId":"OG003","value":"26.5","lowerLimit":"21.6","upperLimit":"32.0"},{"groupId":"OG004","value":"29.3","lowerLimit":"24.2","upperLimit":"34.7"},{"groupId":"OG005","value":"16.7","lowerLimit":"11.6","upperLimit":"22.8"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"8.4","upperLimit":"17.9"},{"groupId":"OG001","value":"12.0","lowerLimit":"7.7","upperLimit":"17.4"},{"groupId":"OG002","value":"10.9","lowerLimit":"7.0","upperLimit":"16.1"},{"groupId":"OG003","value":"34.7","lowerLimit":"29.3","upperLimit":"40.4"},{"groupId":"OG004","value":"28.9","lowerLimit":"23.9","upperLimit":"34.4"},{"groupId":"OG005","value":"22.0","lowerLimit":"16.3","upperLimit":"28.7"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"3.4","lowerLimit":"1.6","upperLimit":"6.2"},{"groupId":"OG004","value":"2.3","lowerLimit":"0.9","upperLimit":"4.7"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"30.9","lowerLimit":"24.7","upperLimit":"37.7"},{"groupId":"OG001","value":"27.1","lowerLimit":"20.9","upperLimit":"34.0"},{"groupId":"OG002","value":"27.4","lowerLimit":"21.3","upperLimit":"34.1"},{"groupId":"OG003","value":"47.6","lowerLimit":"41.8","upperLimit":"53.5"},{"groupId":"OG004","value":"45.1","lowerLimit":"39.4","upperLimit":"50.8"},{"groupId":"OG005","value":"27.4","lowerLimit":"21.1","upperLimit":"34.4"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.3","lowerLimit":"15.0","upperLimit":"26.4"},{"groupId":"OG001","value":"15.6","lowerLimit":"10.8","upperLimit":"21.5"},{"groupId":"OG002","value":"16.4","lowerLimit":"11.6","upperLimit":"22.3"},{"groupId":"OG003","value":"27.2","lowerLimit":"22.2","upperLimit":"32.7"},{"groupId":"OG004","value":"25.7","lowerLimit":"20.8","upperLimit":"31.0"},{"groupId":"OG005","value":"10.2","lowerLimit":"6.3","upperLimit":"15.5"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"6.4","upperLimit":"15.1"},{"groupId":"OG001","value":"9.4","lowerLimit":"5.7","upperLimit":"14.4"},{"groupId":"OG002","value":"10.4","lowerLimit":"6.6","upperLimit":"15.5"},{"groupId":"OG003","value":"18.4","lowerLimit":"14.1","upperLimit":"23.3"},{"groupId":"OG004","value":"17.4","lowerLimit":"13.3","upperLimit":"22.2"},{"groupId":"OG005","value":"16.7","lowerLimit":"11.6","upperLimit":"22.8"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG001","value":"2.1","lowerLimit":"0.6","upperLimit":"5.2"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG003","value":"2.0","lowerLimit":"0.8","upperLimit":"4.4"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.7","upperLimit":"4.2"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"10.4","upperLimit":"20.6"},{"groupId":"OG001","value":"11.5","lowerLimit":"7.3","upperLimit":"16.8"},{"groupId":"OG002","value":"10.4","lowerLimit":"6.6","upperLimit":"15.5"},{"groupId":"OG003","value":"31.6","lowerLimit":"26.4","upperLimit":"37.3"},{"groupId":"OG004","value":"26.3","lowerLimit":"21.5","upperLimit":"31.6"},{"groupId":"OG005","value":"14.0","lowerLimit":"9.3","upperLimit":"19.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"6.4","upperLimit":"15.1"},{"groupId":"OG001","value":"6.8","lowerLimit":"3.7","upperLimit":"11.3"},{"groupId":"OG002","value":"8.0","lowerLimit":"4.6","upperLimit":"12.6"},{"groupId":"OG003","value":"13.3","lowerLimit":"9.6","upperLimit":"17.7"},{"groupId":"OG004","value":"15.1","lowerLimit":"11.3","upperLimit":"19.7"},{"groupId":"OG005","value":"7.0","lowerLimit":"3.8","upperLimit":"11.7"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"2.0","upperLimit":"8.1"},{"groupId":"OG001","value":"4.7","lowerLimit":"2.2","upperLimit":"8.7"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.8","upperLimit":"5.7"},{"groupId":"OG003","value":"17.0","lowerLimit":"12.9","upperLimit":"21.8"},{"groupId":"OG004","value":"10.2","lowerLimit":"7.0","upperLimit":"14.2"},{"groupId":"OG005","value":"7.0","lowerLimit":"3.8","upperLimit":"11.7"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"1.4","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"2.1","lowerLimit":"0.6","upperLimit":"5.2"},{"groupId":"OG002","value":"3.5","lowerLimit":"1.4","upperLimit":"7.0"},{"groupId":"OG003","value":"2.7","lowerLimit":"1.2","upperLimit":"5.3"},{"groupId":"OG004","value":"1.6","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG005","value":"2.2","lowerLimit":"0.6","upperLimit":"5.4"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.3","upperLimit":"4.5"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.8","upperLimit":"5.7"},{"groupId":"OG003","value":"2.4","lowerLimit":"1.0","upperLimit":"4.8"},{"groupId":"OG004","value":"1.6","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"1.6","lowerLimit":"0.3","upperLimit":"4.6"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"5.6","upperLimit":"14.0"},{"groupId":"OG001","value":"8.3","lowerLimit":"4.8","upperLimit":"13.2"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.5","upperLimit":"10.8"},{"groupId":"OG003","value":"8.5","lowerLimit":"5.6","upperLimit":"12.3"},{"groupId":"OG004","value":"11.5","lowerLimit":"8.2","upperLimit":"15.6"},{"groupId":"OG005","value":"8.1","lowerLimit":"4.6","upperLimit":"13.0"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"4.9","upperLimit":"12.8"},{"groupId":"OG001","value":"7.8","lowerLimit":"4.4","upperLimit":"12.6"},{"groupId":"OG002","value":"5.0","lowerLimit":"2.4","upperLimit":"9.0"},{"groupId":"OG003","value":"7.5","lowerLimit":"4.7","upperLimit":"11.1"},{"groupId":"OG004","value":"9.2","lowerLimit":"6.2","upperLimit":"13.0"},{"groupId":"OG005","value":"3.8","lowerLimit":"1.5","upperLimit":"7.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.1","upperLimit":"3.4"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"1.5","lowerLimit":"0.3","upperLimit":"4.3"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.2","upperLimit":"3.0"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.7","upperLimit":"4.2"},{"groupId":"OG005","value":"3.8","lowerLimit":"1.5","upperLimit":"7.6"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"10.8","upperLimit":"21.1"},{"groupId":"OG001","value":"16.1","lowerLimit":"11.2","upperLimit":"22.1"},{"groupId":"OG002","value":"13.9","lowerLimit":"9.5","upperLimit":"19.5"},{"groupId":"OG003","value":"34.0","lowerLimit":"28.6","upperLimit":"39.7"},{"groupId":"OG004","value":"28.3","lowerLimit":"23.3","upperLimit":"33.7"},{"groupId":"OG005","value":"19.9","lowerLimit":"14.4","upperLimit":"26.4"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"4.1","upperLimit":"11.7"},{"groupId":"OG001","value":"6.8","lowerLimit":"3.7","upperLimit":"11.3"},{"groupId":"OG002","value":"7.5","lowerLimit":"4.2","upperLimit":"12.0"},{"groupId":"OG003","value":"14.6","lowerLimit":"10.8","upperLimit":"19.2"},{"groupId":"OG004","value":"16.8","lowerLimit":"12.8","upperLimit":"21.5"},{"groupId":"OG005","value":"6.5","lowerLimit":"3.4","upperLimit":"11.0"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"4.9","upperLimit":"12.8"},{"groupId":"OG001","value":"9.4","lowerLimit":"5.7","upperLimit":"14.4"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.5","upperLimit":"10.8"},{"groupId":"OG003","value":"18.7","lowerLimit":"14.4","upperLimit":"23.6"},{"groupId":"OG004","value":"10.5","lowerLimit":"7.3","upperLimit":"14.5"},{"groupId":"OG005","value":"12.9","lowerLimit":"8.4","upperLimit":"18.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"7.2","upperLimit":"16.2"},{"groupId":"OG001","value":"13.5","lowerLimit":"9.0","upperLimit":"19.2"},{"groupId":"OG002","value":"10.0","lowerLimit":"6.2","upperLimit":"14.9"},{"groupId":"OG003","value":"23.5","lowerLimit":"18.7","upperLimit":"28.7"},{"groupId":"OG004","value":"15.1","lowerLimit":"11.3","upperLimit":"19.7"},{"groupId":"OG005","value":"12.4","lowerLimit":"8.0","upperLimit":"18.0"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"2.7","upperLimit":"9.3"},{"groupId":"OG001","value":"6.8","lowerLimit":"3.7","upperLimit":"11.3"},{"groupId":"OG002","value":"4.5","lowerLimit":"2.1","upperLimit":"8.3"},{"groupId":"OG003","value":"10.2","lowerLimit":"7.0","upperLimit":"14.2"},{"groupId":"OG004","value":"7.9","lowerLimit":"5.1","upperLimit":"11.5"},{"groupId":"OG005","value":"3.8","lowerLimit":"1.5","upperLimit":"7.6"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"2.7","upperLimit":"9.3"},{"groupId":"OG001","value":"6.3","lowerLimit":"3.3","upperLimit":"10.7"},{"groupId":"OG002","value":"5.5","lowerLimit":"2.8","upperLimit":"9.6"},{"groupId":"OG003","value":"12.2","lowerLimit":"8.7","upperLimit":"16.5"},{"groupId":"OG004","value":"7.2","lowerLimit":"4.6","upperLimit":"10.8"},{"groupId":"OG005","value":"8.6","lowerLimit":"5.0","upperLimit":"13.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.2","upperLimit":"3.0"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"2.0"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C, categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants who received Vaccination 2 and 'n' signifies participants evaluable for specified rows and received two doses of study vaccination for SSD. Participants of SSD: Cohort 1: Group 1 did not receive Vaccination 2 and therefore were not analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG002","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG003","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"142"}]}],"classes":[{"title":"Fever: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG001","value":"5.1","lowerLimit":"2.5","upperLimit":"9.2"},{"groupId":"OG002","value":"6.0","lowerLimit":"3.2","upperLimit":"10.0"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Fever:>=38.0 deg C-38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.8","upperLimit":"5.9"},{"groupId":"OG002","value":"3.7","lowerLimit":"1.6","upperLimit":"7.1"},{"groupId":"OG003","value":"0.7","lowerLimit":"0.0","upperLimit":"3.9"}]}]},{"title":"Fever:>38.4 deg C-38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.1","upperLimit":"3.6"},{"groupId":"OG002","value":"1.8","lowerLimit":"0.5","upperLimit":"4.7"},{"groupId":"OG003","value":"1.4","lowerLimit":"0.2","upperLimit":"5.1"}]}]},{"title":"Fever:>38.9 deg C-40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.1","upperLimit":"3.6"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Fever:>40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Fever: Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"12.2","upperLimit":"24.7"},{"groupId":"OG001","value":"60.9","lowerLimit":"53.7","upperLimit":"67.8"},{"groupId":"OG002","value":"54.3","lowerLimit":"47.5","upperLimit":"61.1"},{"groupId":"OG003","value":"27.0","lowerLimit":"19.8","upperLimit":"35.1"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"6.9","upperLimit":"17.5"},{"groupId":"OG001","value":"27.9","lowerLimit":"21.8","upperLimit":"34.7"},{"groupId":"OG002","value":"26.9","lowerLimit":"21.2","upperLimit":"33.3"},{"groupId":"OG003","value":"13.5","lowerLimit":"8.3","upperLimit":"20.2"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"2.7","upperLimit":"10.6"},{"groupId":"OG001","value":"32.0","lowerLimit":"25.5","upperLimit":"39.0"},{"groupId":"OG002","value":"25.1","lowerLimit":"19.5","upperLimit":"31.4"},{"groupId":"OG003","value":"12.1","lowerLimit":"7.2","upperLimit":"18.6"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.1","upperLimit":"3.6"},{"groupId":"OG002","value":"2.3","lowerLimit":"0.7","upperLimit":"5.2"},{"groupId":"OG003","value":"1.4","lowerLimit":"0.2","upperLimit":"5.0"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","lowerLimit":"18.3","upperLimit":"32.4"},{"groupId":"OG001","value":"39.8","lowerLimit":"32.9","upperLimit":"47.0"},{"groupId":"OG002","value":"37.3","lowerLimit":"30.9","upperLimit":"44.1"},{"groupId":"OG003","value":"19.7","lowerLimit":"13.5","upperLimit":"27.2"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","lowerLimit":"8.5","upperLimit":"19.7"},{"groupId":"OG001","value":"26.5","lowerLimit":"20.5","upperLimit":"33.3"},{"groupId":"OG002","value":"18.0","lowerLimit":"13.1","upperLimit":"23.7"},{"groupId":"OG003","value":"10.6","lowerLimit":"6.0","upperLimit":"16.8"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"6.4","upperLimit":"16.8"},{"groupId":"OG001","value":"13.3","lowerLimit":"8.9","upperLimit":"18.8"},{"groupId":"OG002","value":"17.1","lowerLimit":"12.3","upperLimit":"22.7"},{"groupId":"OG003","value":"9.2","lowerLimit":"5.0","upperLimit":"15.1"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"2.3","lowerLimit":"0.8","upperLimit":"5.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"7.4","upperLimit":"18.3"},{"groupId":"OG001","value":"21.8","lowerLimit":"16.3","upperLimit":"28.3"},{"groupId":"OG002","value":"19.4","lowerLimit":"14.3","upperLimit":"25.2"},{"groupId":"OG003","value":"7.1","lowerLimit":"3.5","upperLimit":"12.7"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"3.5","upperLimit":"12.2"},{"groupId":"OG001","value":"10.7","lowerLimit":"6.7","upperLimit":"15.8"},{"groupId":"OG002","value":"12.4","lowerLimit":"8.4","upperLimit":"17.6"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"2.2","upperLimit":"9.8"},{"groupId":"OG001","value":"10.7","lowerLimit":"6.7","upperLimit":"15.8"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.6","upperLimit":"10.6"},{"groupId":"OG003","value":"5.0","lowerLimit":"2.0","upperLimit":"10.0"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.8"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"0.7","upperLimit":"6.4"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.8"},{"groupId":"OG002","value":"1.8","lowerLimit":"0.5","upperLimit":"4.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.4","upperLimit":"5.5"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.8"},{"groupId":"OG002","value":"1.8","lowerLimit":"0.5","upperLimit":"4.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"2.2","upperLimit":"9.8"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.9","upperLimit":"14.7"},{"groupId":"OG002","value":"6.0","lowerLimit":"3.2","upperLimit":"10.0"},{"groupId":"OG003","value":"6.4","lowerLimit":"3.0","upperLimit":"11.9"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"1.4","upperLimit":"8.1"},{"groupId":"OG001","value":"8.2","lowerLimit":"4.7","upperLimit":"12.9"},{"groupId":"OG002","value":"5.1","lowerLimit":"2.6","upperLimit":"8.9"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.6","upperLimit":"9.1"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.3","upperLimit":"4.4"},{"groupId":"OG002","value":"0.9","lowerLimit":"0.1","upperLimit":"3.3"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"New or worsened muscle pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"216"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"6.4","upperLimit":"16.8"},{"groupId":"OG001","value":"27.6","lowerLimit":"21.4","upperLimit":"34.4"},{"groupId":"OG002","value":"26.7","lowerLimit":"21.0","upperLimit":"33.1"},{"groupId":"OG003","value":"8.6","lowerLimit":"4.5","upperLimit":"14.5"}]}]},{"title":"New or worsened muscle pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"2.7","upperLimit":"10.6"},{"groupId":"OG001","value":"17.9","lowerLimit":"12.8","upperLimit":"23.9"},{"groupId":"OG002","value":"14.7","lowerLimit":"10.3","upperLimit":"20.2"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.6","upperLimit":"9.1"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.0"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.9","upperLimit":"14.7"},{"groupId":"OG002","value":"11.1","lowerLimit":"7.2","upperLimit":"16.0"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.6","upperLimit":"9.1"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0.9","lowerLimit":"0.1","upperLimit":"3.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"New or worsened muscle pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"New or worsened joint pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"4.0","upperLimit":"13.0"},{"groupId":"OG001","value":"14.3","lowerLimit":"9.7","upperLimit":"20.0"},{"groupId":"OG002","value":"12.0","lowerLimit":"8.0","upperLimit":"17.1"},{"groupId":"OG003","value":"5.7","lowerLimit":"2.5","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.0","upperLimit":"7.3"},{"groupId":"OG001","value":"7.1","lowerLimit":"4.0","upperLimit":"11.7"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.6","upperLimit":"10.6"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.4","upperLimit":"6.1"}]}]},{"title":"New or worsened joint pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.0"},{"groupId":"OG001","value":"6.1","lowerLimit":"3.2","upperLimit":"10.5"},{"groupId":"OG002","value":"5.5","lowerLimit":"2.9","upperLimit":"9.5"},{"groupId":"OG003","value":"3.6","lowerLimit":"1.2","upperLimit":"8.1"}]}]},{"title":"New or worsened joint pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.1","upperLimit":"3.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]},{"title":"New or worsened joint pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"217"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"2.6"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3","description":"Systemic events were recorded in e-diary. Fever: oral temperature \\>= 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \\>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N'= participants who received vaccination 3. Participants of SSD: Cohort 1: Group 1, Group 2 and SSD Cohort 2: Group 3, Group 4 did not receive Vaccination 3 and therefore were not analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after Vaccination 3","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"}]}],"classes":[{"title":"Fever: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.7","upperLimit":"6.5"}]}]},{"title":"Fever: >=38.0 deg C to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"Fever: >38.4 deg C to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Fever: >38.9 deg C to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"16.4","upperLimit":"30.2"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"1.4","upperLimit":"8.3"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"12.4","upperLimit":"25.2"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.3","lowerLimit":"18.7","upperLimit":"33.0"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"5.1","upperLimit":"14.8"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.9","lowerLimit":"9.7","upperLimit":"21.6"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"5.1","upperLimit":"14.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.1"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.1","upperLimit":"7.4"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.7","upperLimit":"6.5"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.4","upperLimit":"5.6"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"4.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.9","lowerLimit":"9.7","upperLimit":"21.6"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"1.8","upperLimit":"9.1"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"6.1","upperLimit":"16.3"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"5.1","upperLimit":"14.8"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.1","upperLimit":"7.4"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"2.3","upperLimit":"10.0"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.6"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.4"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 up to 1 month after last study vaccination","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"204"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.3","upperLimit":"6.6"},{"groupId":"OG001","value":"6.1","lowerLimit":"3.2","upperLimit":"10.4"},{"groupId":"OG002","value":"2.0","lowerLimit":"0.5","upperLimit":"4.9"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first study vaccination (Day 1) up to 1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"2.2","upperLimit":"7.0"},{"groupId":"OG001","value":"3.7","lowerLimit":"1.9","upperLimit":"6.4"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSD.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Vaccination 2 up to 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.8","upperLimit":"5.4"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.7","upperLimit":"7.1"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSD.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first study vaccination (Day 1) up to 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"3.7","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received three doses of study vaccination for SSD.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Vaccination 3 up to 1 month after Vaccination 3","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.2"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first study vaccination (Day 1) up to 6 months after last study vaccination","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"197"},{"groupId":"OG002","value":"204"},{"groupId":"OG003","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.1","upperLimit":"3.3"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.3","upperLimit":"4.4"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.1","upperLimit":"3.5"},{"groupId":"OG003","value":"3.8","lowerLimit":"1.7","upperLimit":"7.4"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination 1 (Day 1) up to 6 months after vaccination 1 (participants received 1 dose only); From vaccination 1 up to before vaccination 2 (participants received 2 doses)","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.5","upperLimit":"3.7"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.1","upperLimit":"2.2"}]}]}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and received two doses of study vaccination for SSD.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first study vaccination (Day 1) up to 6 months after vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.6"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.3","upperLimit":"3.6"}]}]}]},{"type":"PRIMARY","title":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4","description":"GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"Evaluable immunogenicity population (EIP) included all eligible randomized participants who received 1st study intervention to which they were randomized (Group 3, 4), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Group 3, 4), have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1929.2","lowerLimit":"1631.5","upperLimit":"2281.1"},{"groupId":"OG001","value":"1099.6","lowerLimit":"932.0","upperLimit":"1297.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]) and the corresponding CI (based on the student t distribution).","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ration (GMR)","paramValue":"1.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.39","ciUpperLimit":"2.22"}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.","populationDescription":"Evaluable immunogenicity population (EIP) included all eligible randomized participants who received 1st study intervention to which they were randomized (Group 3, 4), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Group 3, 4), had no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 2: Group 3","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."},{"id":"OG001","title":"SSD: Cohort 2: Group 4","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm. After 3 months, participants upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","lowerLimit":"53.4","upperLimit":"70.7"},{"groupId":"OG001","value":"39.3","lowerLimit":"31.1","upperLimit":"47.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"23.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11.1","ciUpperLimit":"34.3"}]},{"type":"PRIMARY","title":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"Evaluable immunogenicity population (EIP) included all eligible randomized participants who received 1st study intervention to which they were randomized (Groups 1, 2b), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Groups 1, 2b), have no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5094.1","lowerLimit":"4118.2","upperLimit":"6301.2"},{"groupId":"OG001","value":"1775.6","lowerLimit":"1484.8","upperLimit":"2123.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]) and the corresponding CI (based on the student t distribution).","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ration (GMR)","paramValue":"2.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.18","ciUpperLimit":"3.78"}]},{"type":"PRIMARY","title":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b","description":"GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).","populationDescription":"EIP: all eligible participants received 1st study drug as randomized (Group 2b) or received 2 doses of study drug as randomized with Dose 2 received within 19-42 days after Dose1 (Group 2), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Group 2b) or 28-42 days after 2nd study vaccination (Group 2), had no other important protocol deviations as determined by clinician. Here 'N'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4684.3","lowerLimit":"3937.4","upperLimit":"5573.0"},{"groupId":"OG001","value":"1775.6","lowerLimit":"1484.8","upperLimit":"2123.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]) and the corresponding CI (based on the student t distribution).","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (GMR)","paramValue":"2.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.06","ciUpperLimit":"3.38"}]},{"type":"PRIMARY","title":"Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received 1st study intervention to which they were randomized (Group 1, 2b), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Group 1, 2b), had no other important protocol deviations as determined by clinician. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","lowerLimit":"80.0","upperLimit":"93.6"},{"groupId":"OG001","value":"59.0","lowerLimit":"48.7","upperLimit":"68.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"29.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"17.2","ciUpperLimit":"40.3"}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b","description":"Seroresponse: achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \\>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.","populationDescription":"EIP: all eligible participants received 1st study drug as randomized (Group 2b) or received 2 doses of study drug as randomized with Dose 2 received within 19-42 days after Dose1 (Group 2), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 1st study vaccination (Group 2b) or 28-42 days after 2nd study vaccination (Group 2), had no other important protocol deviations as determined by clinician. Here 'N'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 1: Group 2","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"70.8","upperLimit":"87.3"},{"groupId":"OG001","value":"59.0","lowerLimit":"48.7","upperLimit":"68.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"21.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.3","ciUpperLimit":"33.2"}]},{"type":"PRIMARY","title":"SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3","description":"GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).","populationDescription":"EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."},{"id":"OG001","title":"C4591001 Study Cohort","description":"Data of evaluable participants from Study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age who had received 2 doses of BNT162b2 30 mcg in study C4591001 was included for this comparison."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"157"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2892.2","lowerLimit":"2522.3","upperLimit":"3316.3"},{"groupId":"OG001","value":"290.6","lowerLimit":"241.2","upperLimit":"350.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]) and the corresponding CI (based on the student t distribution).","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ration (GMR)","paramValue":"9.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.90","ciUpperLimit":"12.53"}]},{"type":"PRIMARY","title":"SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3","description":"EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.","populationDescription":"EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after Vaccination 2","groups":[{"id":"OG000","title":"SSD: Cohort 3: Group 5","description":"Participants received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm. Participants upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination."},{"id":"OG001","title":"C4591001 Study Cohort","description":"Data of evaluable participants from Study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age who had received 2 doses of BNT162b2 30 mcg in study C4591001 was included for this comparison."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"156"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"79.7","upperLimit":"91.2"},{"groupId":"OG001","value":"80.8","lowerLimit":"73.7","upperLimit":"86.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"5.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.0","ciUpperLimit":"13.8"}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm),severe (\\>10.0 cm) and Grade 4 (necrosis \\[swelling\\] or necrosis/exfoliative dermatitis \\[redness\\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \\[ER\\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed (N)' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after study vaccination","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG006","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG007","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG008","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG009","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG010","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG011","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG012","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG013","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG014","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG015","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG016","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG017","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"480"},{"groupId":"OG004","value":"158"},{"groupId":"OG005","value":"320"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"20"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"20"},{"groupId":"OG012","value":"298"},{"groupId":"OG013","value":"298"},{"groupId":"OG014","value":"301"},{"groupId":"OG015","value":"301"},{"groupId":"OG016","value":"301"},{"groupId":"OG017","value":"312"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG003","value":"8.1","lowerLimit":"5.8","upperLimit":"10.9"},{"groupId":"OG004","value":"6.3","lowerLimit":"3.1","upperLimit":"11.3"},{"groupId":"OG005","value":"10.9","lowerLimit":"7.7","upperLimit":"14.9"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG009","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"6.4","lowerLimit":"3.9","upperLimit":"9.8"},{"groupId":"OG013","value":"10.4","lowerLimit":"7.2","upperLimit":"14.4"},{"groupId":"OG014","value":"6.3","lowerLimit":"3.8","upperLimit":"9.7"},{"groupId":"OG015","value":"10.6","lowerLimit":"7.4","upperLimit":"14.7"},{"groupId":"OG016","value":"7.0","lowerLimit":"4.4","upperLimit":"10.5"},{"groupId":"OG017","value":"7.4","lowerLimit":"4.7","upperLimit":"10.9"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG003","value":"3.8","lowerLimit":"2.2","upperLimit":"5.9"},{"groupId":"OG004","value":"4.4","lowerLimit":"1.8","upperLimit":"8.9"},{"groupId":"OG005","value":"6.3","lowerLimit":"3.9","upperLimit":"9.5"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"4.0","lowerLimit":"2.1","upperLimit":"6.9"},{"groupId":"OG013","value":"6.0","lowerLimit":"3.6","upperLimit":"9.4"},{"groupId":"OG014","value":"3.3","lowerLimit":"1.6","upperLimit":"6.0"},{"groupId":"OG015","value":"4.0","lowerLimit":"2.1","upperLimit":"6.9"},{"groupId":"OG016","value":"4.3","lowerLimit":"2.3","upperLimit":"7.3"},{"groupId":"OG017","value":"3.5","lowerLimit":"1.8","upperLimit":"6.2"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"4.2","lowerLimit":"2.6","upperLimit":"6.4"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.4","upperLimit":"5.4"},{"groupId":"OG005","value":"4.4","lowerLimit":"2.4","upperLimit":"7.2"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"2.0","lowerLimit":"0.7","upperLimit":"4.3"},{"groupId":"OG013","value":"4.0","lowerLimit":"2.1","upperLimit":"6.9"},{"groupId":"OG014","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG015","value":"6.6","lowerLimit":"4.1","upperLimit":"10.1"},{"groupId":"OG016","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG017","value":"3.2","lowerLimit":"1.5","upperLimit":"5.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0.3","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG013","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG014","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0.6","lowerLimit":"0.1","upperLimit":"2.3"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG002","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG003","value":"9.6","lowerLimit":"7.1","upperLimit":"12.6"},{"groupId":"OG004","value":"7.0","lowerLimit":"3.5","upperLimit":"12.1"},{"groupId":"OG005","value":"11.9","lowerLimit":"8.5","upperLimit":"15.9"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"6.0","lowerLimit":"3.6","upperLimit":"9.4"},{"groupId":"OG013","value":"13.1","lowerLimit":"9.5","upperLimit":"17.5"},{"groupId":"OG014","value":"8.3","lowerLimit":"5.4","upperLimit":"12.0"},{"groupId":"OG015","value":"10.0","lowerLimit":"6.8","upperLimit":"13.9"},{"groupId":"OG016","value":"6.6","lowerLimit":"4.1","upperLimit":"10.1"},{"groupId":"OG017","value":"5.4","lowerLimit":"3.2","upperLimit":"8.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"5.0","lowerLimit":"3.2","upperLimit":"7.3"},{"groupId":"OG004","value":"4.4","lowerLimit":"1.8","upperLimit":"8.9"},{"groupId":"OG005","value":"6.3","lowerLimit":"3.9","upperLimit":"9.5"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"3.4","lowerLimit":"1.6","upperLimit":"6.1"},{"groupId":"OG013","value":"7.7","lowerLimit":"5.0","upperLimit":"11.4"},{"groupId":"OG014","value":"5.0","lowerLimit":"2.8","upperLimit":"8.1"},{"groupId":"OG015","value":"4.0","lowerLimit":"2.1","upperLimit":"6.9"},{"groupId":"OG016","value":"4.7","lowerLimit":"2.6","upperLimit":"7.7"},{"groupId":"OG017","value":"2.9","lowerLimit":"1.3","upperLimit":"5.4"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG003","value":"4.4","lowerLimit":"2.7","upperLimit":"6.6"},{"groupId":"OG004","value":"2.5","lowerLimit":"0.7","upperLimit":"6.4"},{"groupId":"OG005","value":"5.3","lowerLimit":"3.1","upperLimit":"8.4"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG013","value":"5.4","lowerLimit":"3.1","upperLimit":"8.6"},{"groupId":"OG014","value":"3.3","lowerLimit":"1.6","upperLimit":"6.0"},{"groupId":"OG015","value":"5.3","lowerLimit":"3.1","upperLimit":"8.5"},{"groupId":"OG016","value":"2.0","lowerLimit":"0.7","upperLimit":"4.3"},{"groupId":"OG017","value":"2.2","lowerLimit":"0.9","upperLimit":"4.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0.3","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"73.5","upperLimit":"97.9"},{"groupId":"OG001","value":"83.3","lowerLimit":"65.3","upperLimit":"94.4"},{"groupId":"OG002","value":"96.7","lowerLimit":"82.8","upperLimit":"99.9"},{"groupId":"OG003","value":"82.9","lowerLimit":"79.2","upperLimit":"86.2"},{"groupId":"OG004","value":"81.0","lowerLimit":"74.0","upperLimit":"86.8"},{"groupId":"OG005","value":"86.3","lowerLimit":"82.0","upperLimit":"89.8"},{"groupId":"OG006","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG007","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG008","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG009","value":"100.0","lowerLimit":"83.2","upperLimit":"100.0"},{"groupId":"OG010","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG011","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG012","value":"60.1","lowerLimit":"54.3","upperLimit":"65.7"},{"groupId":"OG013","value":"71.1","lowerLimit":"65.6","upperLimit":"76.2"},{"groupId":"OG014","value":"66.1","lowerLimit":"60.5","upperLimit":"71.4"},{"groupId":"OG015","value":"70.8","lowerLimit":"65.3","upperLimit":"75.8"},{"groupId":"OG016","value":"58.1","lowerLimit":"52.3","upperLimit":"63.8"},{"groupId":"OG017","value":"67.9","lowerLimit":"62.5","upperLimit":"73.1"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"60.0","lowerLimit":"40.6","upperLimit":"77.3"},{"groupId":"OG001","value":"76.7","lowerLimit":"57.7","upperLimit":"90.1"},{"groupId":"OG002","value":"33.3","lowerLimit":"17.3","upperLimit":"52.8"},{"groupId":"OG003","value":"55.2","lowerLimit":"50.6","upperLimit":"59.7"},{"groupId":"OG004","value":"67.7","lowerLimit":"59.8","upperLimit":"74.9"},{"groupId":"OG005","value":"45.3","lowerLimit":"39.8","upperLimit":"50.9"},{"groupId":"OG006","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG007","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG008","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG009","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"},{"groupId":"OG010","value":"60.0","lowerLimit":"36.1","upperLimit":"80.9"},{"groupId":"OG011","value":"45.0","lowerLimit":"23.1","upperLimit":"68.5"},{"groupId":"OG012","value":"51.7","lowerLimit":"45.8","upperLimit":"57.5"},{"groupId":"OG013","value":"53.4","lowerLimit":"47.5","upperLimit":"59.1"},{"groupId":"OG014","value":"52.8","lowerLimit":"47.0","upperLimit":"58.6"},{"groupId":"OG015","value":"44.9","lowerLimit":"39.1","upperLimit":"50.7"},{"groupId":"OG016","value":"52.8","lowerLimit":"47.0","upperLimit":"58.6"},{"groupId":"OG017","value":"55.4","lowerLimit":"49.7","upperLimit":"61.0"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"14.7","upperLimit":"49.4"},{"groupId":"OG001","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG002","value":"60.0","lowerLimit":"40.6","upperLimit":"77.3"},{"groupId":"OG003","value":"26.0","lowerLimit":"22.2","upperLimit":"30.2"},{"groupId":"OG004","value":"13.3","lowerLimit":"8.4","upperLimit":"19.6"},{"groupId":"OG005","value":"39.4","lowerLimit":"34.0","upperLimit":"45.0"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG012","value":"8.1","lowerLimit":"5.2","upperLimit":"11.7"},{"groupId":"OG013","value":"17.4","lowerLimit":"13.3","upperLimit":"22.2"},{"groupId":"OG014","value":"13.3","lowerLimit":"9.7","upperLimit":"17.7"},{"groupId":"OG015","value":"25.2","lowerLimit":"20.4","upperLimit":"30.6"},{"groupId":"OG016","value":"5.0","lowerLimit":"2.8","upperLimit":"8.1"},{"groupId":"OG017","value":"12.2","lowerLimit":"8.8","upperLimit":"16.3"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG003","value":"1.7","lowerLimit":"0.7","upperLimit":"3.3"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"1.6","lowerLimit":"0.5","upperLimit":"3.6"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG013","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG016","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG017","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C \\& \\>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after study vaccination","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG006","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG007","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG008","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG009","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG010","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG011","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG012","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG013","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG014","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG015","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG016","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG017","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"480"},{"groupId":"OG004","value":"158"},{"groupId":"OG005","value":"320"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"20"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"20"},{"groupId":"OG012","value":"298"},{"groupId":"OG013","value":"298"},{"groupId":"OG014","value":"301"},{"groupId":"OG015","value":"301"},{"groupId":"OG016","value":"301"},{"groupId":"OG017","value":"312"}]}],"classes":[{"title":"Fever: >= 38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG003","value":"10.0","lowerLimit":"7.5","upperLimit":"13.0"},{"groupId":"OG004","value":"10.8","lowerLimit":"6.4","upperLimit":"16.7"},{"groupId":"OG005","value":"19.4","lowerLimit":"15.2","upperLimit":"24.1"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG011","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG012","value":"3.7","lowerLimit":"1.9","upperLimit":"6.5"},{"groupId":"OG013","value":"7.4","lowerLimit":"4.7","upperLimit":"11.0"},{"groupId":"OG014","value":"8.3","lowerLimit":"5.4","upperLimit":"12.0"},{"groupId":"OG015","value":"9.0","lowerLimit":"6.0","upperLimit":"12.8"},{"groupId":"OG016","value":"5.0","lowerLimit":"2.8","upperLimit":"8.1"},{"groupId":"OG017","value":"7.7","lowerLimit":"5.0","upperLimit":"11.2"}]}]},{"title":"Fever: >= 38.0 deg C to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG003","value":"4.2","lowerLimit":"2.6","upperLimit":"6.4"},{"groupId":"OG004","value":"6.3","lowerLimit":"3.1","upperLimit":"11.3"},{"groupId":"OG005","value":"6.9","lowerLimit":"4.4","upperLimit":"10.2"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"2.0","lowerLimit":"0.7","upperLimit":"4.3"},{"groupId":"OG013","value":"3.7","lowerLimit":"1.9","upperLimit":"6.5"},{"groupId":"OG014","value":"3.7","lowerLimit":"1.8","upperLimit":"6.4"},{"groupId":"OG015","value":"4.7","lowerLimit":"2.6","upperLimit":"7.7"},{"groupId":"OG016","value":"3.7","lowerLimit":"1.8","upperLimit":"6.4"},{"groupId":"OG017","value":"5.4","lowerLimit":"3.2","upperLimit":"8.6"}]}]},{"title":"Fever: >38.4 deg C to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"3.8","lowerLimit":"2.2","upperLimit":"5.9"},{"groupId":"OG004","value":"3.8","lowerLimit":"1.4","upperLimit":"8.1"},{"groupId":"OG005","value":"8.1","lowerLimit":"5.4","upperLimit":"11.7"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"1.7","lowerLimit":"0.5","upperLimit":"3.9"},{"groupId":"OG013","value":"3.7","lowerLimit":"1.9","upperLimit":"6.5"},{"groupId":"OG014","value":"3.7","lowerLimit":"1.8","upperLimit":"6.4"},{"groupId":"OG015","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"1.6","lowerLimit":"0.5","upperLimit":"3.7"}]}]},{"title":"Fever: >38.9 deg C to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"2.1","lowerLimit":"1.0","upperLimit":"3.8"},{"groupId":"OG004","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG005","value":"4.4","lowerLimit":"2.4","upperLimit":"7.2"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG015","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG016","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG017","value":"0.6","lowerLimit":"0.1","upperLimit":"2.3"}]}]},{"title":"Fever: >40 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"66.7","lowerLimit":"47.2","upperLimit":"82.7"},{"groupId":"OG001","value":"63.3","lowerLimit":"43.9","upperLimit":"80.1"},{"groupId":"OG002","value":"70.0","lowerLimit":"50.6","upperLimit":"85.3"},{"groupId":"OG003","value":"73.8","lowerLimit":"69.6","upperLimit":"77.6"},{"groupId":"OG004","value":"68.4","lowerLimit":"60.5","upperLimit":"75.5"},{"groupId":"OG005","value":"77.5","lowerLimit":"72.5","upperLimit":"82.0"},{"groupId":"OG006","value":"45.0","lowerLimit":"23.1","upperLimit":"68.5"},{"groupId":"OG007","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG008","value":"45.0","lowerLimit":"23.1","upperLimit":"68.5"},{"groupId":"OG009","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG010","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG011","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG012","value":"45.3","lowerLimit":"39.6","upperLimit":"51.1"},{"groupId":"OG013","value":"52.3","lowerLimit":"46.5","upperLimit":"58.1"},{"groupId":"OG014","value":"52.5","lowerLimit":"46.7","upperLimit":"58.3"},{"groupId":"OG015","value":"58.8","lowerLimit":"53.0","upperLimit":"64.4"},{"groupId":"OG016","value":"49.2","lowerLimit":"43.4","upperLimit":"55.0"},{"groupId":"OG017","value":"57.4","lowerLimit":"51.7","upperLimit":"62.9"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG001","value":"26.7","lowerLimit":"12.3","upperLimit":"45.9"},{"groupId":"OG002","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG003","value":"25.2","lowerLimit":"21.4","upperLimit":"29.3"},{"groupId":"OG004","value":"32.3","lowerLimit":"25.1","upperLimit":"40.2"},{"groupId":"OG005","value":"25.9","lowerLimit":"21.2","upperLimit":"31.1"},{"groupId":"OG006","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG010","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG011","value":"45.0","lowerLimit":"23.1","upperLimit":"68.5"},{"groupId":"OG012","value":"23.5","lowerLimit":"18.8","upperLimit":"28.7"},{"groupId":"OG013","value":"22.5","lowerLimit":"17.9","upperLimit":"27.7"},{"groupId":"OG014","value":"20.3","lowerLimit":"15.9","upperLimit":"25.3"},{"groupId":"OG015","value":"24.6","lowerLimit":"19.8","upperLimit":"29.9"},{"groupId":"OG016","value":"29.2","lowerLimit":"24.2","upperLimit":"34.7"},{"groupId":"OG017","value":"27.2","lowerLimit":"22.4","upperLimit":"32.5"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"43.3","lowerLimit":"25.5","upperLimit":"62.6"},{"groupId":"OG001","value":"33.3","lowerLimit":"17.3","upperLimit":"52.8"},{"groupId":"OG002","value":"40.0","lowerLimit":"22.7","upperLimit":"59.4"},{"groupId":"OG003","value":"44.0","lowerLimit":"39.5","upperLimit":"48.5"},{"groupId":"OG004","value":"34.8","lowerLimit":"27.4","upperLimit":"42.8"},{"groupId":"OG005","value":"46.9","lowerLimit":"41.3","upperLimit":"52.5"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG008","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG009","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG010","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG011","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG012","value":"21.5","lowerLimit":"17.0","upperLimit":"26.6"},{"groupId":"OG013","value":"26.8","lowerLimit":"21.9","upperLimit":"32.3"},{"groupId":"OG014","value":"29.6","lowerLimit":"24.5","upperLimit":"35.1"},{"groupId":"OG015","value":"30.6","lowerLimit":"25.4","upperLimit":"36.1"},{"groupId":"OG016","value":"18.3","lowerLimit":"14.1","upperLimit":"23.1"},{"groupId":"OG017","value":"28.2","lowerLimit":"23.3","upperLimit":"33.5"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG002","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG003","value":"4.6","lowerLimit":"2.9","upperLimit":"6.9"},{"groupId":"OG004","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG005","value":"4.7","lowerLimit":"2.6","upperLimit":"7.6"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG013","value":"3.0","lowerLimit":"1.4","upperLimit":"5.7"},{"groupId":"OG014","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG015","value":"3.7","lowerLimit":"1.8","upperLimit":"6.4"},{"groupId":"OG016","value":"1.7","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG017","value":"1.9","lowerLimit":"0.7","upperLimit":"4.1"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"46.7","lowerLimit":"28.3","upperLimit":"65.7"},{"groupId":"OG001","value":"30.0","lowerLimit":"14.7","upperLimit":"49.4"},{"groupId":"OG002","value":"60.0","lowerLimit":"40.6","upperLimit":"77.3"},{"groupId":"OG003","value":"53.5","lowerLimit":"49.0","upperLimit":"58.1"},{"groupId":"OG004","value":"50.0","lowerLimit":"42.0","upperLimit":"58.0"},{"groupId":"OG005","value":"57.5","lowerLimit":"51.9","upperLimit":"63.0"},{"groupId":"OG006","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG007","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG008","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG009","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG010","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG011","value":"50.0","lowerLimit":"27.2","upperLimit":"72.8"},{"groupId":"OG012","value":"26.5","lowerLimit":"21.6","upperLimit":"31.9"},{"groupId":"OG013","value":"38.9","lowerLimit":"33.4","upperLimit":"44.7"},{"groupId":"OG014","value":"36.5","lowerLimit":"31.1","upperLimit":"42.3"},{"groupId":"OG015","value":"36.5","lowerLimit":"31.1","upperLimit":"42.3"},{"groupId":"OG016","value":"33.6","lowerLimit":"28.2","upperLimit":"39.2"},{"groupId":"OG017","value":"36.5","lowerLimit":"31.2","upperLimit":"42.1"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"22.7","upperLimit":"59.4"},{"groupId":"OG001","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG002","value":"26.7","lowerLimit":"12.3","upperLimit":"45.9"},{"groupId":"OG003","value":"27.7","lowerLimit":"23.7","upperLimit":"31.9"},{"groupId":"OG004","value":"29.1","lowerLimit":"22.2","upperLimit":"36.9"},{"groupId":"OG005","value":"27.5","lowerLimit":"22.7","upperLimit":"32.7"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG008","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG009","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG010","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG011","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG012","value":"15.8","lowerLimit":"11.8","upperLimit":"20.4"},{"groupId":"OG013","value":"23.5","lowerLimit":"18.8","upperLimit":"28.7"},{"groupId":"OG014","value":"22.3","lowerLimit":"17.7","upperLimit":"27.4"},{"groupId":"OG015","value":"20.6","lowerLimit":"16.2","upperLimit":"25.6"},{"groupId":"OG016","value":"23.6","lowerLimit":"18.9","upperLimit":"28.8"},{"groupId":"OG017","value":"24.4","lowerLimit":"19.7","upperLimit":"29.5"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG001","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG002","value":"30.0","lowerLimit":"14.7","upperLimit":"49.4"},{"groupId":"OG003","value":"24.2","lowerLimit":"20.4","upperLimit":"28.3"},{"groupId":"OG004","value":"19.0","lowerLimit":"13.2","upperLimit":"26.0"},{"groupId":"OG005","value":"27.2","lowerLimit":"22.4","upperLimit":"32.4"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG011","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG012","value":"10.4","lowerLimit":"7.2","upperLimit":"14.4"},{"groupId":"OG013","value":"14.4","lowerLimit":"10.6","upperLimit":"18.9"},{"groupId":"OG014","value":"13.3","lowerLimit":"9.7","upperLimit":"17.7"},{"groupId":"OG015","value":"14.6","lowerLimit":"10.8","upperLimit":"19.1"},{"groupId":"OG016","value":"9.6","lowerLimit":"6.5","upperLimit":"13.5"},{"groupId":"OG017","value":"10.9","lowerLimit":"7.7","upperLimit":"14.9"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG003","value":"1.7","lowerLimit":"0.7","upperLimit":"3.3"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.4","upperLimit":"5.4"},{"groupId":"OG005","value":"2.8","lowerLimit":"1.3","upperLimit":"5.3"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG013","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG014","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG015","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG016","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG017","value":"1.3","lowerLimit":"0.4","upperLimit":"3.2"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG001","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG002","value":"40.0","lowerLimit":"22.7","upperLimit":"59.4"},{"groupId":"OG003","value":"35.6","lowerLimit":"31.3","upperLimit":"40.1"},{"groupId":"OG004","value":"27.8","lowerLimit":"21.0","upperLimit":"35.5"},{"groupId":"OG005","value":"38.4","lowerLimit":"33.1","upperLimit":"44.0"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG010","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG011","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG012","value":"16.4","lowerLimit":"12.4","upperLimit":"21.1"},{"groupId":"OG013","value":"24.2","lowerLimit":"19.4","upperLimit":"29.4"},{"groupId":"OG014","value":"25.6","lowerLimit":"20.7","upperLimit":"30.9"},{"groupId":"OG015","value":"25.6","lowerLimit":"20.7","upperLimit":"30.9"},{"groupId":"OG016","value":"13.0","lowerLimit":"9.4","upperLimit":"17.3"},{"groupId":"OG017","value":"23.7","lowerLimit":"19.1","upperLimit":"28.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG001","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"20.4","lowerLimit":"16.9","upperLimit":"24.3"},{"groupId":"OG004","value":"15.8","lowerLimit":"10.5","upperLimit":"22.5"},{"groupId":"OG005","value":"18.8","lowerLimit":"14.6","upperLimit":"23.5"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"10.7","lowerLimit":"7.5","upperLimit":"14.8"},{"groupId":"OG013","value":"13.1","lowerLimit":"9.5","upperLimit":"17.5"},{"groupId":"OG014","value":"13.0","lowerLimit":"9.4","upperLimit":"17.3"},{"groupId":"OG015","value":"11.3","lowerLimit":"8.0","upperLimit":"15.4"},{"groupId":"OG016","value":"8.3","lowerLimit":"5.4","upperLimit":"12.0"},{"groupId":"OG017","value":"13.5","lowerLimit":"9.9","upperLimit":"17.8"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG001","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG002","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG003","value":"14.6","lowerLimit":"11.5","upperLimit":"18.1"},{"groupId":"OG004","value":"11.4","lowerLimit":"6.9","upperLimit":"17.4"},{"groupId":"OG005","value":"17.8","lowerLimit":"13.8","upperLimit":"22.5"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG011","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG012","value":"5.7","lowerLimit":"3.4","upperLimit":"9.0"},{"groupId":"OG013","value":"10.4","lowerLimit":"7.2","upperLimit":"14.4"},{"groupId":"OG014","value":"12.0","lowerLimit":"8.5","upperLimit":"16.2"},{"groupId":"OG015","value":"12.0","lowerLimit":"8.5","upperLimit":"16.2"},{"groupId":"OG016","value":"4.7","lowerLimit":"2.6","upperLimit":"7.7"},{"groupId":"OG017","value":"10.3","lowerLimit":"7.1","upperLimit":"14.2"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG003","value":"0.6","lowerLimit":"0.1","upperLimit":"1.8"},{"groupId":"OG004","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.7","upperLimit":"4.0"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG014","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG015","value":"2.3","lowerLimit":"0.9","upperLimit":"4.7"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"3.1","lowerLimit":"1.8","upperLimit":"5.1"},{"groupId":"OG004","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG005","value":"3.8","lowerLimit":"2.0","upperLimit":"6.5"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG013","value":"1.7","lowerLimit":"0.5","upperLimit":"3.9"},{"groupId":"OG014","value":"3.0","lowerLimit":"1.4","upperLimit":"5.6"},{"groupId":"OG015","value":"2.7","lowerLimit":"1.2","upperLimit":"5.2"},{"groupId":"OG016","value":"1.7","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG017","value":"1.3","lowerLimit":"0.4","upperLimit":"3.2"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"2.7","lowerLimit":"1.4","upperLimit":"4.6"},{"groupId":"OG004","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG005","value":"3.4","lowerLimit":"1.7","upperLimit":"6.1"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG013","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG014","value":"2.3","lowerLimit":"0.9","upperLimit":"4.7"},{"groupId":"OG015","value":"2.3","lowerLimit":"0.9","upperLimit":"4.7"},{"groupId":"OG016","value":"1.7","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG017","value":"1.3","lowerLimit":"0.4","upperLimit":"3.2"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0.4","lowerLimit":"0.1","upperLimit":"1.5"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0.3","lowerLimit":"0.0","upperLimit":"1.7"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG013","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG014","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG015","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"12.7","lowerLimit":"9.9","upperLimit":"16.0"},{"groupId":"OG004","value":"10.8","lowerLimit":"6.4","upperLimit":"16.7"},{"groupId":"OG005","value":"12.2","lowerLimit":"8.8","upperLimit":"16.3"},{"groupId":"OG006","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"4.4","lowerLimit":"2.3","upperLimit":"7.3"},{"groupId":"OG013","value":"5.7","lowerLimit":"3.4","upperLimit":"9.0"},{"groupId":"OG014","value":"8.0","lowerLimit":"5.2","upperLimit":"11.6"},{"groupId":"OG015","value":"10.3","lowerLimit":"7.1","upperLimit":"14.3"},{"groupId":"OG016","value":"9.0","lowerLimit":"6.0","upperLimit":"12.8"},{"groupId":"OG017","value":"6.4","lowerLimit":"4.0","upperLimit":"9.7"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"5.6","upperLimit":"34.7"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"9.6","lowerLimit":"7.1","upperLimit":"12.6"},{"groupId":"OG004","value":"9.5","lowerLimit":"5.4","upperLimit":"15.2"},{"groupId":"OG005","value":"10.0","lowerLimit":"6.9","upperLimit":"13.8"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"3.4","lowerLimit":"1.6","upperLimit":"6.1"},{"groupId":"OG013","value":"3.7","lowerLimit":"1.9","upperLimit":"6.5"},{"groupId":"OG014","value":"6.6","lowerLimit":"4.1","upperLimit":"10.1"},{"groupId":"OG015","value":"9.0","lowerLimit":"6.0","upperLimit":"12.8"},{"groupId":"OG016","value":"6.0","lowerLimit":"3.6","upperLimit":"9.3"},{"groupId":"OG017","value":"5.8","lowerLimit":"3.5","upperLimit":"9.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"3.1","lowerLimit":"1.8","upperLimit":"5.1"},{"groupId":"OG004","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG005","value":"2.2","lowerLimit":"0.9","upperLimit":"4.5"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG013","value":"2.0","lowerLimit":"0.7","upperLimit":"4.3"},{"groupId":"OG014","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG015","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG016","value":"1.7","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG017","value":"0.6","lowerLimit":"0.1","upperLimit":"2.3"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"1.3","lowerLimit":"0.4","upperLimit":"3.4"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"14.7","upperLimit":"49.4"},{"groupId":"OG001","value":"30.0","lowerLimit":"14.7","upperLimit":"49.4"},{"groupId":"OG002","value":"46.7","lowerLimit":"28.3","upperLimit":"65.7"},{"groupId":"OG003","value":"39.8","lowerLimit":"35.4","upperLimit":"44.3"},{"groupId":"OG004","value":"36.7","lowerLimit":"29.2","upperLimit":"44.7"},{"groupId":"OG005","value":"42.2","lowerLimit":"36.7","upperLimit":"47.8"},{"groupId":"OG006","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG007","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG008","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG009","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG010","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG011","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG012","value":"19.8","lowerLimit":"15.4","upperLimit":"24.8"},{"groupId":"OG013","value":"25.5","lowerLimit":"20.7","upperLimit":"30.8"},{"groupId":"OG014","value":"23.9","lowerLimit":"19.2","upperLimit":"29.1"},{"groupId":"OG015","value":"30.6","lowerLimit":"25.4","upperLimit":"36.1"},{"groupId":"OG016","value":"22.3","lowerLimit":"17.7","upperLimit":"27.4"},{"groupId":"OG017","value":"27.2","lowerLimit":"22.4","upperLimit":"32.5"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG001","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG002","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG003","value":"18.3","lowerLimit":"15.0","upperLimit":"22.1"},{"groupId":"OG004","value":"20.3","lowerLimit":"14.3","upperLimit":"27.4"},{"groupId":"OG005","value":"17.8","lowerLimit":"13.8","upperLimit":"22.5"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG012","value":"11.7","lowerLimit":"8.3","upperLimit":"16.0"},{"groupId":"OG013","value":"10.1","lowerLimit":"6.9","upperLimit":"14.1"},{"groupId":"OG014","value":"11.6","lowerLimit":"8.2","upperLimit":"15.8"},{"groupId":"OG015","value":"12.6","lowerLimit":"9.1","upperLimit":"16.9"},{"groupId":"OG016","value":"13.3","lowerLimit":"9.7","upperLimit":"17.7"},{"groupId":"OG017","value":"14.1","lowerLimit":"10.4","upperLimit":"18.5"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG001","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG002","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG003","value":"21.3","lowerLimit":"17.7","upperLimit":"25.2"},{"groupId":"OG004","value":"15.8","lowerLimit":"10.5","upperLimit":"22.5"},{"groupId":"OG005","value":"22.2","lowerLimit":"17.8","upperLimit":"27.1"},{"groupId":"OG006","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG007","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG010","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG011","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG012","value":"8.1","lowerLimit":"5.2","upperLimit":"11.7"},{"groupId":"OG013","value":"14.4","lowerLimit":"10.6","upperLimit":"18.9"},{"groupId":"OG014","value":"12.0","lowerLimit":"8.5","upperLimit":"16.2"},{"groupId":"OG015","value":"15.9","lowerLimit":"12.0","upperLimit":"20.6"},{"groupId":"OG016","value":"9.0","lowerLimit":"6.0","upperLimit":"12.8"},{"groupId":"OG017","value":"12.8","lowerLimit":"9.3","upperLimit":"17.0"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG004","value":"0.6","lowerLimit":"0.0","upperLimit":"3.5"},{"groupId":"OG005","value":"2.2","lowerLimit":"0.9","upperLimit":"4.5"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"1.0","lowerLimit":"0.2","upperLimit":"2.9"},{"groupId":"OG014","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG015","value":"2.0","lowerLimit":"0.7","upperLimit":"4.3"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"},{"groupId":"OG001","value":"16.7","lowerLimit":"5.6","upperLimit":"34.7"},{"groupId":"OG002","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG003","value":"25.4","lowerLimit":"21.6","upperLimit":"29.6"},{"groupId":"OG004","value":"20.9","lowerLimit":"14.8","upperLimit":"28.1"},{"groupId":"OG005","value":"24.1","lowerLimit":"19.5","upperLimit":"29.1"},{"groupId":"OG006","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG007","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG010","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG011","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG012","value":"9.1","lowerLimit":"6.1","upperLimit":"12.9"},{"groupId":"OG013","value":"16.1","lowerLimit":"12.1","upperLimit":"20.8"},{"groupId":"OG014","value":"16.6","lowerLimit":"12.6","upperLimit":"21.3"},{"groupId":"OG015","value":"19.6","lowerLimit":"15.3","upperLimit":"24.5"},{"groupId":"OG016","value":"11.3","lowerLimit":"8.0","upperLimit":"15.4"},{"groupId":"OG017","value":"18.6","lowerLimit":"14.4","upperLimit":"23.4"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG001","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG002","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG003","value":"12.5","lowerLimit":"9.7","upperLimit":"15.8"},{"groupId":"OG004","value":"10.1","lowerLimit":"5.9","upperLimit":"15.9"},{"groupId":"OG005","value":"9.1","lowerLimit":"6.2","upperLimit":"12.8"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG008","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG009","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG012","value":"5.4","lowerLimit":"3.1","upperLimit":"8.6"},{"groupId":"OG013","value":"9.7","lowerLimit":"6.6","upperLimit":"13.7"},{"groupId":"OG014","value":"9.3","lowerLimit":"6.3","upperLimit":"13.2"},{"groupId":"OG015","value":"8.3","lowerLimit":"5.4","upperLimit":"12.0"},{"groupId":"OG016","value":"7.6","lowerLimit":"4.9","upperLimit":"11.2"},{"groupId":"OG017","value":"10.3","lowerLimit":"7.1","upperLimit":"14.2"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"2.1","upperLimit":"26.5"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.1","upperLimit":"17.2"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"12.5","lowerLimit":"9.7","upperLimit":"15.8"},{"groupId":"OG004","value":"10.8","lowerLimit":"6.4","upperLimit":"16.7"},{"groupId":"OG005","value":"14.1","lowerLimit":"10.4","upperLimit":"18.4"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG008","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG011","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG012","value":"3.7","lowerLimit":"1.9","upperLimit":"6.5"},{"groupId":"OG013","value":"6.0","lowerLimit":"3.6","upperLimit":"9.4"},{"groupId":"OG014","value":"7.3","lowerLimit":"4.6","upperLimit":"10.9"},{"groupId":"OG015","value":"11.0","lowerLimit":"7.7","upperLimit":"15.1"},{"groupId":"OG016","value":"3.7","lowerLimit":"1.8","upperLimit":"6.4"},{"groupId":"OG017","value":"8.0","lowerLimit":"5.3","upperLimit":"11.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0.4","lowerLimit":"0.1","upperLimit":"1.5"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0.9","lowerLimit":"0.2","upperLimit":"2.7"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0.3","lowerLimit":"0.0","upperLimit":"1.9"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0.3","lowerLimit":"0.0","upperLimit":"1.8"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"2.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG012","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG013","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG014","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG015","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG017","value":"0","lowerLimit":"0.0","upperLimit":"1.2"}]}]}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From study vaccination up to 1 Month after study vaccination","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG006","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG007","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG008","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG009","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG010","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG011","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG012","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG013","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG014","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG015","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG016","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG017","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"482"},{"groupId":"OG004","value":"159"},{"groupId":"OG005","value":"321"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"20"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"20"},{"groupId":"OG012","value":"305"},{"groupId":"OG013","value":"302"},{"groupId":"OG014","value":"307"},{"groupId":"OG015","value":"306"},{"groupId":"OG016","value":"305"},{"groupId":"OG017","value":"313"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG001","value":"6.7","lowerLimit":"0.8","upperLimit":"22.1"},{"groupId":"OG002","value":"13.3","lowerLimit":"3.8","upperLimit":"30.7"},{"groupId":"OG003","value":"7.7","lowerLimit":"5.5","upperLimit":"10.4"},{"groupId":"OG004","value":"6.3","lowerLimit":"3.1","upperLimit":"11.3"},{"groupId":"OG005","value":"9.3","lowerLimit":"6.4","upperLimit":"13.1"},{"groupId":"OG006","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG009","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG010","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"5.9","lowerLimit":"3.5","upperLimit":"9.2"},{"groupId":"OG013","value":"6.6","lowerLimit":"4.1","upperLimit":"10.0"},{"groupId":"OG014","value":"8.5","lowerLimit":"5.6","upperLimit":"12.2"},{"groupId":"OG015","value":"3.6","lowerLimit":"1.8","upperLimit":"6.3"},{"groupId":"OG016","value":"6.2","lowerLimit":"3.8","upperLimit":"9.6"},{"groupId":"OG017","value":"10.4","lowerLimit":"7.3","upperLimit":"14.4"}]}]}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From study vaccination up to 6 Months after study vaccination","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG006","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG007","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG008","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG009","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG010","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG011","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG012","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG013","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG014","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG015","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG016","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG017","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"482"},{"groupId":"OG004","value":"159"},{"groupId":"OG005","value":"321"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"20"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"20"},{"groupId":"OG012","value":"305"},{"groupId":"OG013","value":"302"},{"groupId":"OG014","value":"307"},{"groupId":"OG015","value":"307"},{"groupId":"OG016","value":"304"},{"groupId":"OG017","value":"313"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG003","value":"0.6","lowerLimit":"0.1","upperLimit":"1.8"},{"groupId":"OG004","value":"1.3","lowerLimit":"0.2","upperLimit":"4.5"},{"groupId":"OG005","value":"0.9","lowerLimit":"0.2","upperLimit":"2.7"},{"groupId":"OG006","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG007","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG008","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG009","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG010","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG011","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG012","value":"2.0","lowerLimit":"0.7","upperLimit":"4.2"},{"groupId":"OG013","value":"0.7","lowerLimit":"0.1","upperLimit":"2.4"},{"groupId":"OG014","value":"3.9","lowerLimit":"2.0","upperLimit":"6.7"},{"groupId":"OG015","value":"1.3","lowerLimit":"0.4","upperLimit":"3.3"},{"groupId":"OG016","value":"1.3","lowerLimit":"0.4","upperLimit":"3.3"},{"groupId":"OG017","value":"1.9","lowerLimit":"0.7","upperLimit":"4.1"}]}]}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age","description":"Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. As pre-specified in the protocol, this outcome measure was planned to be analyzed only in the Sentinel Cohort in participants of 18 to 55 years of age.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before study vaccination (pre-dose)","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"}]}]}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age","description":"Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. As pre-specified in the protocol, this outcome measure was planned to be analyzed only in the Sentinel Cohort in participants of 18 to 55 years of age.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"3 days after study vaccination","groups":[{"id":"OG000","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"11.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"11.6"}]}]}]},{"type":"PRIMARY","title":"SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination","description":"GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"EIP: all eligible randomized participants who received study intervention to which they were randomized, had valid and determinate immunogenicity result within 28-42 days after study vaccination, had no other important protocol deviations as determined by the clinician. 'N' = participants evaluable for this outcome measure. As pre-specified in the protocol, this outcome measure was not planned to be analyzed in ''SSE: Expanded Cohort (\\> 55 Years): BNT162b2 60 mcg''.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after study vaccination","groups":[{"id":"OG000","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"169"},{"groupId":"OG002","value":"174"},{"groupId":"OG003","value":"178"},{"groupId":"OG004","value":"175"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"455.8","lowerLimit":"365.9","upperLimit":"567.6"},{"groupId":"OG001","value":"1014.5","lowerLimit":"825.6","upperLimit":"1246.7"},{"groupId":"OG002","value":"1435.2","lowerLimit":"1208.1","upperLimit":"1704.8"},{"groupId":"OG003","value":"711.0","lowerLimit":"588.3","upperLimit":"859.2"},{"groupId":"OG004","value":"900.1","lowerLimit":"726.3","upperLimit":"1115.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.65","ciUpperLimit":"3.00"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"3.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.38","ciUpperLimit":"4.16"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.17","ciUpperLimit":"2.08"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.45","ciUpperLimit":"2.68"}]},{"type":"PRIMARY","title":"SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \\>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","populationDescription":"EIP: all eligible randomized participants who received study intervention to which they were randomized, had valid and determinate immunogenicity result within 28-42 days after study vaccination, had no other important protocol deviations as determined by the clinician. 'N' = participants evaluable for this outcome measure. As pre-specified in the protocol, this outcome measure was not planned to be analyzed in ''SSE: Expanded Cohort (\\> 55 Years): BNT162b2 60 mcg''.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after study vaccination","groups":[{"id":"OG000","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"166"},{"groupId":"OG003","value":"169"},{"groupId":"OG004","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","lowerLimit":"48.7","upperLimit":"65.1"},{"groupId":"OG001","value":"76.7","lowerLimit":"69.4","upperLimit":"82.9"},{"groupId":"OG002","value":"86.1","lowerLimit":"79.9","upperLimit":"91.0"},{"groupId":"OG003","value":"71.6","lowerLimit":"64.2","upperLimit":"78.3"},{"groupId":"OG004","value":"67.9","lowerLimit":"60.1","upperLimit":"75.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in percentages","paramValue":"19.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"9.3","ciUpperLimit":"29.7"},{"groupIds":["OG000","OG002"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 μg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"29.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"19.4","ciUpperLimit":"38.5"},{"groupIds":["OG000","OG003"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 μg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in percentages","paramValue":"14.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.0","ciUpperLimit":"24.9"},{"groupIds":["OG000","OG004"],"groupDescription":"Difference in proportions, expressed as a percentage (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 μg\\]). 2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"10.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.1","ciUpperLimit":"21.4"}]},{"type":"PRIMARY","title":"SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before vaccination (pre-dose)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","lowerLimit":"22.4","upperLimit":"77.4"},{"groupId":"OG001","value":"33.2","lowerLimit":"17.6","upperLimit":"62.6"},{"groupId":"OG002","value":"32.0","lowerLimit":"17.0","upperLimit":"60.1"},{"groupId":"OG003","value":"36.8","lowerLimit":"17.5","upperLimit":"77.1"},{"groupId":"OG004","value":"78.8","lowerLimit":"29.3","upperLimit":"211.6"},{"groupId":"OG005","value":"21.5","lowerLimit":"14.2","upperLimit":"32.7"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination","description":"Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and Grade 4 (emergency room \\[ER\\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \\[swelling\\] or necrosis/exfoliative dermatitis \\[redness\\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after the study vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"},{"groupId":"OG001","value":"21.1","lowerLimit":"6.1","upperLimit":"45.6"},{"groupId":"OG002","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"},{"groupId":"OG003","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG004","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG005","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"47.8","upperLimit":"88.7"},{"groupId":"OG001","value":"94.7","lowerLimit":"74.0","upperLimit":"99.9"},{"groupId":"OG002","value":"90.5","lowerLimit":"69.6","upperLimit":"98.8"},{"groupId":"OG003","value":"80.0","lowerLimit":"56.3","upperLimit":"94.3"},{"groupId":"OG004","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"},{"groupId":"OG005","value":"90.5","lowerLimit":"69.6","upperLimit":"98.8"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"52.4","lowerLimit":"29.8","upperLimit":"74.3"},{"groupId":"OG001","value":"52.6","lowerLimit":"28.9","upperLimit":"75.6"},{"groupId":"OG002","value":"66.7","lowerLimit":"43.0","upperLimit":"85.4"},{"groupId":"OG003","value":"45.0","lowerLimit":"23.1","upperLimit":"68.5"},{"groupId":"OG004","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG005","value":"57.1","lowerLimit":"34.0","upperLimit":"78.2"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"},{"groupId":"OG001","value":"36.8","lowerLimit":"16.3","upperLimit":"61.6"},{"groupId":"OG002","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"},{"groupId":"OG003","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG004","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG005","value":"33.3","lowerLimit":"14.6","upperLimit":"57.0"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination","description":"Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \\>=38.0-38.4 deg C, \\>38.4-38.9 deg C, \\>38.9-40.0 deg C \\& \\>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \\> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population included all participants receiving at least 1 dose of study intervention. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 up to Day 7 after the study vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"title":"Fever: >= 38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"Fever: >= 38.0 deg C to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"Fever: >38.4 deg C to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Fever: >38.9 deg C to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"47.6","lowerLimit":"25.7","upperLimit":"70.2"},{"groupId":"OG001","value":"36.8","lowerLimit":"16.3","upperLimit":"61.6"},{"groupId":"OG002","value":"42.9","lowerLimit":"21.8","upperLimit":"66.0"},{"groupId":"OG003","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG004","value":"50.0","lowerLimit":"27.2","upperLimit":"72.8"},{"groupId":"OG005","value":"57.1","lowerLimit":"34.0","upperLimit":"78.2"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"23.8","lowerLimit":"8.5","upperLimit":"47.2"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"},{"groupId":"OG001","value":"21.1","lowerLimit":"6.1","upperLimit":"45.6"},{"groupId":"OG002","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"},{"groupId":"OG003","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG004","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG005","value":"33.3","lowerLimit":"14.6","upperLimit":"57.0"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"},{"groupId":"OG001","value":"26.3","lowerLimit":"9.1","upperLimit":"51.2"},{"groupId":"OG002","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"},{"groupId":"OG003","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG004","value":"35.0","lowerLimit":"15.4","upperLimit":"59.2"},{"groupId":"OG005","value":"38.1","lowerLimit":"18.1","upperLimit":"61.6"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"},{"groupId":"OG001","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG004","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG005","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG004","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG005","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.7"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"},{"groupId":"OG002","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"},{"groupId":"OG003","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"},{"groupId":"OG001","value":"42.1","lowerLimit":"20.3","upperLimit":"66.5"},{"groupId":"OG002","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"},{"groupId":"OG003","value":"30.0","lowerLimit":"11.9","upperLimit":"54.3"},{"groupId":"OG004","value":"25.0","lowerLimit":"8.7","upperLimit":"49.1"},{"groupId":"OG005","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.9"},{"groupId":"OG004","value":"15.0","lowerLimit":"3.2","upperLimit":"37.9"},{"groupId":"OG005","value":"23.8","lowerLimit":"8.2","upperLimit":"47.2"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"31.6","lowerLimit":"12.6","upperLimit":"56.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG001","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"},{"groupId":"OG002","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"},{"groupId":"OG003","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"17.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From study vaccination up to 1 Month after study vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG002","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"},{"groupId":"OG003","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG004","value":"10.0","lowerLimit":"1.2","upperLimit":"31.7"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From study vaccination up to 6 Months after study vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.1"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"},{"groupId":"OG002","value":"4.8","lowerLimit":"0.1","upperLimit":"23.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"16.8"},{"groupId":"OG004","value":"5.0","lowerLimit":"0.1","upperLimit":"24.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"16.1"}]}]}]},{"type":"PRIMARY","title":"SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before vaccination (pre-dose)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"541.1","lowerLimit":"345.1","upperLimit":"848.3"},{"groupId":"OG001","value":"382.4","lowerLimit":"176.3","upperLimit":"829.3"},{"groupId":"OG002","value":"437.5","lowerLimit":"244.0","upperLimit":"784.2"},{"groupId":"OG003","value":"315.2","lowerLimit":"188.0","upperLimit":"528.4"},{"groupId":"OG004","value":"803.4","lowerLimit":"347.8","upperLimit":"1855.8"},{"groupId":"OG005","value":"256.0","lowerLimit":"135.1","upperLimit":"485.0"}]}]}]},{"type":"PRIMARY","title":"SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination","description":"GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before vaccination (pre-dose)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","lowerLimit":"16.8","upperLimit":"43.7"},{"groupId":"OG001","value":"18.0","lowerLimit":"12.1","upperLimit":"26.7"},{"groupId":"OG002","value":"20.2","lowerLimit":"12.6","upperLimit":"32.3"},{"groupId":"OG003","value":"23.4","lowerLimit":"13.9","upperLimit":"39.4"},{"groupId":"OG004","value":"42.2","lowerLimit":"19.6","upperLimit":"91.1"},{"groupId":"OG005","value":"15.0","lowerLimit":"11.8","upperLimit":"19.1"}]}]}]},{"type":"PRIMARY","title":"SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146.1","lowerLimit":"102.5","upperLimit":"208.2"},{"groupId":"OG001","value":"101.6","lowerLimit":"48.6","upperLimit":"212.6"},{"groupId":"OG002","value":"217.1","lowerLimit":"97.8","upperLimit":"481.9"},{"groupId":"OG003","value":"315.2","lowerLimit":"164.6","upperLimit":"603.5"},{"groupId":"OG004","value":"337.8","lowerLimit":"133.8","upperLimit":"852.7"},{"groupId":"OG005","value":"222.9","lowerLimit":"125.7","upperLimit":"395.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.79","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"1.56"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"3.43"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.22","ciUpperLimit":"4.55"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\]- BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"2.89"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.20","ciUpperLimit":"4.53"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1917.2","lowerLimit":"1153.8","upperLimit":"3185.7"},{"groupId":"OG001","value":"1241.4","lowerLimit":"624.3","upperLimit":"2468.6"},{"groupId":"OG002","value":"1472.3","lowerLimit":"855.4","upperLimit":"2534.0"},{"groupId":"OG003","value":"1499.2","lowerLimit":"838.6","upperLimit":"2680.4"},{"groupId":"OG004","value":"2702.4","lowerLimit":"1419.7","upperLimit":"5143.8"},{"groupId":"OG005","value":"1845.8","lowerLimit":"1087.4","upperLimit":"3133.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"1.42"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.47","ciUpperLimit":"1.58"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.57","ciUpperLimit":"1.95"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.61","ciUpperLimit":"2.09"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"2.50"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","lowerLimit":"52.7","upperLimit":"108.0"},{"groupId":"OG001","value":"56.6","lowerLimit":"32.1","upperLimit":"99.8"},{"groupId":"OG002","value":"73.0","lowerLimit":"38.7","upperLimit":"137.9"},{"groupId":"OG003","value":"76.1","lowerLimit":"46.0","upperLimit":"125.9"},{"groupId":"OG004","value":"123.6","lowerLimit":"63.8","upperLimit":"239.5"},{"groupId":"OG005","value":"70.7","lowerLimit":"48.5","upperLimit":"103.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.58","ciUpperLimit":"1.56"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.93"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.80"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.84"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"2.37"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"420.0","lowerLimit":"252.2","upperLimit":"699.5"},{"groupId":"OG001","value":"188.1","lowerLimit":"88.9","upperLimit":"398.2"},{"groupId":"OG002","value":"699.4","lowerLimit":"398.9","upperLimit":"1226.4"},{"groupId":"OG003","value":"675.6","lowerLimit":"343.2","upperLimit":"1329.8"},{"groupId":"OG004","value":"1024.0","lowerLimit":"509.4","upperLimit":"2058.3"},{"groupId":"OG005","value":"477.7","lowerLimit":"236.0","upperLimit":"967.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"1.03"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"3.76"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"3.50"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"3.59"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"3.20"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4674.1","lowerLimit":"3112.1","upperLimit":"7020.2"},{"groupId":"OG001","value":"2048.4","lowerLimit":"1007.8","upperLimit":"4163.7"},{"groupId":"OG002","value":"3327.0","lowerLimit":"1867.6","upperLimit":"5926.9"},{"groupId":"OG003","value":"3565.8","lowerLimit":"1992.1","upperLimit":"6382.7"},{"groupId":"OG004","value":"5404.7","lowerLimit":"3359.8","upperLimit":"8694.1"},{"groupId":"OG005","value":"2521.4","lowerLimit":"1388.9","upperLimit":"4577.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.26","ciUpperLimit":"0.95"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"1.43"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"1.84"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"1.80"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"1.34"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157.6","lowerLimit":"94.0","upperLimit":"264.2"},{"groupId":"OG001","value":"85.7","lowerLimit":"52.5","upperLimit":"139.8"},{"groupId":"OG002","value":"151.0","lowerLimit":"72.6","upperLimit":"314.1"},{"groupId":"OG003","value":"230.7","lowerLimit":"140.0","upperLimit":"379.2"},{"groupId":"OG004","value":"284.0","lowerLimit":"134.7","upperLimit":"599.1"},{"groupId":"OG005","value":"147.0","lowerLimit":"86.3","upperLimit":"250.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"1.37"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.65","ciUpperLimit":"2.21"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"3.02"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"2.39"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"2.67"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 3 (3 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247.3","lowerLimit":"119.7","upperLimit":"510.7"},{"groupId":"OG001","value":"118.5","lowerLimit":"54.6","upperLimit":"257.1"},{"groupId":"OG002","value":"461.4","lowerLimit":"203.8","upperLimit":"1044.7"},{"groupId":"OG003","value":"711.0","lowerLimit":"388.8","upperLimit":"1300.1"},{"groupId":"OG004","value":"512.0","lowerLimit":"246.9","upperLimit":"1061.6"},{"groupId":"OG005","value":"285.6","lowerLimit":"132.8","upperLimit":"614.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.21","ciUpperLimit":"1.25"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"4.88"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.24","ciUpperLimit":"7.06"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"3.62"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio","paramValue":"1.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"3.67"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 3 (3 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2896.3","lowerLimit":"1738.8","upperLimit":"4824.3"},{"groupId":"OG001","value":"1290.2","lowerLimit":"675.2","upperLimit":"2465.3"},{"groupId":"OG002","value":"2610.3","lowerLimit":"1265.9","upperLimit":"5382.4"},{"groupId":"OG003","value":"2949.6","lowerLimit":"1550.2","upperLimit":"5612.3"},{"groupId":"OG004","value":"2610.3","lowerLimit":"1506.5","upperLimit":"4522.8"},{"groupId":"OG005","value":"1474.8","lowerLimit":"815.0","upperLimit":"2668.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.25","ciUpperLimit":"1.09"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"2.04"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"2.68"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"1.59"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.32","ciUpperLimit":"1.36"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 3 (3 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222.9","lowerLimit":"123.3","upperLimit":"402.7"},{"groupId":"OG001","value":"132.8","lowerLimit":"63.7","upperLimit":"276.7"},{"groupId":"OG002","value":"322.5","lowerLimit":"147.6","upperLimit":"704.6"},{"groupId":"OG003","value":"458.9","lowerLimit":"206.8","upperLimit":"1018.6"},{"groupId":"OG004","value":"296.2","lowerLimit":"143.2","upperLimit":"612.6"},{"groupId":"OG005","value":"141.3","lowerLimit":"86.4","upperLimit":"231.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.32","ciUpperLimit":"1.76"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"3.85"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.92","ciUpperLimit":"4.91"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.43","ciUpperLimit":"2.33"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"2.04"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 6 (6 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239.6","lowerLimit":"98.8","upperLimit":"581.4"},{"groupId":"OG001","value":"229.5","lowerLimit":"68.7","upperLimit":"766.4"},{"groupId":"OG002","value":"1058.4","lowerLimit":"490.3","upperLimit":"2284.6"},{"groupId":"OG003","value":"1722.2","lowerLimit":"844.3","upperLimit":"3512.9"},{"groupId":"OG004","value":"588.1","lowerLimit":"280.3","upperLimit":"1234.2"},{"groupId":"OG005","value":"284.0","lowerLimit":"131.8","upperLimit":"612.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.31","ciUpperLimit":"3.12"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"4.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.49","ciUpperLimit":"14.07"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"7.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.34","ciUpperLimit":"22.76"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"7.10"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"4.03"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 6 (6 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1424.5","lowerLimit":"667.9","upperLimit":"3037.9"},{"groupId":"OG001","value":"1371.0","lowerLimit":"508.5","upperLimit":"3696.4"},{"groupId":"OG002","value":"2756.4","lowerLimit":"1328.0","upperLimit":"5721.4"},{"groupId":"OG003","value":"3956.5","lowerLimit":"2256.3","upperLimit":"6937.8"},{"groupId":"OG004","value":"2702.4","lowerLimit":"1457.6","upperLimit":"5010.0"},{"groupId":"OG005","value":"1097.5","lowerLimit":"555.3","upperLimit":"2169.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"2.70"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"5.20"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.13","ciUpperLimit":"7.94"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"4.75"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.32","ciUpperLimit":"2.24"}]},{"type":"PRIMARY","title":"SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6","description":"GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","populationDescription":"All-available immunogenicity population included all randomized participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Month 6 (6 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203.2","lowerLimit":"85.5","upperLimit":"483.1"},{"groupId":"OG001","value":"265.5","lowerLimit":"75.9","upperLimit":"928.9"},{"groupId":"OG002","value":"645.1","lowerLimit":"281.1","upperLimit":"1480.5"},{"groupId":"OG003","value":"1305.2","lowerLimit":"601.1","upperLimit":"2834.1"},{"groupId":"OG004","value":"430.5","lowerLimit":"204.7","upperLimit":"905.4"},{"groupId":"OG005","value":"187.4","lowerLimit":"80.5","upperLimit":"436.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.44","ciUpperLimit":"5.12"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"3.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.99","ciUpperLimit":"10.46"},{"groupIds":["OG000","OG003"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 OMI \\[60 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"6.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.96","ciUpperLimit":"21.27"},{"groupIds":["OG000","OG004"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"2.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"6.89"},{"groupIds":["OG000","OG005"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the difference in LS means (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of baseline assay results (log scale) and vaccine group.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"3.17"}]},{"type":"PRIMARY","title":"SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.1","upperLimit":"5.8"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.6","upperLimit":"5.4"},{"groupId":"OG002","value":"6.8","lowerLimit":"4.3","upperLimit":"10.7"},{"groupId":"OG003","value":"8.6","lowerLimit":"5.1","upperLimit":"14.3"},{"groupId":"OG004","value":"4.3","lowerLimit":"2.0","upperLimit":"9.1"},{"groupId":"OG005","value":"9.8","lowerLimit":"6.9","upperLimit":"14.0"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.5","upperLimit":"5.0"},{"groupId":"OG001","value":"3.1","lowerLimit":"1.8","upperLimit":"5.2"},{"groupId":"OG002","value":"3.4","lowerLimit":"2.2","upperLimit":"5.1"},{"groupId":"OG003","value":"4.8","lowerLimit":"3.0","upperLimit":"7.5"},{"groupId":"OG004","value":"3.4","lowerLimit":"1.4","upperLimit":"8.1"},{"groupId":"OG005","value":"6.3","lowerLimit":"3.9","upperLimit":"10.2"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"2.1","upperLimit":"3.7"},{"groupId":"OG001","value":"2.8","lowerLimit":"1.8","upperLimit":"4.4"},{"groupId":"OG002","value":"3.6","lowerLimit":"2.5","upperLimit":"5.2"},{"groupId":"OG003","value":"3.2","lowerLimit":"2.2","upperLimit":"4.8"},{"groupId":"OG004","value":"2.9","lowerLimit":"1.9","upperLimit":"4.4"},{"groupId":"OG005","value":"4.7","lowerLimit":"3.4","upperLimit":"6.5"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 1 month after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"5.5","upperLimit":"18.4"},{"groupId":"OG001","value":"5.4","lowerLimit":"2.6","upperLimit":"11.4"},{"groupId":"OG002","value":"20.4","lowerLimit":"11.8","upperLimit":"35.3"},{"groupId":"OG003","value":"18.4","lowerLimit":"9.5","upperLimit":"35.6"},{"groupId":"OG004","value":"13.0","lowerLimit":"6.7","upperLimit":"25.1"},{"groupId":"OG005","value":"21.1","lowerLimit":"11.5","upperLimit":"38.8"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 1 month after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"5.5","upperLimit":"13.6"},{"groupId":"OG001","value":"5.0","lowerLimit":"2.5","upperLimit":"10.0"},{"groupId":"OG002","value":"7.2","lowerLimit":"4.7","upperLimit":"10.9"},{"groupId":"OG003","value":"11.3","lowerLimit":"6.2","upperLimit":"20.8"},{"groupId":"OG004","value":"6.7","lowerLimit":"3.7","upperLimit":"12.1"},{"groupId":"OG005","value":"8.6","lowerLimit":"4.1","upperLimit":"17.8"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 1 month after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"3.8","upperLimit":"9.1"},{"groupId":"OG001","value":"4.7","lowerLimit":"3.1","upperLimit":"7.1"},{"groupId":"OG002","value":"7.5","lowerLimit":"4.6","upperLimit":"12.3"},{"groupId":"OG003","value":"9.8","lowerLimit":"7.3","upperLimit":"13.3"},{"groupId":"OG004","value":"6.7","lowerLimit":"3.5","upperLimit":"13.0"},{"groupId":"OG005","value":"9.5","lowerLimit":"6.0","upperLimit":"15.2"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 3 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"2.7","upperLimit":"12.8"},{"groupId":"OG001","value":"3.3","lowerLimit":"1.4","upperLimit":"7.5"},{"groupId":"OG002","value":"13.5","lowerLimit":"6.0","upperLimit":"30.0"},{"groupId":"OG003","value":"17.9","lowerLimit":"8.7","upperLimit":"36.5"},{"groupId":"OG004","value":"6.5","lowerLimit":"3.2","upperLimit":"13.1"},{"groupId":"OG005","value":"12.0","lowerLimit":"6.4","upperLimit":"22.3"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 3 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"2.9","upperLimit":"8.5"},{"groupId":"OG001","value":"3.2","lowerLimit":"1.6","upperLimit":"6.3"},{"groupId":"OG002","value":"5.6","lowerLimit":"2.6","upperLimit":"11.9"},{"groupId":"OG003","value":"8.6","lowerLimit":"4.3","upperLimit":"17.2"},{"groupId":"OG004","value":"3.2","lowerLimit":"1.8","upperLimit":"5.8"},{"groupId":"OG005","value":"4.5","lowerLimit":"2.4","upperLimit":"8.2"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 3 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"4.3","upperLimit":"16.9"},{"groupId":"OG001","value":"7.4","lowerLimit":"3.7","upperLimit":"14.9"},{"groupId":"OG002","value":"16.0","lowerLimit":"7.5","upperLimit":"34.0"},{"groupId":"OG003","value":"18.5","lowerLimit":"9.2","upperLimit":"37.3"},{"groupId":"OG004","value":"7.2","lowerLimit":"4.1","upperLimit":"12.7"},{"groupId":"OG005","value":"9.4","lowerLimit":"5.9","upperLimit":"15.2"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 6 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"2.2","upperLimit":"15.0"},{"groupId":"OG001","value":"6.9","lowerLimit":"1.6","upperLimit":"30.4"},{"groupId":"OG002","value":"33.1","lowerLimit":"13.7","upperLimit":"79.6"},{"groupId":"OG003","value":"46.9","lowerLimit":"17.6","upperLimit":"124.7"},{"groupId":"OG004","value":"7.5","lowerLimit":"2.4","upperLimit":"22.8"},{"groupId":"OG005","value":"12.6","lowerLimit":"5.8","upperLimit":"27.3"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 6 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.1","upperLimit":"6.1"},{"groupId":"OG001","value":"3.6","lowerLimit":"1.0","upperLimit":"12.7"},{"groupId":"OG002","value":"6.3","lowerLimit":"2.6","upperLimit":"15.2"},{"groupId":"OG003","value":"12.6","lowerLimit":"6.0","upperLimit":"26.1"},{"groupId":"OG004","value":"3.4","lowerLimit":"1.3","upperLimit":"8.9"},{"groupId":"OG005","value":"3.9","lowerLimit":"1.8","upperLimit":"8.2"}]}]}]},{"type":"PRIMARY","title":"SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination","description":"GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before the study vaccination to 6 months after vaccination","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"2.8","upperLimit":"20.2"},{"groupId":"OG001","value":"16.6","lowerLimit":"4.1","upperLimit":"66.8"},{"groupId":"OG002","value":"32.0","lowerLimit":"12.7","upperLimit":"80.7"},{"groupId":"OG003","value":"55.7","lowerLimit":"22.2","upperLimit":"140.0"},{"groupId":"OG004","value":"10.2","lowerLimit":"3.7","upperLimit":"28.0"},{"groupId":"OG005","value":"13.0","lowerLimit":"5.4","upperLimit":"31.4"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","lowerLimit":"29.8","upperLimit":"74.3"},{"groupId":"OG001","value":"44.4","lowerLimit":"21.5","upperLimit":"69.2"},{"groupId":"OG002","value":"71.4","lowerLimit":"47.8","upperLimit":"88.7"},{"groupId":"OG003","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG004","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG005","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","lowerLimit":"29.8","upperLimit":"74.3"},{"groupId":"OG001","value":"55.6","lowerLimit":"30.8","upperLimit":"78.5"},{"groupId":"OG002","value":"61.9","lowerLimit":"38.4","upperLimit":"81.9"},{"groupId":"OG003","value":"80.0","lowerLimit":"56.3","upperLimit":"94.3"},{"groupId":"OG004","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG005","value":"80.0","lowerLimit":"56.3","upperLimit":"94.3"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 7 (7 days after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"14.6","upperLimit":"57.0"},{"groupId":"OG001","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"},{"groupId":"OG002","value":"42.9","lowerLimit":"21.8","upperLimit":"66.0"},{"groupId":"OG003","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG004","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG005","value":"61.9","lowerLimit":"38.4","upperLimit":"81.9"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","lowerLimit":"63.7","upperLimit":"97.0"},{"groupId":"OG001","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"},{"groupId":"OG002","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"},{"groupId":"OG003","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG004","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"},{"groupId":"OG005","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","lowerLimit":"58.1","upperLimit":"94.6"},{"groupId":"OG001","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"},{"groupId":"OG002","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG003","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG004","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG005","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 1 (1 month after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"},{"groupId":"OG001","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"},{"groupId":"OG002","value":"66.7","lowerLimit":"43.0","upperLimit":"85.4"},{"groupId":"OG003","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"},{"groupId":"OG004","value":"80.0","lowerLimit":"56.3","upperLimit":"94.3"},{"groupId":"OG005","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 3 (3 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG001","value":"50.0","lowerLimit":"26.0","upperLimit":"74.0"},{"groupId":"OG002","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"},{"groupId":"OG003","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG004","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG005","value":"89.5","lowerLimit":"66.9","upperLimit":"98.7"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 3 (3 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Edit Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG001","value":"55.6","lowerLimit":"30.8","upperLimit":"78.5"},{"groupId":"OG002","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG003","value":"78.9","lowerLimit":"54.4","upperLimit":"93.9"},{"groupId":"OG004","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG005","value":"63.2","lowerLimit":"38.4","upperLimit":"83.7"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 3 (3 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"},{"groupId":"OG001","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"},{"groupId":"OG002","value":"85.7","lowerLimit":"63.7","upperLimit":"97.0"},{"groupId":"OG003","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG004","value":"63.2","lowerLimit":"38.4","upperLimit":"83.7"},{"groupId":"OG005","value":"85.7","lowerLimit":"63.7","upperLimit":"97.0"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 6 (6 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","lowerLimit":"21.8","upperLimit":"66.0"},{"groupId":"OG001","value":"47.4","lowerLimit":"24.4","upperLimit":"71.1"},{"groupId":"OG002","value":"85.7","lowerLimit":"63.7","upperLimit":"97.0"},{"groupId":"OG003","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"},{"groupId":"OG004","value":"65.0","lowerLimit":"40.8","upperLimit":"84.6"},{"groupId":"OG005","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 6 (6 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","lowerLimit":"21.8","upperLimit":"66.0"},{"groupId":"OG001","value":"42.1","lowerLimit":"20.3","upperLimit":"66.5"},{"groupId":"OG002","value":"61.9","lowerLimit":"38.4","upperLimit":"81.9"},{"groupId":"OG003","value":"85.0","lowerLimit":"62.1","upperLimit":"96.8"},{"groupId":"OG004","value":"55.0","lowerLimit":"31.5","upperLimit":"76.9"},{"groupId":"OG005","value":"50.0","lowerLimit":"27.2","upperLimit":"72.8"}]}]}]},{"type":"PRIMARY","title":"SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6","description":"Seroresponse was defined as achieving \\>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Month 6 (6 months after vaccination)","groups":[{"id":"OG000","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG003","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG004","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG005","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","lowerLimit":"29.8","upperLimit":"74.3"},{"groupId":"OG001","value":"50.0","lowerLimit":"26.0","upperLimit":"74.0"},{"groupId":"OG002","value":"85.7","lowerLimit":"63.7","upperLimit":"97.0"},{"groupId":"OG003","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"},{"groupId":"OG004","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG005","value":"75.0","lowerLimit":"50.9","upperLimit":"91.3"}]}]}]},{"type":"SECONDARY","title":"SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population","description":"Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \\[\\>=\\]30 breaths per minute, heart rate \\>= 125 beats per minute, oxygen saturation less than or equal to \\[\\<=\\]93% on room air at sea level, or Horovitz quotient \\<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \\[BP\\] \\<90 mmHg, diastolic BP \\<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.","populationDescription":"SSA evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of 1st severe Covid19cases/1000PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.105 and for Placebo was 0.951","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4639"},{"groupId":"OG001","value":"4601"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.103"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"100.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-358.6","ciUpperLimit":"100.0"}]},{"type":"SECONDARY","title":"SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population","description":"Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \\>= 30 breaths per minute, heart rate \\>= 125 beats per minute, oxygen saturation \\<= 93% on room air at sea level, or Horovitz quotient \\<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \\<90 mm Hg, diastolic BP \\<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.","populationDescription":"Evaluable efficacy population included all eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'N' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of 1st severe Covid19cases/1000PY","timeFrame":"From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.182 and for Placebo was 1.011","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4911"},{"groupId":"OG001","value":"4861"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.978"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Sided CI for RVE is derived based on the Clopper and Pearson method adjusted for surveillance time.","nonInferiorityType":"OTHER","paramType":"Adjusted Surveillance Time","paramValue":"100.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-355.5","ciUpperLimit":"100.0"}]},{"type":"SECONDARY","title":"SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection","description":"Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.","populationDescription":"Evaluable efficacy population included eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of 1st severe Covid19cases/1000PY","timeFrame":"From 7 Days after booster vaccination","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4689"},{"groupId":"OG001","value":"4664"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection","description":"Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.","populationDescription":"Evaluable efficacy population included eligible randomized participants who received the booster vaccination as randomized and had no other important protocol deviations as determined by the clinician. HIV positive participants were excluded from this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of 1st severe Covid19cases/1000PY","timeFrame":"From 7 Days after booster vaccination","groups":[{"id":"OG000","title":"SSA: BNT162b2 30 mcg: Blinded and Open Label Period","description":"Participants received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4977"},{"groupId":"OG001","value":"4942"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"SSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose","description":"GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At baseline and 7 days after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1846.7","lowerLimit":"1232.1","upperLimit":"2767.9"},{"groupId":"OG001","value":"2230.4","lowerLimit":"1451.8","upperLimit":"3426.7"}]}]},{"title":"Day 7","categories":[{"measurements":[{"groupId":"OG000","value":"15193.4","lowerLimit":"12335.9","upperLimit":"18712.8"},{"groupId":"OG001","value":"22689.7","lowerLimit":"18949.8","upperLimit":"27167.7"}]}]}]},{"type":"SECONDARY","title":"SSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose","description":"GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'n' signifies participants evaluable at specified timepoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At baseline and 7 days after booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","lowerLimit":"39.1","upperLimit":"119.1"},{"groupId":"OG001","value":"131.1","lowerLimit":"68.7","upperLimit":"250.7"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1356.4","lowerLimit":"970.1","upperLimit":"1896.4"},{"groupId":"OG001","value":"2655.7","lowerLimit":"2046.7","upperLimit":"3445.9"}]}]}]},{"type":"SECONDARY","title":"SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose","description":"GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From baseline (before booster dose) to 7 days after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"5.9","upperLimit":"11.5"},{"groupId":"OG001","value":"10.2","lowerLimit":"6.8","upperLimit":"15.2"}]}]}]},{"type":"SECONDARY","title":"SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose","description":"GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From baseline (before booster dose) to 7 days after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"12.3","upperLimit":"31.6"},{"groupId":"OG001","value":"20.2","lowerLimit":"11.7","upperLimit":"35.0"}]}]}]},{"type":"SECONDARY","title":"SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"7 days after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","lowerLimit":"56.9","upperLimit":"82.9"},{"groupId":"OG001","value":"68.1","lowerLimit":"52.9","upperLimit":"80.9"}]}]}]},{"type":"SECONDARY","title":"SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose","description":"Seroresponse was defined as achieving \\>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \\>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.","populationDescription":"All-available immunogenicity population included all randomized or assigned participants who received the study intervention with a valid and determinate immunogenicity result after vaccination. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"7 days after the booster dose","groups":[{"id":"OG000","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSC: BNT162b2 30 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","lowerLimit":"63.4","upperLimit":"88.2"},{"groupId":"OG001","value":"74.5","lowerLimit":"59.7","upperLimit":"86.1"}]}]}]},{"type":"SECONDARY","title":"SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age","description":"GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).","populationDescription":"Evaluable immunogenicity population was analyzed. Participants without evidence of prior infection were included in the analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed only in Expanded cohort \\>55 years BNT162b2 30 mcg, BNT162b2 15 mcg + BNT162b2 OMI 15 mcg and BNT162b2 30 mcg + BNT162b2 OMI 30 mcg, as pre-specified in protocol.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after study vaccination","groups":[{"id":"OG000","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG001","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."},{"id":"OG002","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"180"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5998.1","lowerLimit":"5223.6","upperLimit":"6887.4"},{"groupId":"OG001","value":"5933.2","lowerLimit":"5188.2","upperLimit":"6785.2"},{"groupId":"OG002","value":"7816.9","lowerLimit":"6820.7","upperLimit":"8958.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 \\[15 mcg\\] + BNT162b2 OMI \\[15 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.20"},{"groupIds":["OG000","OG002"],"groupDescription":"GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (BNT162b2 \\[30 mcg\\] + BNT162b2 OMI \\[30 mcg\\] - BNT162b2 \\[30 mcg\\]) and the corresponding CIs based on the student t distribution.","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio (GMR)","paramValue":"1.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.07","ciUpperLimit":"1.58"}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Death/SAEs: 6 months after last dose (or 1 month after each dose for SSB, or 6 months after BNT162b2 for SSA original placebo). Non-SAEs: 1 month after each booster dose (or after Dose 2 for SSD naïve group, or after BNT162b2 for SSA original placebo)","description":"Same event may appear as both AE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both AE and non-SAE. For SSB, SSC, SSE and SSF, MedDRA version used is v25.1. For SSD, MedDRA version used is v26.0.","eventGroups":[{"id":"EG000","title":"SSA: BNT162b2 30 mcg- Blinded and Open Label Period","description":"Subjects received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":5,"deathsNumAtRisk":5080,"seriousNumAffected":73,"seriousNumAtRisk":5080,"otherNumAffected":1201,"otherNumAtRisk":5080},{"id":"EG001","title":"SSA: Placebo: Blinded Period","description":"Participants received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly.","deathsNumAffected":2,"deathsNumAtRisk":5041,"seriousNumAffected":42,"seriousNumAtRisk":5041,"otherNumAffected":202,"otherNumAtRisk":5041},{"id":"EG002","title":"SSA: Original Placebo/BNT162b2 (30 mcg)- Open Label Period","description":"Subjects received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly and then one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":5,"deathsNumAtRisk":4429,"seriousNumAffected":45,"seriousNumAtRisk":4429,"otherNumAffected":771,"otherNumAtRisk":4429},{"id":"EG003","title":"SSB: BNT162b2","description":"Subjects received one dose (30 microgram) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":1453,"seriousNumAffected":2,"seriousNumAtRisk":1453,"otherNumAffected":1180,"otherNumAtRisk":1453},{"id":"EG004","title":"SSB: Placebo","description":"Subjects received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly.","deathsNumAffected":0,"deathsNumAtRisk":1463,"seriousNumAffected":2,"seriousNumAtRisk":1463,"otherNumAffected":615,"otherNumAtRisk":1463},{"id":"EG005","title":"SSF: BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":21,"seriousNumAffected":0,"seriousNumAtRisk":21,"otherNumAffected":17,"otherNumAtRisk":21},{"id":"EG006","title":"SSF: BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":19,"seriousNumAffected":1,"seriousNumAtRisk":19,"otherNumAffected":19,"otherNumAtRisk":19},{"id":"EG007","title":"SSF: BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":21,"seriousNumAffected":1,"seriousNumAtRisk":21,"otherNumAffected":20,"otherNumAtRisk":21},{"id":"EG008","title":"SSF: BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":18,"otherNumAtRisk":20},{"id":"EG009","title":"SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":18,"otherNumAtRisk":20},{"id":"EG010","title":"SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":21,"seriousNumAffected":0,"seriousNumAtRisk":21,"otherNumAffected":20,"otherNumAtRisk":21},{"id":"EG011","title":"SSC: BNT162b2 10 mcg","description":"Participants who previously received two booster doses of BNT162b2 prior to enrollment in SSC, received one booster dose (10 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":75,"seriousNumAffected":0,"seriousNumAtRisk":75,"otherNumAffected":49,"otherNumAtRisk":75},{"id":"EG012","title":"SSC: BNT162b2 30 mcg","description":"Subjects received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":65,"seriousNumAffected":1,"seriousNumAtRisk":65,"otherNumAffected":57,"otherNumAtRisk":65},{"id":"EG013","title":"SSD: Cohort 1: Group 1","description":"Participants received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":216,"seriousNumAffected":2,"seriousNumAtRisk":216,"otherNumAffected":124,"otherNumAtRisk":216},{"id":"EG014","title":"SSD: Cohort 1: Group 2a","description":"Subjects received two doses (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly 4 weeks apart in the deltoid muscle of the non-dominant arm.","deathsNumAffected":2,"deathsNumAtRisk":197,"seriousNumAffected":3,"seriousNumAtRisk":197,"otherNumAffected":131,"otherNumAtRisk":197},{"id":"EG015","title":"SSD: Cohort 1: Group 2b","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":1,"deathsNumAtRisk":204,"seriousNumAffected":2,"seriousNumAtRisk":204,"otherNumAffected":109,"otherNumAtRisk":204},{"id":"EG016","title":"SSD: Cohort 2: Group 3a","description":"Subjects received one dose (30 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm (Vaccination 1).","deathsNumAffected":1,"deathsNumAtRisk":315,"seriousNumAffected":5,"seriousNumAtRisk":315,"otherNumAffected":260,"otherNumAtRisk":315},{"id":"EG017","title":"SSD: Cohort 2: Group 3 b","description":"After 3 months of Vaccination 1, subjects upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI (Vaccination 2).","deathsNumAffected":0,"deathsNumAtRisk":213,"seriousNumAffected":1,"seriousNumAtRisk":213,"otherNumAffected":167,"otherNumAtRisk":213},{"id":"EG018","title":"SSD: Cohort 2: Group 4a","description":"Subjects received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm (Vaccination 1).","deathsNumAffected":0,"deathsNumAtRisk":323,"seriousNumAffected":2,"seriousNumAtRisk":323,"otherNumAffected":270,"otherNumAtRisk":323},{"id":"EG019","title":"SSD: Cohort 2: Group 4b","description":"After 3 months of Vaccination 1, subjects upon their consent received optional additional one dose (30 mcg) of BNT162b2 OMI (Vaccination 2).","deathsNumAffected":0,"deathsNumAtRisk":238,"seriousNumAffected":3,"seriousNumAtRisk":238,"otherNumAffected":175,"otherNumAtRisk":238},{"id":"EG020","title":"SSD: Cohort 3: Group 5a","description":"Subjects received two doses (30 mcg) of BNT162b2 Omicron (OMI) 3 weeks apart intramuscularly in the deltoid muscle of the non-dominant arm (Vaccination 1 and 2).","deathsNumAffected":1,"deathsNumAtRisk":210,"seriousNumAffected":7,"seriousNumAtRisk":210,"otherNumAffected":135,"otherNumAtRisk":210},{"id":"EG021","title":"SSD: Cohort 3: Group 5b","description":"Subjects upon their consent received one dose (30 mcg) of BNT162b2 5 months after second dose of BNT162b2 OMI vaccination (Vaccination 3).","deathsNumAffected":1,"deathsNumAtRisk":172,"seriousNumAffected":1,"seriousNumAtRisk":172,"otherNumAffected":69,"otherNumAtRisk":172},{"id":"EG022","title":"SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":29,"otherNumAtRisk":30},{"id":"EG023","title":"SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":27,"otherNumAtRisk":30},{"id":"EG024","title":"SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":29,"otherNumAtRisk":30},{"id":"EG025","title":"SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":482,"seriousNumAffected":3,"seriousNumAtRisk":482,"otherNumAffected":431,"otherNumAtRisk":482},{"id":"EG026","title":"SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":159,"seriousNumAffected":2,"seriousNumAtRisk":159,"otherNumAffected":143,"otherNumAtRisk":159},{"id":"EG027","title":"SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":321,"seriousNumAffected":3,"seriousNumAtRisk":321,"otherNumAffected":297,"otherNumAtRisk":321},{"id":"EG028","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":15,"otherNumAtRisk":20},{"id":"EG029","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":15,"otherNumAtRisk":20},{"id":"EG030","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":15,"otherNumAtRisk":20},{"id":"EG031","title":"SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":20,"otherNumAtRisk":20},{"id":"EG032","title":"SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":16,"otherNumAtRisk":20},{"id":"EG033","title":"SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":1,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":17,"otherNumAtRisk":20},{"id":"EG034","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":305,"seriousNumAffected":6,"seriousNumAtRisk":305,"otherNumAffected":220,"otherNumAtRisk":305},{"id":"EG035","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":302,"seriousNumAffected":2,"seriousNumAtRisk":302,"otherNumAffected":243,"otherNumAtRisk":302},{"id":"EG036","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg","description":"Participants received one dose (30 mcg) of BNT162b2 OMI intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":1,"deathsNumAtRisk":307,"seriousNumAffected":12,"seriousNumAtRisk":307,"otherNumAffected":241,"otherNumAtRisk":307},{"id":"EG037","title":"SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg","description":"Participants received one dose (60 mcg) of BNT162b2 Omicron (OMI) intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":1,"deathsNumAtRisk":307,"seriousNumAffected":4,"seriousNumAtRisk":307,"otherNumAffected":248,"otherNumAtRisk":307},{"id":"EG038","title":"SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg","description":"Participants received a total of 30 mcg bivalent BNT162b2 (15 mcg BNT162b2 and 15 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":0,"deathsNumAtRisk":308,"seriousNumAffected":4,"seriousNumAtRisk":308,"otherNumAffected":226,"otherNumAtRisk":308},{"id":"EG039","title":"SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg","description":"Participants received a total of 60 mcg bivalent BNT162b2 (30 mcg BNT162b2 and 30 mcg BNT162b2 OMI) as a single dose intramuscularly in the deltoid muscle of the non-dominant arm.","deathsNumAffected":1,"deathsNumAtRisk":313,"seriousNumAffected":6,"seriousNumAtRisk":313,"otherNumAffected":247,"otherNumAtRisk":313}],"seriousEvents":[{"term":"Sickle cell anaemia with crisis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":1,"numAffected":1,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":3,"numAffected":3,"numAtRisk":313}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Myopericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Coronary artery insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastric fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Sudden cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abdominal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acquired immunodeficiency syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":1,"numAffected":1,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cholangitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Complicated appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":1,"numAffected":1,"numAtRisk":313}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Infected skin ulcer","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Liver abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Lyme disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":2,"numAffected":2,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Salmonellosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Staphylococcal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hypervolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acetabulum fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Arterial injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Stoma complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Intervertebral disc space narrowing","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acute lymphocytic leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Adrenocortical carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Biliary neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Brain neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Breast cancer stage II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Follicular lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hepatic adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hepatic cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":1,"numAffected":1,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Lung carcinoma cell type unspecified stage II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Nervous system neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pancreatic carcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pituitary tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":1,"numAffected":1,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Squamous cell carcinoma of the vagina","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Uterine cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Breast cancer stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Colorectal adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cerebral venous thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":1,"numAffected":1,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Toxic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Toxic leukoencephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abortion complete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abortion incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5041},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"End stage renal disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Renal infarct","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Adenomyosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Vitiligo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pancreatic pseudocyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Penetrating aortic ulcer","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hypertrophic cardiomyopathy","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Rhabdomyosarcomas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":2,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dilated cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Meningitis cryptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Viral myocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":1,"numAffected":1,"numAtRisk":313}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":1,"numAffected":1,"numAtRisk":313}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Fluid retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Rheumatoid arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Vertebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Heavy menstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Scapula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Traumatic haemothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Traumatic liver injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Throat cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":1,"numAffected":1,"numAtRisk":313}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":1,"numAffected":1,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":1,"numAffected":1,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":1,"numAffected":1,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":1,"numAffected":1,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Adenocarcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cervical radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Prostatomegaly","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":1,"numAffected":1,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Brain neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Blood loss anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":1,"numAffected":1,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":1,"numAffected":1,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":1,"numAffected":1,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]}],"otherEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":147,"numAffected":141,"numAtRisk":5080},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":5041},{"groupId":"EG002","numEvents":59,"numAffected":59,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":4,"numAffected":4,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG025","numEvents":7,"numAffected":7,"numAtRisk":482},{"groupId":"EG026","numEvents":3,"numAffected":3,"numAtRisk":159},{"groupId":"EG027","numEvents":4,"numAffected":4,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":54,"numAtRisk":5080},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":243,"numAffected":243,"numAtRisk":5080},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":5041},{"groupId":"EG002","numEvents":107,"numAffected":107,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":4,"numAffected":4,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":383,"numAffected":383,"numAtRisk":5080},{"groupId":"EG001","numEvents":66,"numAffected":66,"numAtRisk":5041},{"groupId":"EG002","numEvents":228,"numAffected":228,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":315},{"groupId":"EG017","numEvents":6,"numAffected":6,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":5,"numAffected":5,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":675,"numAffected":673,"numAtRisk":5080},{"groupId":"EG001","numEvents":83,"numAffected":83,"numAtRisk":5041},{"groupId":"EG002","numEvents":412,"numAffected":412,"numAtRisk":4429},{"groupId":"EG003","numEvents":17,"numAffected":17,"numAtRisk":1453},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":4,"numAffected":4,"numAtRisk":213},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":323},{"groupId":"EG019","numEvents":3,"numAffected":3,"numAtRisk":238},{"groupId":"EG020","numEvents":7,"numAffected":6,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":3,"numAffected":3,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":4,"numAffected":4,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":140,"numAffected":139,"numAtRisk":5080},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":5041},{"groupId":"EG002","numEvents":122,"numAffected":122,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":258,"numAffected":258,"numAtRisk":5080},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":5041},{"groupId":"EG002","numEvents":143,"numAffected":142,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":248,"numAffected":248,"numAtRisk":5080},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":5041},{"groupId":"EG002","numEvents":119,"numAffected":118,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":315},{"groupId":"EG017","numEvents":4,"numAffected":4,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":58,"numAtRisk":5080},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":269,"numAffected":267,"numAtRisk":5080},{"groupId":"EG001","numEvents":54,"numAffected":54,"numAtRisk":5041},{"groupId":"EG002","numEvents":144,"numAffected":144,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":197},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":4,"numAffected":4,"numAtRisk":238},{"groupId":"EG020","numEvents":4,"numAffected":4,"numAtRisk":210},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Diarrhoea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":109,"numAffected":109,"numAtRisk":1453},{"groupId":"EG004","numEvents":77,"numAffected":77,"numAtRisk":1463},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":75},{"groupId":"EG012","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG013","numEvents":19,"numAffected":19,"numAtRisk":216},{"groupId":"EG014","numEvents":24,"numAffected":20,"numAtRisk":197},{"groupId":"EG015","numEvents":13,"numAffected":13,"numAtRisk":204},{"groupId":"EG016","numEvents":25,"numAffected":25,"numAtRisk":315},{"groupId":"EG017","numEvents":18,"numAffected":18,"numAtRisk":213},{"groupId":"EG018","numEvents":35,"numAffected":35,"numAtRisk":323},{"groupId":"EG019","numEvents":13,"numAffected":13,"numAtRisk":238},{"groupId":"EG020","numEvents":24,"numAffected":20,"numAtRisk":210},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":172},{"groupId":"EG022","numEvents":6,"numAffected":6,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":4,"numAffected":4,"numAtRisk":30},{"groupId":"EG025","numEvents":61,"numAffected":61,"numAtRisk":482},{"groupId":"EG026","numEvents":17,"numAffected":17,"numAtRisk":159},{"groupId":"EG027","numEvents":39,"numAffected":39,"numAtRisk":321},{"groupId":"EG028","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG029","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG030","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":13,"numAffected":13,"numAtRisk":305},{"groupId":"EG035","numEvents":17,"numAffected":17,"numAtRisk":302},{"groupId":"EG036","numEvents":24,"numAffected":24,"numAtRisk":307},{"groupId":"EG037","numEvents":31,"numAffected":31,"numAtRisk":307},{"groupId":"EG038","numEvents":26,"numAffected":26,"numAtRisk":308},{"groupId":"EG039","numEvents":21,"numAffected":21,"numAtRisk":313}]},{"term":"Vomiting (VOMITING)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":37,"numAffected":37,"numAtRisk":1453},{"groupId":"EG004","numEvents":13,"numAffected":13,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":75},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":216},{"groupId":"EG014","numEvents":8,"numAffected":8,"numAtRisk":197},{"groupId":"EG015","numEvents":7,"numAffected":7,"numAtRisk":204},{"groupId":"EG016","numEvents":8,"numAffected":8,"numAtRisk":315},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":213},{"groupId":"EG018","numEvents":5,"numAffected":5,"numAtRisk":323},{"groupId":"EG019","numEvents":4,"numAffected":4,"numAtRisk":238},{"groupId":"EG020","numEvents":7,"numAffected":7,"numAtRisk":210},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":15,"numAffected":15,"numAtRisk":482},{"groupId":"EG026","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG027","numEvents":12,"numAffected":12,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":4,"numAffected":4,"numAtRisk":305},{"groupId":"EG035","numEvents":5,"numAffected":5,"numAtRisk":302},{"groupId":"EG036","numEvents":9,"numAffected":9,"numAtRisk":307},{"groupId":"EG037","numEvents":8,"numAffected":8,"numAtRisk":307},{"groupId":"EG038","numEvents":4,"numAffected":4,"numAtRisk":308},{"groupId":"EG039","numEvents":4,"numAffected":4,"numAtRisk":313}]},{"term":"Chills (CHILLS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":278,"numAffected":278,"numAtRisk":1453},{"groupId":"EG004","numEvents":69,"numAffected":69,"numAtRisk":1463},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG010","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG011","numEvents":10,"numAffected":10,"numAtRisk":75},{"groupId":"EG012","numEvents":15,"numAffected":15,"numAtRisk":65},{"groupId":"EG013","numEvents":31,"numAffected":31,"numAtRisk":216},{"groupId":"EG014","numEvents":39,"numAffected":35,"numAtRisk":197},{"groupId":"EG015","numEvents":21,"numAffected":21,"numAtRisk":204},{"groupId":"EG016","numEvents":93,"numAffected":93,"numAtRisk":315},{"groupId":"EG017","numEvents":39,"numAffected":39,"numAtRisk":213},{"groupId":"EG018","numEvents":80,"numAffected":80,"numAtRisk":323},{"groupId":"EG019","numEvents":41,"numAffected":41,"numAtRisk":238},{"groupId":"EG020","numEvents":36,"numAffected":32,"numAtRisk":210},{"groupId":"EG021","numEvents":14,"numAffected":14,"numAtRisk":172},{"groupId":"EG022","numEvents":7,"numAffected":7,"numAtRisk":30},{"groupId":"EG023","numEvents":7,"numAffected":7,"numAtRisk":30},{"groupId":"EG024","numEvents":12,"numAffected":12,"numAtRisk":30},{"groupId":"EG025","numEvents":171,"numAffected":171,"numAtRisk":482},{"groupId":"EG026","numEvents":44,"numAffected":44,"numAtRisk":159},{"groupId":"EG027","numEvents":123,"numAffected":123,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG030","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG031","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG032","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG033","numEvents":6,"numAffected":6,"numAtRisk":20},{"groupId":"EG034","numEvents":49,"numAffected":49,"numAtRisk":305},{"groupId":"EG035","numEvents":72,"numAffected":72,"numAtRisk":302},{"groupId":"EG036","numEvents":77,"numAffected":77,"numAtRisk":307},{"groupId":"EG037","numEvents":78,"numAffected":78,"numAtRisk":307},{"groupId":"EG038","numEvents":38,"numAffected":38,"numAtRisk":308},{"groupId":"EG039","numEvents":74,"numAffected":74,"numAtRisk":313}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":723,"numAffected":723,"numAtRisk":1453},{"groupId":"EG004","numEvents":356,"numAffected":356,"numAtRisk":1463},{"groupId":"EG005","numEvents":10,"numAffected":10,"numAtRisk":21},{"groupId":"EG006","numEvents":7,"numAffected":7,"numAtRisk":19},{"groupId":"EG007","numEvents":9,"numAffected":9,"numAtRisk":21},{"groupId":"EG008","numEvents":11,"numAffected":11,"numAtRisk":20},{"groupId":"EG009","numEvents":10,"numAffected":10,"numAtRisk":20},{"groupId":"EG010","numEvents":12,"numAffected":12,"numAtRisk":21},{"groupId":"EG011","numEvents":37,"numAffected":37,"numAtRisk":75},{"groupId":"EG012","numEvents":35,"numAffected":35,"numAtRisk":65},{"groupId":"EG013","numEvents":67,"numAffected":67,"numAtRisk":216},{"groupId":"EG014","numEvents":79,"numAffected":61,"numAtRisk":197},{"groupId":"EG015","numEvents":57,"numAffected":57,"numAtRisk":204},{"groupId":"EG016","numEvents":189,"numAffected":189,"numAtRisk":315},{"groupId":"EG017","numEvents":119,"numAffected":119,"numAtRisk":213},{"groupId":"EG018","numEvents":184,"numAffected":184,"numAtRisk":323},{"groupId":"EG019","numEvents":117,"numAffected":117,"numAtRisk":238},{"groupId":"EG020","numEvents":109,"numAffected":87,"numAtRisk":210},{"groupId":"EG021","numEvents":35,"numAffected":35,"numAtRisk":172},{"groupId":"EG022","numEvents":20,"numAffected":20,"numAtRisk":30},{"groupId":"EG023","numEvents":19,"numAffected":19,"numAtRisk":30},{"groupId":"EG024","numEvents":21,"numAffected":21,"numAtRisk":30},{"groupId":"EG025","numEvents":354,"numAffected":354,"numAtRisk":482},{"groupId":"EG026","numEvents":108,"numAffected":108,"numAtRisk":159},{"groupId":"EG027","numEvents":248,"numAffected":248,"numAtRisk":321},{"groupId":"EG028","numEvents":9,"numAffected":9,"numAtRisk":20},{"groupId":"EG029","numEvents":11,"numAffected":11,"numAtRisk":20},{"groupId":"EG030","numEvents":9,"numAffected":9,"numAtRisk":20},{"groupId":"EG031","numEvents":13,"numAffected":13,"numAtRisk":20},{"groupId":"EG032","numEvents":8,"numAffected":8,"numAtRisk":20},{"groupId":"EG033","numEvents":14,"numAffected":14,"numAtRisk":20},{"groupId":"EG034","numEvents":135,"numAffected":135,"numAtRisk":305},{"groupId":"EG035","numEvents":156,"numAffected":156,"numAtRisk":302},{"groupId":"EG036","numEvents":158,"numAffected":158,"numAtRisk":307},{"groupId":"EG037","numEvents":177,"numAffected":177,"numAtRisk":307},{"groupId":"EG038","numEvents":147,"numAffected":147,"numAtRisk":308},{"groupId":"EG039","numEvents":177,"numAffected":177,"numAtRisk":313}]},{"term":"Injection site erythema (REDNESS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":74,"numAffected":74,"numAtRisk":1453},{"groupId":"EG004","numEvents":9,"numAffected":9,"numAtRisk":1463},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":19},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG010","numEvents":6,"numAffected":6,"numAtRisk":21},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":75},{"groupId":"EG012","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG013","numEvents":7,"numAffected":7,"numAtRisk":216},{"groupId":"EG014","numEvents":20,"numAffected":18,"numAtRisk":197},{"groupId":"EG015","numEvents":5,"numAffected":5,"numAtRisk":204},{"groupId":"EG016","numEvents":21,"numAffected":21,"numAtRisk":315},{"groupId":"EG017","numEvents":10,"numAffected":10,"numAtRisk":213},{"groupId":"EG018","numEvents":13,"numAffected":13,"numAtRisk":323},{"groupId":"EG019","numEvents":9,"numAffected":9,"numAtRisk":238},{"groupId":"EG020","numEvents":16,"numAffected":14,"numAtRisk":210},{"groupId":"EG021","numEvents":7,"numAffected":7,"numAtRisk":172},{"groupId":"EG022","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG025","numEvents":39,"numAffected":39,"numAtRisk":482},{"groupId":"EG026","numEvents":10,"numAffected":10,"numAtRisk":159},{"groupId":"EG027","numEvents":35,"numAffected":35,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG030","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG031","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG034","numEvents":19,"numAffected":19,"numAtRisk":305},{"groupId":"EG035","numEvents":31,"numAffected":31,"numAtRisk":302},{"groupId":"EG036","numEvents":19,"numAffected":19,"numAtRisk":307},{"groupId":"EG037","numEvents":33,"numAffected":33,"numAtRisk":307},{"groupId":"EG038","numEvents":22,"numAffected":22,"numAtRisk":308},{"groupId":"EG039","numEvents":22,"numAffected":22,"numAtRisk":313}]},{"term":"Injection site pain (PAIN)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":1038,"numAffected":1038,"numAtRisk":1453},{"groupId":"EG004","numEvents":163,"numAffected":163,"numAtRisk":1463},{"groupId":"EG005","numEvents":15,"numAffected":15,"numAtRisk":21},{"groupId":"EG006","numEvents":18,"numAffected":18,"numAtRisk":19},{"groupId":"EG007","numEvents":19,"numAffected":19,"numAtRisk":21},{"groupId":"EG008","numEvents":16,"numAffected":16,"numAtRisk":20},{"groupId":"EG009","numEvents":15,"numAffected":15,"numAtRisk":20},{"groupId":"EG010","numEvents":19,"numAffected":19,"numAtRisk":21},{"groupId":"EG011","numEvents":42,"numAffected":42,"numAtRisk":75},{"groupId":"EG012","numEvents":50,"numAffected":50,"numAtRisk":65},{"groupId":"EG013","numEvents":96,"numAffected":96,"numAtRisk":216},{"groupId":"EG014","numEvents":145,"numAffected":110,"numAtRisk":197},{"groupId":"EG015","numEvents":85,"numAffected":85,"numAtRisk":204},{"groupId":"EG016","numEvents":229,"numAffected":229,"numAtRisk":315},{"groupId":"EG017","numEvents":145,"numAffected":145,"numAtRisk":213},{"groupId":"EG018","numEvents":239,"numAffected":239,"numAtRisk":323},{"groupId":"EG019","numEvents":153,"numAffected":153,"numAtRisk":238},{"groupId":"EG020","numEvents":146,"numAffected":109,"numAtRisk":210},{"groupId":"EG021","numEvents":60,"numAffected":60,"numAtRisk":172},{"groupId":"EG022","numEvents":27,"numAffected":27,"numAtRisk":30},{"groupId":"EG023","numEvents":25,"numAffected":25,"numAtRisk":30},{"groupId":"EG024","numEvents":29,"numAffected":29,"numAtRisk":30},{"groupId":"EG025","numEvents":398,"numAffected":398,"numAtRisk":482},{"groupId":"EG026","numEvents":128,"numAffected":128,"numAtRisk":159},{"groupId":"EG027","numEvents":276,"numAffected":276,"numAtRisk":321},{"groupId":"EG028","numEvents":14,"numAffected":14,"numAtRisk":20},{"groupId":"EG029","numEvents":14,"numAffected":14,"numAtRisk":20},{"groupId":"EG030","numEvents":13,"numAffected":13,"numAtRisk":20},{"groupId":"EG031","numEvents":20,"numAffected":20,"numAtRisk":20},{"groupId":"EG032","numEvents":131,"numAffected":13,"numAtRisk":20},{"groupId":"EG033","numEvents":17,"numAffected":17,"numAtRisk":20},{"groupId":"EG034","numEvents":179,"numAffected":179,"numAtRisk":305},{"groupId":"EG035","numEvents":212,"numAffected":212,"numAtRisk":302},{"groupId":"EG036","numEvents":199,"numAffected":199,"numAtRisk":307},{"groupId":"EG037","numEvents":214,"numAffected":214,"numAtRisk":307},{"groupId":"EG038","numEvents":177,"numAffected":177,"numAtRisk":308},{"groupId":"EG039","numEvents":208,"numAffected":208,"numAtRisk":313}]},{"term":"Injection site swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":86,"numAffected":86,"numAtRisk":1453},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":1463},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG009","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG010","numEvents":6,"numAffected":6,"numAtRisk":21},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":75},{"groupId":"EG012","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG013","numEvents":17,"numAffected":17,"numAtRisk":216},{"groupId":"EG014","numEvents":28,"numAffected":23,"numAtRisk":197},{"groupId":"EG015","numEvents":11,"numAffected":11,"numAtRisk":204},{"groupId":"EG016","numEvents":25,"numAffected":25,"numAtRisk":315},{"groupId":"EG017","numEvents":8,"numAffected":8,"numAtRisk":213},{"groupId":"EG018","numEvents":27,"numAffected":27,"numAtRisk":323},{"groupId":"EG019","numEvents":14,"numAffected":14,"numAtRisk":238},{"groupId":"EG020","numEvents":32,"numAffected":27,"numAtRisk":210},{"groupId":"EG021","numEvents":16,"numAffected":16,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG024","numEvents":6,"numAffected":6,"numAtRisk":30},{"groupId":"EG025","numEvents":46,"numAffected":46,"numAtRisk":482},{"groupId":"EG026","numEvents":11,"numAffected":11,"numAtRisk":159},{"groupId":"EG027","numEvents":38,"numAffected":38,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG030","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG031","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG032","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG033","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG034","numEvents":18,"numAffected":18,"numAtRisk":305},{"groupId":"EG035","numEvents":39,"numAffected":39,"numAtRisk":302},{"groupId":"EG036","numEvents":25,"numAffected":25,"numAtRisk":307},{"groupId":"EG037","numEvents":31,"numAffected":31,"numAtRisk":307},{"groupId":"EG038","numEvents":20,"numAffected":20,"numAtRisk":308},{"groupId":"EG039","numEvents":17,"numAffected":17,"numAtRisk":313}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":74,"numAffected":74,"numAtRisk":1453},{"groupId":"EG004","numEvents":17,"numAffected":17,"numAtRisk":1463},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":75},{"groupId":"EG012","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG013","numEvents":12,"numAffected":12,"numAtRisk":216},{"groupId":"EG014","numEvents":7,"numAffected":7,"numAtRisk":197},{"groupId":"EG015","numEvents":10,"numAffected":10,"numAtRisk":204},{"groupId":"EG016","numEvents":25,"numAffected":25,"numAtRisk":315},{"groupId":"EG017","numEvents":9,"numAffected":9,"numAtRisk":213},{"groupId":"EG018","numEvents":22,"numAffected":22,"numAtRisk":323},{"groupId":"EG019","numEvents":13,"numAffected":13,"numAtRisk":238},{"groupId":"EG020","numEvents":12,"numAffected":11,"numAtRisk":210},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":172},{"groupId":"EG022","numEvents":4,"numAffected":4,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG025","numEvents":48,"numAffected":48,"numAtRisk":482},{"groupId":"EG026","numEvents":17,"numAffected":17,"numAtRisk":159},{"groupId":"EG027","numEvents":62,"numAffected":62,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG030","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG031","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG032","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG033","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG034","numEvents":11,"numAffected":11,"numAtRisk":305},{"groupId":"EG035","numEvents":22,"numAffected":22,"numAtRisk":302},{"groupId":"EG036","numEvents":25,"numAffected":25,"numAtRisk":307},{"groupId":"EG037","numEvents":27,"numAffected":27,"numAtRisk":307},{"groupId":"EG038","numEvents":15,"numAffected":15,"numAtRisk":308},{"groupId":"EG039","numEvents":24,"numAffected":24,"numAtRisk":313}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":18,"numAffected":18,"numAtRisk":1453},{"groupId":"EG004","numEvents":26,"numAffected":26,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":178,"numAffected":178,"numAtRisk":1453},{"groupId":"EG004","numEvents":55,"numAffected":55,"numAtRisk":1463},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":23,"numAffected":23,"numAtRisk":216},{"groupId":"EG014","numEvents":38,"numAffected":33,"numAtRisk":197},{"groupId":"EG015","numEvents":20,"numAffected":20,"numAtRisk":204},{"groupId":"EG016","numEvents":69,"numAffected":69,"numAtRisk":315},{"groupId":"EG017","numEvents":28,"numAffected":28,"numAtRisk":213},{"groupId":"EG018","numEvents":46,"numAffected":46,"numAtRisk":323},{"groupId":"EG019","numEvents":26,"numAffected":26,"numAtRisk":238},{"groupId":"EG020","numEvents":30,"numAffected":29,"numAtRisk":210},{"groupId":"EG021","numEvents":14,"numAffected":14,"numAtRisk":172},{"groupId":"EG022","numEvents":6,"numAffected":6,"numAtRisk":30},{"groupId":"EG023","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG024","numEvents":7,"numAffected":7,"numAtRisk":30},{"groupId":"EG025","numEvents":122,"numAffected":122,"numAtRisk":482},{"groupId":"EG026","numEvents":33,"numAffected":33,"numAtRisk":159},{"groupId":"EG027","numEvents":77,"numAffected":77,"numAtRisk":321},{"groupId":"EG028","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG029","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG030","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG031","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG032","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG033","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG034","numEvents":27,"numAffected":27,"numAtRisk":305},{"groupId":"EG035","numEvents":48,"numAffected":48,"numAtRisk":302},{"groupId":"EG036","numEvents":50,"numAffected":50,"numAtRisk":307},{"groupId":"EG037","numEvents":59,"numAffected":59,"numAtRisk":307},{"groupId":"EG038","numEvents":34,"numAffected":34,"numAtRisk":308},{"groupId":"EG039","numEvents":57,"numAffected":57,"numAtRisk":313}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":402,"numAffected":402,"numAtRisk":1453},{"groupId":"EG004","numEvents":88,"numAffected":88,"numAtRisk":1463},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG006","numEvents":8,"numAffected":8,"numAtRisk":19},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG008","numEvents":6,"numAffected":6,"numAtRisk":20},{"groupId":"EG009","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG010","numEvents":6,"numAffected":6,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":32,"numAffected":32,"numAtRisk":216},{"groupId":"EG014","numEvents":48,"numAffected":41,"numAtRisk":197},{"groupId":"EG015","numEvents":28,"numAffected":28,"numAtRisk":204},{"groupId":"EG016","numEvents":99,"numAffected":99,"numAtRisk":315},{"groupId":"EG017","numEvents":51,"numAffected":51,"numAtRisk":213},{"groupId":"EG018","numEvents":86,"numAffected":86,"numAtRisk":323},{"groupId":"EG019","numEvents":58,"numAffected":58,"numAtRisk":238},{"groupId":"EG020","numEvents":48,"numAffected":45,"numAtRisk":210},{"groupId":"EG021","numEvents":23,"numAffected":23,"numAtRisk":172},{"groupId":"EG022","numEvents":9,"numAffected":9,"numAtRisk":30},{"groupId":"EG023","numEvents":9,"numAffected":9,"numAtRisk":30},{"groupId":"EG024","numEvents":14,"numAffected":14,"numAtRisk":30},{"groupId":"EG025","numEvents":191,"numAffected":191,"numAtRisk":482},{"groupId":"EG026","numEvents":58,"numAffected":58,"numAtRisk":159},{"groupId":"EG027","numEvents":135,"numAffected":135,"numAtRisk":321},{"groupId":"EG028","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG029","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG030","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG031","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG032","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG033","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG034","numEvents":59,"numAffected":59,"numAtRisk":305},{"groupId":"EG035","numEvents":76,"numAffected":76,"numAtRisk":302},{"groupId":"EG036","numEvents":72,"numAffected":72,"numAtRisk":307},{"groupId":"EG037","numEvents":92,"numAffected":92,"numAtRisk":307},{"groupId":"EG038","numEvents":70,"numAffected":70,"numAtRisk":308},{"groupId":"EG039","numEvents":82,"numAffected":82,"numAtRisk":313}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":585,"numAffected":585,"numAtRisk":1453},{"groupId":"EG004","numEvents":332,"numAffected":332,"numAtRisk":1463},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":21},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG008","numEvents":11,"numAffected":11,"numAtRisk":20},{"groupId":"EG009","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG010","numEvents":8,"numAffected":8,"numAtRisk":21},{"groupId":"EG011","numEvents":31,"numAffected":31,"numAtRisk":75},{"groupId":"EG012","numEvents":34,"numAffected":34,"numAtRisk":65},{"groupId":"EG013","numEvents":64,"numAffected":64,"numAtRisk":216},{"groupId":"EG014","numEvents":89,"numAffected":70,"numAtRisk":197},{"groupId":"EG015","numEvents":55,"numAffected":55,"numAtRisk":204},{"groupId":"EG016","numEvents":140,"numAffected":140,"numAtRisk":315},{"groupId":"EG017","numEvents":78,"numAffected":78,"numAtRisk":213},{"groupId":"EG018","numEvents":137,"numAffected":137,"numAtRisk":323},{"groupId":"EG019","numEvents":81,"numAffected":81,"numAtRisk":238},{"groupId":"EG020","numEvents":77,"numAffected":67,"numAtRisk":210},{"groupId":"EG021","numEvents":39,"numAffected":39,"numAtRisk":172},{"groupId":"EG022","numEvents":14,"numAffected":14,"numAtRisk":30},{"groupId":"EG023","numEvents":9,"numAffected":9,"numAtRisk":30},{"groupId":"EG024","numEvents":18,"numAffected":18,"numAtRisk":30},{"groupId":"EG025","numEvents":257,"numAffected":257,"numAtRisk":482},{"groupId":"EG026","numEvents":79,"numAffected":79,"numAtRisk":159},{"groupId":"EG027","numEvents":184,"numAffected":184,"numAtRisk":321},{"groupId":"EG028","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG029","numEvents":6,"numAffected":6,"numAtRisk":20},{"groupId":"EG030","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG031","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG032","numEvents":6,"numAffected":6,"numAtRisk":20},{"groupId":"EG033","numEvents":10,"numAffected":10,"numAtRisk":20},{"groupId":"EG034","numEvents":79,"numAffected":79,"numAtRisk":305},{"groupId":"EG035","numEvents":116,"numAffected":116,"numAtRisk":302},{"groupId":"EG036","numEvents":110,"numAffected":110,"numAtRisk":307},{"groupId":"EG037","numEvents":110,"numAffected":110,"numAtRisk":307},{"groupId":"EG038","numEvents":99,"numAffected":99,"numAtRisk":308},{"groupId":"EG039","numEvents":114,"numAffected":114,"numAtRisk":313}]},{"term":"Eye pruritis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ear infections","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Attention deficit-hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":3,"numAffected":3,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Corneal abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Bone swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Panic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Onychomycosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5080},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5041},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4429},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1453},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":1463},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":75},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":197},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":213},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":323},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":238},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":172},{"groupId":"EG022","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG023","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG024","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG025","numEvents":0,"numAffected":0,"numAtRisk":482},{"groupId":"EG026","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG027","numEvents":0,"numAffected":0,"numAtRisk":321},{"groupId":"EG028","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG029","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG030","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG031","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG032","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG033","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG034","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG035","numEvents":0,"numAffected":0,"numAtRisk":302},{"groupId":"EG036","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG037","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG038","numEvents":0,"numAffected":0,"numAtRisk":308},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":313}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"BioNTech SE","organization":"BioNTech clinical trials patient information","email":"patients@biontech.de","phone":"+49 6131 90840"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-09-20","uploadDate":"2024-05-14T14:32","filename":"Prot_000.pdf","size":1914569},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy A","date":"2022-08-16","uploadDate":"2024-05-14T14:51","filename":"SAP_001.pdf","size":546857},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy B","date":"2022-12-08","uploadDate":"2024-05-14T14:52","filename":"SAP_002.pdf","size":522388},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy C","date":"2023-09-25","uploadDate":"2024-05-14T14:53","filename":"SAP_003.pdf","size":320117},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy D","date":"2023-09-28","uploadDate":"2024-05-14T14:54","filename":"SAP_004.pdf","size":392133},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy E","date":"2022-09-01","uploadDate":"2024-05-14T14:54","filename":"SAP_005.pdf","size":717511},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: substudy F","date":"2022-09-30","uploadDate":"2024-05-14T14:55","filename":"SAP_006.pdf","size":496508}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Canada"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-06-13","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"},{"id":"D018352","term":"Coronavirus Infections"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000090982","term":"BNT162 Vaccine"}],"ancestors":[{"id":"D000087503","term":"mRNA Vaccines"},{"id":"D000087504","term":"Nucleic Acid-Based Vaccines"},{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D000086663","term":"COVID-19 Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}